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Abstract 
Modern day medicine is on the brink of a new age of therapy, which aims to 
harness the natural power of molecular biology for disease treatment. This 
therapy could include replacement of dysfunctional genes that cause disorders 
such as cystic fibrosis (Lommatzsch and Aris, 2009), or silencing the over-
expression of genes that cause disorders such as cancer (Pelengaris and Khan, 
2003). In both examples, the treatment of these genetic diseases lies in the 
delivery of synthetic nucleic acids into diseased cells, the former being called 
gene replacement therapy (Dobson, 2006a), and the latter being called RNA 
interference (RNAi) therapy (Whitehead et al., 2009). While these techniques 
have long been in use as genetic research tools for gene transfection or silencing 
in vitro, their translation for use in clinical disease treatment has yet to be 
achieved. The main problem facing the development of these novel therapies is 
the specific delivery of nucleic acids into diseased cells within the body.  It is 
hoped that nanoparticles (NPs) can be used to overcome this problem, by acting 
as vehicles to transport nucleic acids through the body for specific delivery into 
diseased cells. This feat can be aided by the attachment of additional functional 
molecules such as cell penetrating peptides (CPPs), targeting peptides, 
additional drug types and molecules for imaging during treatment. Many 
different NP design strategies are currently under development. It is essential 
for new designs to be extensively tested for toxicity and efficiency in human 
cells before they can be successfully released into the clinic.  
 
As part of this effort, this PhD project has investigated two different NP design 
strategies for drug delivery: 1) the use of a magnetic field (MF) and a CPP to 
increase the delivery of iron oxide magnetic NPs (mNPs) to cells grown in tissue-
equivalent 3D collagen gels, and 2) gold NPs (AuNPs) for the delivery of siRNA to 
silence the c-myc oncogene for cancer treatment. In the first investigation, a MF 
and the CPP penetratin were found to increase mNP delivery to cells grown in 
3D. In the second investigation, AuNPs were assessed in a range of different cell 
types (grown in 2D) for their performance in 4 main areas; cellular toxicity, 
cellular uptake, c-myc knockdown and effect on the cell cycle.  
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1.1 Genetic Disease 
Many human diseases are caused by incorrect expression of one or more genes. 
For example cystic fibrosis is an autosomal recessive disorder caused by 
mutations in the gene encoding the cystic fibrosis transmembrane conductance 
regulator (CFTR) (Lommatzsch and Aris, 2009). Similarly, Huntington’s disease is 
an autosomal dominant disorder caused by mutations in the Huntingtin gene 
(Walker, 2007), and Duchenne muscular dystrophy is an x-linked recessive 
disorder caused by mutation in the dystrophin gene (Odom et al., 2010). In 
addition to these quite rare single gene disorders, one of the most common 
genetic diseases is cancer; which accounts for approximately 13% of all deaths 
annually across the globe (Ferlay et al., 2010). Curing diseases that have a 
known genetic cause is now one of the main targets of nanomedicine, and it is 
envisaged that nanoparticles (NPs) will play a major role by facilitating the 
delivery of novel oligonucleotide-based therapeutics into diseased cells to either 
replace dysfunctional genes or to reduce those that are expressed in 
overabundance. Whilst the number of genetic diseases that NPs can potentially 
target is extensive, this thesis will mainly focus on their use in the treatment of 
cancer. 
1.1.1 Cancer 
Cancer is a disease of unregulated cell growth, where cells divide and grow 
uncontrollably, resulting in the formation of tumours. The earliest written 
record of cancer dates back to 3000BC when a description of breast cancer was 
included in the Ancient Egyptian medical text, the Egyptian Edwin Smith Papyrus 
(Hajdu, 2011). Since then, many different theories have been proposed as to the 
causes of cancer, although after the discovery of DNA and the ensuing revolution 
of molecular biology, and in particular advances in proteomics and genomics, it 
is now clear that cancer is caused by genetic mutations in genes that regulate 
cell division. Of the 30,000 genes within the human genome, around 2% of these 
are involved in the formation of cancer (Santarius et al., 2010). Such genes 
include those involved in cell cycle control, apoptosis, DNA repair, ageing and 
immortalisation, angiogenesis, invasion and metastasis (Pawaiya et al., 2011). 
Hannah W. Child, 2012                                                                        Chapter 1, 16 
 
These cancer-related genes can be split into two main categories; oncogenes 
and tumour suppressor genes. Genes that promote the cell cycle are termed 
proto-oncogenes, which induce cancer when they become oncogenes upon the 
acquisition of an upregulating mutation that leads to their overexpression. 
Around 90 oncogenes have so far been identified, including growth factors (sis), 
growth factor receptors (K-sam), tyrosine kinases (Src), G-protein coupled 
receptors, G-proteins (gsp), serine/threonine kinases (akt) and transcription 
factors (c-myc) (Pawaiya et al., 2011).  
 
Conversely, tumour suppressor genes inhibit the cell cycle, inducing cancer 
when they acquire a downregulating mutation that leads to their 
underexpression. Around 30 tumour suppressor genes have so far been 
identified, including those that function to control the cell cycle (Rb, PTEN, and 
APC), repair DNA damage (BRCA1, and BRCA2), and induce apoptosis (p53) 
(Pawaiya et al., 2011).  
1.1.2 The c-myc Oncogene 
c-myc is one if the most studied oncogenes. It was first identified in early 
studies of chicken tumours caused by avian myelocytomatosis retroviruses. 
Publications emerged in 1979 reporting that the transforming gene found within 
the RNA genome of these retroviruses had been identified (Duesberg and Vogt, 
1979; Hu et al., 1979), and that this nucleotide sequence had homology to DNA 
and RNA from uninfected vertebrate cells (Sheiness and Bishop, 1979). After the 
discovery that cancer could be caused by viral myc (v-myc) in chickens, it was 
realised in 1982 that the homologous gene found in vertebrate cells (c-myc) was 
causally implicated in non-viral induced cancers in humans. This was based on 
the finding that human c-myc was consistently altered in Burkitt lymphoma by 
balanced chromosomal translocation (Dallafavera et al., 1982; Taub et al., 
1982). Since then, c-myc has been found to be translocated in multiple myeloma 
and is one of the most highly amplified oncogenes identified in many different 
human cancers (Beroukhim et al., 2010a).  
 
c-myc encodes a transcription factor and has been described as an intermediate 
to mass signal transduction through the cell. In normal cells, the expression of c-
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myc is tightly controlled throughout all stages of the central dogma. For 
example, the expression of c-myc is regulated at the levels of transcription by a 
host of transcription factors and DNA structures, translation by microRNA, 
protein by phosphorylation, and finally the cellular effect of c-myc is inhibited 
by feedback loops involving genes such as Arf and p53. Once transcribed, c-myc 
dimerises with another transcription factor called max, and the c-myc/max 
dimmer binds to DNA at the canonical c-myc E box 5’-CACGTG-3’, which 
activates the expression of many target genes (Liao and Dickson, 2000) (see 
Figure 1-1). Genome wide studies have tried to determine the exact number of 
c-myc target genes. In 2003, Li et al described c-myc as a ‘global transcription 
factor’, after they used 4,839 promoter sequences to map c-myc-binding sites, 
and found that 15% bound to c-myc (Li et al., 2003). This corresponds to another 
genome-wide study performed by Zeller et al in 2006, which used ChiP-PET to 
map c-myc binding sites, and found that although 6000 genes bound c-myc, only 
700 of these responded to c-myc activation with alterations in their mRNA levels 
(Zeller et al., 2006). This highlights that many of c-myc’s targets also require 
the binding of other transcription factors in addition to c-myc before they can 
be activated. More recently, microarray analysis performed by Ji et al has 
identified a 50 gene c-myc core signature (MCS), which is considered to 
constitute the main targets of c-myc (Ji et al., 2011). In his 2012 review of the 
literature, Dang concludes that the body of work that has aimed to identify c-
myc targets suggests that c-myc functions as a master regulator affecting a 
broad spectrum of genes to coordinate energy metabolism with biomass 
accumulation in preparation for DNA replication and cell division (Dang, 2012). 
Due to the central role this oncogene plays in regulation of the cell cycle, 
teamed with the fact that it is so frequently found to be overexpressed in cancer 
cells, c-myc presents as a very promising candidate for targeted gene therapy to 
treat cancer, since normalising its expression should normalise the increased cell 
division associated with tumour formation.  
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Figure 1-1 c-myc regulates cell growth and proliferation 
A) Mitogenic signaling pathways, mediated by cell-surface receptors, regulate c-myc 
expression. Once expressed, the c-myc protein acts as a transcription factor and dimerises 
with max in order to bind the E-box domain of many target genes. c-myc/max activation 
leads to the transcription of the target genes, many of which are involved in cell growth and 
proliferation. B) The action of c-myc is negatively regulated by the tumour suppressor 
genes Arf and p53. Image from (Dang, 2012). 
1.1.3 Cancer Treatment 
1.1.3.1 Traditional Approach 
Due to increased understanding of the genes and pathways involved in regulating 
the cell cycle and the formation of cancer, medical research now has a much 
greater chance of curing this disease than in the past. The main goal of cancer 
treatment is to either kill or arrest cancer cell division, without affecting 
surrounding healthy cells and tissue. Traditional cancer treatment has involved 
administering chemotherapeutic drugs into the patient’s bloodstream. 
Chemotherapy was first used to treat cancer patients in 1946, when Gilman et al 
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administered tris (ß-chloroethyl) amine hydrochloride (derived from mustard 
gas) to 6 cancer patients, which resulted in regression of the cancer (Gilman and 
Philips, 1946). Chemotherapeutic drugs work by killing rapidly dividing cells, 
such as cancer cells. However, the main drawback is that they are 
indiscriminate, and will also kill any other rapidly dividing cells found within the 
body including those in hair follicles, bone marrow and the digestive tract, 
which leads to undesirable side effects such as hair loss, immunosuppression and 
mucositis (inflammation of the digestive tract). Common chemotherapeutic 
drugs used in modern chemotherapy to date include docetaxel, doxorubicin, 
pacilitaxel and fluorouracil, all of which interfere with cell division.  
1.1.3.2 Targeted Therapy 
It is now understood that in order to overcome the deleterious side effects 
associated with chemotherapy drugs, new medications will need to be designed 
which are specific to cancer cells. This approach has been termed ‘targeted 
therapy’ and aims to inhibit the proliferation of cancer cells by interfering with 
specific molecules that are essential for tumour growth. This includes the use of 
oligonucleotide-based gene correction therapies such as RNA interference 
(RNAi), which aim to reduce cancer cell specific oncogene overexpression (e.g. 
c-myc), in addition to new small molecule drugs. The development of targeted 
therapeutics for the treatment of cancer has been advanced by the current 
knowledge base of cancer genetics, and also an increasing awareness of cancer 
cell behaviour. One of the most cited descriptions of cancer cell behaviour is 
that of Hanahan and Weinberg, who in 2000 published a list of the “6 hallmarks 
of cancer” (Hanahan and Weinberg, 2000), and in 2010, expanded upon this list 
by publishing a description of 10 acquired cancer cell capabilities necessary for 
tumour growth, which can thus pose as targets for new therapeutics. This 
included targeting cancer cells’ sustained proliferative signaling with epidermal 
growth factor receptor (EGFR) inhibitors, their avoidance of immune destruction 
with immune activating anti-CTLA4 mAb, their induction of angiogenesis with 
inhibitors of vascular endothelial growth factor (VEGF) signaling and their 
resistance of cell death with proapoptotic BH3 mimetics (Hanahan and 
Weinberg, 2011). This highlights the clinical potential of developing new cancer 
drugs to target the unique physiological aspects of cancer cell behaviour caused 
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by the extensive alterations to gene expression within these diseased cells. All 
targeted therapeutics, including oligonucleotides and small molecule drugs, are 
candidates for NP-mediated delivery to cancer cells. 
1.1.4 Oncogene Addiction 
A recently proposed theory with big implications for targeted cancer therapy is 
that of oncogene addiction, whereby cancer cells become dependent on the 
expression of one main oncogene. This phenomenon has been described as the 
‘Achilles heel of cancer’, and anticipates that rather than requiring correction of 
the many complex genetic pathways involved, cancer can instead be challenged 
by targeted therapy to reduce the expression of one key oncogene (Weinstein, 
2002). Studies have shown that c-myc is one of the major oncogenes to which 
cancer cells can become addicted, and that in some cases, a brief suppression of 
c-myc is sufficient to reverse in vivo tumourigenesis. For example, Jain et al 
used a conditional transgenic mouse model for c-myc-induced tumourigenesis 
where c-myc transcription was activated upon doxycycline (dox) treatment, to 
investigate the effect of pharmacological inactivation of c-myc as a therapeutic 
strategy for cancer. They reported that brief inactivation of c-myc expression 
with dox treatment caused osteogenic sarcoma cells to differentiate into mature 
osteocytes. Interestingly, this study found that upon reactivation of c-myc 
expression by removing dox treatment, 99% of the tumour cells did not regain 
their neoplastic growth properties (Jain et al., 2002). The authors hypothesise 
that this unexpected prolonged anti-cancer effect was due to the fact that brief 
oncogene inactivation can induce epigenetic changes that revoke its ability to 
maintain tumourigenesis. This experimental evidence, that cancer cells can be 
made to regress upon the reduction of c-myc expression, clearly identifies c-myc 
as a potential candidate for targeted therapy. Of course in a clinical setting, 
oncogenes cannot be inactivated by dox treatment, and so oligonucleotide-based 
gene correction therapies such as RNAi present as the best method for targeted 
inactivation of oncogenes, which can be facilitated by NP-mediated delivery to 
cancer cells. 
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1.2 RNAi for Targeted Therapy Against Oncogenes 
RNAi is a naturally occurring cellular mechanism for gene silencing induced by 
RNA molecules that have complementarity to the target gene’s mRNA. The 
action of RNAi is highly conserved across all species and is believed to have 
evolved from a defense mechanism against viruses and genetic instability arising 
from mobile genetic elements such as transposons (Kurreck, 2009). In its natural 
context, RNAi is mediated by the transcription of double-stranded RNA (dsRNA), 
>30 nucleotides (nt) in length, which gets exported into the cytoplasm by the 
nuclear export receptor, Exportin-5 (Ohrt et al., 2006; Lommatzsch and Aris, 
2009). Once in the cytoplasm, these dsRNAs get cleaved by the ribonuclease 
enzyme, DICER, into 21-23nt fragments, thereafter named small interfering RNAs 
(siRNAs) (Bernstein et al., 2001; Elbashir et al., 2001). These siRNA molecules 
get loaded into the RNA-induced silencing complex (RISC) (Rand et al., 2004), 
become single stranded (Matranga et al., 2005), and bind complementary mRNA 
(Ameres et al., 2007). Argonaute 2, a multifunctional protein found within RISC, 
cleaves the bound mRNA between nucleotides 10 and 11 (relative to the 5’ end) 
(Whitehead et al., 2009). This renders it unable to continue through the central 
dogma and be translated into protein. Thus the process of gene silencing by RNAi 
becomes complete (see Figure 1-2).  
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Figure 1-2 Simplified schematic of the mechanism of mammalian RNAi  
Natural RNAi is mediated by the transcription of dsRNA in the nucleus by RNA Polymerase 
III. This dsRNA gets exported into the cytoplasm, cleaved by DICER, and incorporated into 
RISC. The sense strand is removed, and the remaining antisense strand activates RISC. 
Activated RISC then finds and cleaves mRNA with complementarity to the antisense strand. 
This cleavage prevents the mRNA from being translated into protein. Synthetic siRNA can 
be artificially transfected into the cytoplasm, where it gets processed by the natural RNAi 
machinery to prevent translation of a target mRNA. Image modified from (Kurreck, 2009). 
 
The fact that RNA could induce gene silencing was first identified in plants in 
1990, being originally termed ‘co-suppression’ and incorrectly attributed to the 
already established and similar mechanism of antisense gene silencing (Napoli et 
al., 1990; Vanderkrol et al., 1990). Eight years later, Fire and Mello proved that 
this RNA-based silencing phenomenon was in fact distinct from antisense gene 
silencing. They elucidated that eukaryotic cells perceive dsRNA as a sequence 
specific signal to inhibit expression of the corresponding mRNA (Fire et al., 
1998). In light of this discovery they were awarded the Nobel Prize in Physiology 
or Medicine in 2006 (Zamore, 2006). In their original experiments, Fire and Mello 
achieved potent and specific gene silencing in C.elegans after dsRNA molecules, 
742nt in length, were injected directly into nematodes. In the immediate years 
following this pioneering work, many studies continued to demonstrate that long 
dsRNAs >30nt, similar to those used by Fire and Mello, could also induce gene 
silencing in other eukaryotic organisms, such as D.melanogaster (Kennerdell and 
Carthew, 1998), and plants (Hamilton and Baulcombe, 1999). This demonstrated 
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that RNAi was very highly conserved across species, which lead researchers to 
envisage that it could also be adopted to silence gene expression in humans. 
However, it was found that the long dsRNAs that had been used in the original 
group of RNAi studies invoked a severe interferon (IFN) immune response in 
mammalian cells (Manche et al., 1992), rendering them useless for gene 
silencing in humans. This problem was solved in 2001, when Thomas Tuschl et 
al, discovered that artificial, synthetic dsRNA molecules of approximately 21nt 
in length were sufficiently long to perform gene silencing in mammalian cells, 
but small enough to prevent an IFN immune response (Elbashir et al., 2001). This 
key finding demonstrated that RNAi could be exploited artificially to silence 
gene expression in human cells, facilitated by the transfection of synthetic, 
exogenous 21-23nt siRNA molecules.  
 
Artificial RNAi has the potential to be used for many applications, and is already 
a multimillion dollar business (Castanotto and Rossi, 2009). Primarily, RNAi 
became a universal research tool for gene knockdown studies (Gondi and Rao, 
2009), fueled by the fact that RNAi holds numerous advantages over traditional 
methods of gene knockdown. This includes having a broader target range than 
classical small-molecule inhibitory drugs (Whitehead et al., 2009), since any 
gene of known sequence can be silenced by appropriately designed siRNA (Huang 
et al., 2008). RNAi is also less toxic than chemical inhibitors, and less time-
consuming than constructing dominant negative mutants (Huang et al., 2008). 
These advantages have also led RNAi to emerge as an attractive therapeutic tool 
for targeted therapy of human genetic disease caused by abhorrent gene 
expression (Kurreck, 2009), such as cancer.  
 
Therapeutic RNAi involves the transfection of mammalian cells with siRNA 
designed with complementarity to a target gene. These siRNA molecules can 
then use the inherent cellular RNAi machinery within the cytoplasm to silence 
that target gene by cleaving its mRNA (as depicted in Figure 1-2). Cells can 
alternatively be transfected with vector-based siRNA (shRNA), which provides a 
more stable and longer-lasting silencing effect (Shi, 2003; Huang et al., 2008). 
As such, RNAi is now being heralded as a promising strategy that can meet the 
medical need for in vivo inactivation of key oncogenes such as c-myc for cancer 
treatment. The progress of clinical RNAi therapy from bench to bedside has 
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moved amazingly fast, with a gap of only 6 years between the initial discover of 
this technology in 1998 and the first RNAi-based clinical trial which was 
conducted in 2004 by Acuity Pharmaceuticals. This trial involved direct 
administration of a siRNA therapeutic (termed Cand5) into the eye, to reduce 
expression of the VEGF receptor as a treatment for patients with wet age-
related macular degeneration (AMD), a leading cause of adult blindness. This 
siRNA treatment has since reached phase III clinical trials, and has been reported 
to improve near vision and lesion size (Bumcrot et al., 2006). Acuity 
Pharmaceuticals have also since begun another clinical trial using Cand5 to treat 
patients with diabetic macular edema (DME). The eye has been a popular choice 
in the development of RNAi-based therapeutics, and siRNA against the VEGF 
receptor has also entered Phase II clinical trials under Merck-siRNA Therapeutics, 
with reports suggesting it to be well tolerated and to improve visual acuity. 
Another popular choice of disease target for RNAi has been the lungs, with siRNA 
(termed ALN-RSV01) to treat respiratory syncytial virus (RSV) infections entering 
Phase II clinical trials under Alnylam Pharmaceuticals. ALN-RSV01 aims to treat 
patients by reducing viral replication, and is the first antiviral siRNA to enter 
clinical trials (Castanotto and Rossi, 2009).  
 
The reason why the eye and the lungs have been the main focus of 
pharmaceutical companies for RNAi therapeutics over other tissues, is that they 
present as easily accessible sites for direct administration of siRNA. 
Unfortunately, administering siRNA to less accessible sites within the body, such 
as deep solid tumours is more difficult since these sites cannot be reached by 
direct injection or inhalation. These sites must instead be reached by systemic 
delivery of siRNA via intravenous injection, after which the siRNA can be carried 
to the target site of disease within the body by the blood stream; a significant 
challenge to the success of this novel therapeutic strategy.  
 
Systemic delivery of siRNA suffers from three main problems; 1) naked 
oligonucleotides have a short half-life inside the human body due to enzymatic 
degradation by nucleases within the bloodstream (Dykxhoorn and Lieberman, 
2005); 2) they have no way of distinguishing between diseased and healthy cells, 
leading to nontargeted tissue distribution (Derfus et al., 2007); and 3) they 
cannot easily cross cell membranes (Akhtar et al., 1991; Wittung et al., 1995). 
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Bumcrot et al attribute this lack of cellular uptake to the fact that siRNA 
molecules do not adhere to the ‘Lipinski Rules’; a set of criteria that ascribes to 
most small-molecule pharmaceutical drugs. In particular, these rules state that 
drugs must have high lipophilicity and molecular weight less than 500 Dalton 
(Da) to be effective. In stark contrast, siRNA naturally lacks these drug-like 
properties due to their large size (two turns of a nucleic acid double helix), 
nearly 40 anionic charges provided by the phosphodiester backbone, and high 
molecular weight (over 13kDa) (Bumcrot et al., 2006). siRNA also suffers from a 
range of more acute systemic delivery problems including rapid excretion by the 
kidney (Gao et al., 2009), poor vascular permeability, difficult extracellular 
matrix (ECM) diffusion, and clearance by phagocytes of the reticuloendothelial 
system (RES) (Barry, 2008; Juliano et al., 2008). At the subcellular level, siRNA 
delivery problems include poor endocytotic uptake and inefficient endosomal 
escape (Juliano et al., 2008).  
 
Unfortunately, due to this range of problems, naked siRNA molecules have very 
limited practical use in systemic delivery for disease treatment. Therefore, if 
widescale therapeutic RNAi is to become a reality, a protective and 
multifunctional delivery vehicle must be developed that can overcome these 
problems to administer siRNA molecules into human cells in vivo.  
1.3 Delivery Vehicles for siRNA 
The first clinical RNAi cancer trial in humans was conducted in 2006 and aimed 
to treat human glioblastoma multiforme brain tumors (Zukiel et al., 2006). This 
study concluded that while direct, local injection of siRNA did successfully 
inhibit cancer, systemic siRNA administration via a delivery vehicle would 
maximize its therapeutic potential. Mounting evidence clearly shows that 
attachment to a delivery vehicle aids systemic siRNA administration, by 
imparting desirable pharmacokinetic properties to the siRNA molecule and 
promoting its cellular uptake in tissues (Bumcrot et al., 2006). Various delivery 
vehicles have proved successful, including liposome delivery of siRNA to treat 
liver cirrhosis (Sato et al., 2008), human papilloma-virus (Niu et al., 2006) and 
ovarian cancer (Halder et al., 2006). Also, atelocollagen delivery of siRNA has 
been used to treat bone cancer (Takeshita et al., 2005).   
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In 2004, Soutschek et al reported that conjugation to cholesterol enhanced the 
pharmacokinetic and cellular uptake properties of systemically delivered siRNA 
in mice, resulting in reduction of the target mRNA (ApoB) by 57% and 73% in the 
liver and jejunum respectively, after intravenous injection (Soutschek et al., 
2004). However, following this success, in 2006 Zimmerman et al reported that 
conjugation to stable nucleic acid lipid particles (SNALPs) produced an even 
greater silencing of ApoB in mice than was attained in the earlier study using 
cholesterol-conjugated siRNA, demonstrating that NPs are a more effective type 
of siRNA delivery vehicle. In addition, the authors used SNALP delivery to 
achieve a 90% reduction in ApoB mRNA in non-human primates (Zimmermann et 
al., 2006), proving the feasibility of using NP-mediated delivery of siRNA in 
humans.  
 
Recent work by Kovtun et al reported that triple-shelled, biodegradable, 
calcium phosphate NPs carrying siRNA, enabled increased transfection and gene 
silencing compared to both naked siRNA and Polyfect (Kovtun et al., 2009). This 
study further demonstrates the huge potential of NPs as an effective delivery 
vehicle for siRNA.  
1.4 Nanoparticles (NPs)  
NPs are defined as submicron colloidal particles ranging in size from 10 to 
1000nm (Bosselmann and Williams; Rao et al., 2004). Many types of NPs are 
currently being developed as prospective siRNA delivery vehicles. Those 
composed of organic polymers include liposomes (Torchilin, 2005), dendrimers 
(Lee et al., 2005) and carbon nanotubes (Polizu et al., 2006), while those 
composed of non-organic polymers include quantum dots (Medintz et al., 2005), 
magnetic (Lu et al., 2007) and gold NPs (Huang et al., 2007; Sanvicens and 
Marco, 2008). NPs have many unique and advantageous chemical and physical 
properties inherently associated with their size. Sanvicens and Marco have listed 
these properties as optical, magnetic, catalytic, thermodynamic and 
electrochemical (Sanvicens and Marco, 2008). Furthermore, NPs have an 
advantageous high surface-volume ratio, are multivalent, and carry both 
inherent and tailored multifunctional properties, allowing them to overcome 
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many of the problems associated with systemic siRNA delivery. For example, NPs 
inherently extend the half-life of siRNA molecules circulating within the blood 
stream by preventing rapid excretion by the kidney - a fate that succumbs naked 
siRNA molecules (Soutschek et al., 2004; Derfus et al., 2007; Juliano et al., 
2008). 
 
In 2010, Nature published results from the first human phase I clinical trial 
involving the systemic administration of siRNA to patients with solid cancers 
using a targeted, nanoparticle delivery system (Davis et al., 2010). This study 
used a multifunctional delivery vehicle, featuring a cyclodextran-based polymer 
(CDP) NP, stabilised with polyethylene glycol (PEG), and functionalised with 
transferrin and siRNA. Biopsies revealed that after intravenous injection, the NPs 
accumulated within tumours, and were located intracellularly. In addition, 
quantitative real-time PCR (qRT-PCR) and Western blot analysis demonstrated 
reduced levels of the target mRNA and protein after treatment. The authors 
proved that this reduction in target gene expression was caused by siRNA-
mediated mRNA cleavage, since they observed mRNA fragments of the correct 
size to support site-specific cleavage by RNAi. This pioneering study has proved 
that reduction of oncogene expression in tumours by RNAi is possible in humans, 
mediated by NP systemic delivery. Furthermore, it is an excellent example of 
how tailored NP multifunctionality can be used to improve the success of NP-
mediated siRNA delivery.  
1.4.1 Tailored Nanoparticle Multifunctionality 
Aside from the inherent protection and increased half-life that attachment to a 
NP provides, NPs also offer a second level of systemic delivery assistance to 
siRNA molecules, as they can confer multifunctional properties via attachment 
of different surface groups. Popular functional groups that are currently used to 
aid NP delivery include cell-penetrating peptides (CPPs) (Meade and Dowdy, 
2008), such as the human immunodeficiency virus (HIV)-1 Tat peptide (Berry, 
2008), which enhance cell uptake. In addition, targeting ligands are used to 
allow cell selective recognition, by binding to receptors that are expressed on 
target cell membranes (Howard, 2009). Many targeting ligands against cancer 
cells are postulated, as cancer cells have a unique pattern of receptor 
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overexpression that is distinct from normal cells. Such targeting ligands include 
folate (Leamon and Low, 1991), transferrin (Davis et al., 2010) and the integrin-
binding Arg-Gly-Asp (RGD) tripeptide (Arap et al., 1998; Singh et al., 2009). The 
majority of NP designs include the attachment of organic oligomers, such as 
PEG, which increases NP stability and therapeutic efficiency (Howard et al., 
2008). The attachment of PEG (termed PEGylation) has been shown to inhibit 
phagocytotic clearance of NPs since it reduces opsonisation (the process of 
plasma protein adsorbtion to material, leading to its phagocytosis) (Juliano et 
al., 2008).   
 
The success of NP-mediated cell-targeted siRNA delivery was demonstrated by 
Kim et al, who reported that attachment of folate and PEG to polyethylenimine 
(PEI) NPs caused a ~3-fold increase in gene silencing compared to unmodified PEI 
NPs, when applied to folate-expressing cells (Kim et al., 2006). Similarly, in an 
in vivo murine study, Schiffelers et al reported that PEI-PEG NPs, functionalised 
with RGD could deliver siRNA to cancer cells, resulting in silencing of the VEGF 
R2 oncogene and a subsequent reduction in tumour angiogenesis and growth rate 
(Schiffelers et al., 2004). These studies exemplify that NP multifunctionality is a 
very useful tool to enhance the success of systemic siRNA delivery. 
1.4.2 Multivalency 
A further advantage of NPs, compared to other types of delivery vehicles, is that 
they are multivalent. This property allows NPs to be functionalised with many 
different siRNAs and peptides at once, potentially allowing multiple gene 
knockdowns, higher affinity for the target cell and ultimately more powerful 
disease treatment (Juliano et al., 2008). Indeed, Paciotti et al believe that 
tailoring vectors to deliver multiple therapeutic agents is of the utmost 
importance to their effectiveness as a cancer treatment (Paciotti et al., 2006). 
This is because, as has been discussed in earlier reports (Spremulli and Dexter, 
1983; Dexter et al., 1978), solid tumours are composed of heterogeneous cell 
populations. Therefore the future development of multi-targeting NPs is deemed 
necessary in order for them to effectively destroy the diverse populations of 
cells found within typical tumours (Paciotti et al., 2006). This could entail the 
attachment of multiple siRNAs able to knockdown a range of oncogenes, possibly 
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in combination with the attachment of various anti-cancer drugs, such as 
paclitaxel (Iwase et al., 2006), and tumor necrosis factor (TNF) (Helson et al., 
1975).  
 
Interestingly, Derfus et al analysed the optimal number of siRNA and cancer 
targeting peptides that could be accommodated by covalent attachment on a 
single NP, in this case PEGylated quantum dots (QDs). They reported that one 
siRNA per particle in conjunction with >15 peptides, or two siRNA per particle in 
conjunction with <10 peptides gave optimal knockdown and targeting (Derfus et 
al., 2007). This study highlights the importance of identifying the optimal load 
requirements of each NP when designed with multiple functional molecules. 
 
A study by Song et al demonstrated the effectiveness of using multiple siRNAs 
for cancer treatment (Song et al., 2005). This study targeted siRNAs against 
three oncogenes: MDM2, c-myc, and VGEF; which were all bound to a fusion 
protein for systemic murine delivery. MDM2 is an inactivator of p53 (Halaby and 
Yang, 2007), c-myc promotes cell proliferation (De Nigris et al., 2006), and VGEF 
is a tumour secreted growth factor that mediates angiogenesis and metastasis 
(Grothey, 2006). This three-fold siRNA design resulted in reduced melanoma cell 
proliferation. This work was taken a step further in a recent study by Li et al 
that demonstrated the use of siRNAs against the same three oncogenes, this 
time bound to liposome-based NPs (Li et al., 2008). These multi-siRNA NPs were 
injected into a murine lung cancer model, and caused simultaneous silencing of 
the three target genes. The authors compared the anti-cancer effect of NP-
bound siRNA, to free siRNA. Remarkably, a ~70-80% decrease in lung metastasis 
was reported after siRNA-NP treatment, compared to little effect after free 
siRNA treatment. Secondly, the mice that were given the siRNA-NP injection 
showed a 30% increase in survival time compared to untreated controls. These 
results support the use of NPs to deliver siRNA, and the results from both Li et al 
and Song et al promote the effectiveness of using multiple oncogene 
knockdowns simultaneously. 
Hannah W. Child, 2012                                                                        Chapter 1, 30 
 
1.4.3 Theranostics  
In addition to the attachment of therapeutic molecules, such as siRNA; dyes and 
fluorescent molecules can also be attached to NPs, allowing imaging for 
diagnostics. Indeed, it is now becoming a widespread belief that multifunctional 
NPs can be used to supply both therapy and diagnosis, as a novel “theranostic” 
siRNA delivery platform (Derfus et al., 2007; Lee et al., 2009b). This approach is 
reliant on NPs being able to: 1) specifically target a disease site within the 
human body; 2) allow for that site to be diagnostically imaged; and 3) deliver a 
therapeutic treatment (e.g. siRNA). 
 
In 2007 Medarova et al reported the development of magnetic NPs that became 
localised inside tumours, delivered covalently attached siRNA into cancer cells, 
and were detectable by imaging (Medarova et al., 2007). These NPs were 
functionalised with a myristoyl-coupled polyarginine peptide to facilitate 
membrane translocation. Subsequent imaging was two-fold; via attachment of a 
near-infrared dye (Cy5.5) to allow noninvasive near-infrared (NIR) imaging and 
also by magnetic resonance imaging (MRI), mediated by the magnetic nature of 
the NPs. The authors deduced that the NP tumour-accumulation observed during 
imaging was probably due to the enhanced permeability and retention (EPR) 
effect associated with the leaky vasculature of tumours. This study concluded 
that NPs further functionalised with tumour-targeting moieties would increase 
tumour localisation in order to deliver siRNA treatment.  
 
Derfus et al have reported the development of theranostic quantum dot (QD) 
NPs, capable of tumour localisation, siRNA delivery and imaging (Derfus et al., 
2007). In this particular design, tumour targeting was facilitated by the 
attachment of a tumour-homing peptide (F3), which binds to nucleolin expressed 
on the surface of cancer cells (Christian et al., 2003). This addition of F3 
increased QD tumour cell uptake by 2 orders of magnitude compared to non-
targeting QDs. Diagnostic imaging was facilitated by the photostable QD core 
with emission in the near-infrared (NIR). The attached siRNA silenced the 
enhanced green fluorescent protein (EGFP) gene, but the authors noted that 
their theranostic design could also be applied to silence oncogenes for cancer 
treatment. The siRNA conjugation chemistry was also investigated in this paper, 
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comparing a cleavable disulphide bond with covalent attachment. The former 
demonstrated higher knockdown, presumably due to an increase in siRNA-RISC 
interaction as the disulphide bond is cleaved once inside the reducing 
environment of the cell. This clarifies the importance of such acute attention to 
molecular design in the development of an efficient NP-based theranostic RNAi 
platform. 
 
A recent study by Lee et al provides an example of another type of theranostic 
multifunctional NP that utilised the disulphide bond cleavage for siRNA release, 
in this case with a magnetic NP (Lee et al., 2009b). In this design, tumour 
selectivity was facilitated by the attachment of a cyclic RGD peptide, and 
PEGylation of this targeting peptide increased NP stability. Diagnostic imaging 
was facilitated by the magnetic nature of the NP, which could be visualized by 
MIR, and further by the attachment of a Cy5 near-infrared dye that could be 
visualized by NIR. Treatment delivery was facilitated by the attachment of siRNA 
to silence the green fluorescent protein (GFP). Interestingly, the authors state 
that their magnetic NPs provided better targeting and reduced toxicity 
compared to the popular delivery vehicle polyethyleneimine (PEI), famous for its 
“proton sponge” method of endosomal escape. This study concluded that joining 
the tasks of diagnosis and treatment in future in vivo and clinical applications 
will reduce invasiveness and side effects (Lee et al., 2009b). 
1.4.4 Choice of NP Material 
1.4.4.1 Gold NPs (AuNPs) 
Gold has been used in medicine since ancient times to treat a range of ailments 
(Chen Pc, 2008). During the 19th century, gold was used to treat nervous 
disorders, depression, epilepsy, migraine and glandular problems (Richards et 
al., 2002). In modern medicine, gold is commonly used in pacemakers, dental 
restoration and the treatment of rheumatoid arthritis (Chen Pc, 2008). Colloidal 
gold NPs (AuNPs) were first synthesised in 1857 by Michael Faraday (Faraday, 
1857; Paciotti et al., 2006), however the method described by Brust et al (Brust 
et al., 1994) is traditionally one of the most popular methods for AuNP synthesis 
(De La Fuente et al., 2006a). In 1950 it was discovered that AuNPs could bind 
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protein biologics without affecting their activity, leading to their later use in 
immunodiagnostics and histopathology (Chandler et al., 2001). AuNPs were first 
used for biological applications in 1971, when Frank and Taylor devised the 
immunogold staining procedure (De La Fuente and Berry, 2005). In the 1990s, 
AuNPs found a role as scaffolds for DNA diagnostics and biosensors (Mirkin et al., 
1996). Paciotti et al have concluded that based on this historical data, and their 
own toxicology studies, AuNPs are relatively inert and biologically compatible 
delivery vehicles (Paciotti et al., 2006). Due to this biological compatibility 
teamed with their distinct optical properties, AuNPs have become powerful tools 
in various nanomedical applications (Chen Pc, 2008). For example, a 2003 study 
by Hirsch et al demonstrated thermal ablation of solid tumors using gold coated 
silica NPs that had been tuned to absorb light in the near infrared (NIR) (Hirsch 
et al., 2003). Once internalised inside cancer cells, exposure to NIR light caused 
localised AuNP heating that killed the surrounding cancer cells, a process now 
termed intracellular hyperthermia therapy (or thermal ablation). 
 
Much research has highlighted the potential use of gold as a multi-functional NP 
for RNAi therapeutics. This potential is due to many factors, including low 
cytotoxicity (Connor et al., 2005), easy size control (Daniel and Astruc, 2004), 
and well-developed surface chemistry for dense loading of functional groups 
(Love et al., 2005; Lee et al., 2009a). A study by Braun et al demonstrated gene 
silencing using AuNPs functionalised with the CPP Tat to enable cell entry, and 
siRNA against the reporter gene GFP (Braun et al., 2009). The authors used a 
pulsed NIR laser for the dual purposes of both siRNA-NP detachment and 
subsequent endosomal escape, allowing the free siRNA to become incorporated 
into RISC for efficient gene silencing. It is considered that future studies on 
AuNPs for RNAi therapy should focus on investigation of oncogene knockdown 
efficiency, and also NP cytotoxicity. This latter point is deemed very important 
because, somewhat in contradiction to the reported biocompatibility of gold, 
organogold compounds such as auranofin have been associated with toxic side 
effects including proteinuria and skin reaction during its use in arthritis patients 
(Chen Pc, 2008). Indeed, Chen et al state that more needs to be done to better 
our understanding of the pharmacokinetics and toxicological profiles of AuNPs 
(Chen Pc, 2008). 
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1.4.4.2 Iron, Magnetic Nanoparticles (mNPs) 
Iron is another excellent choice of material from which to fabricate therapeutic 
NPs, since the magnetism it bestows is very useful for systemic drug delivery. 
The main benefits of magnetism are that it allows the movement of mNPs to be 
controlled by an externally applied magnetic field, and it also enables mNPs to 
be imaged within the body by MRI. The literature suggests that mNPs composed 
of iron oxide are ideal for systemic drug delivery since they display good 
biocompatibility (Jain et al., 2008), strong magnetism (Corchero and Villaverde, 
2009), useful imaging properties (such as MRI) (Wu et al., 2010), ease of 
functionalisation and have been extensively researched in vitro (Dobson, 2006a).  
 
Magnetic targeting of drug delivery vehicles was first demonstrated by Widder et 
al in 1978, when they showed that iron oxide microspheres loaded with the 
chemotherapeutic drug adriamycin could be injected into rat tails, and directed 
to a target site elsewhere in the body where a magnet had been externally 
placed. This resulted in intracellular accumulation of the drug at the site of the 
magnet, which was comparable to that achieved by administration of a 100-fold 
higher dose of the free drug (Widder et al., 1978a). This early study, and many 
more since, have demonstrated the huge potential of mNPs for magnetically 
targeted systemic drug delivery. 
1.4.5 NP Uptake and Intracellular Processing 
In order for therapeutic NPs to cause gene silencing by RNAi, their cellular 
internalisation and subsequent cytoplasmic delivery of siRNA are essential. This 
is because the RNAi machinery, with which the delivered siRNA must associate  
(DICER and RISC), is located in the cytoplasm. Endocytosis is the main route for 
NPs to achieve cell internalisation. Three types of this process can occur: 1) 
phagocytosis, 2) pinocytosis (a.k.a. fluid-phase endocytosis), and 3) receptor-
mediated endocytosis (Berry et al., 2004b) as shown in Figure 1-3.  
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Figure 1-3 Mechanisms of endocytosis 
This figure outlines the three main mechanisms of endocytosis; phagocytosis, pinocytosis 
and receptor-mediated endocytosis. These natural cellular uptake mechanisms can be 
exploited for the uptake of therapeutic nanoparticles. (Image freely available from Mariana 
Ruiz Villarreal). 
 
All forms of endocytosis involve membrane invagination. In addition, pinocytosis 
and receptor-mediated endocytosis also involve clathrin- or caveolin- coated pit 
formation, detachment of the newly formed vesicle via the action of the small 
GTPase dynamin, and finally movement of the vesicle, termed the endosome, 
into the cytosol (Schafer, 2002). Endocytosis is a very efficient process; 
however, it can lead to undesirable fates for therapeutic NPs. For example, 
endosomes fuse with lysosomes, which have a destructive chemical environment 
that can degrade siRNA. Also, material contained within lysosomes is designated 
to be removed from the cell, in a process called exocytosis. Therefore, it seems 
clear that endosomal escape must take place before endo-lysosomal fusion, if 
therapeutic NPs are to deliver their siRNA payload into the cytoplasm (see Figure 
1-4).  
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Figure 1-4 The cellular endo-lysosomal pathway of nanoparticles 
This simplified schematic outlines the 5 main steps involved in the endo-lysosomal pathway 
of nanoparticles (NPs) through the cell. 1) Binding of NPs to cell-surface receptors causes 
membrane invagination. 2) This membrane invagination results in an endosome containing 
NPs. 3) Endosomes fuse with lysosomes. 4) This endo-lysosomal fusion results in a 
lysosome containing NPs. The destructive chemical environment of the lysosome can 
degrade siRNA. 5) Lysosomes fuse with the plasma membrane, expelling their contents out 
of the cell in a process called exocytosis. Therapeutic NPs must avoid/escape this endo-
lysosomal pathway if they are to successfully deliver their siRNA payload into the 
cytoplasm to cause gene silencing by RNAi. Image modified from (Chithrani et al., 2009). 
 
 
The requirement for cytoplasmic siRNA delivery, coupled with interest in 
nanotoxicology, has lead to increased research into NP uptake and intracellular 
processing. It has been widely reported that NP uptake is dependent on size and 
surface properties (Chithrani et al., 2009). For example, Verma and Stellacci 
reported that 50nm was the optimal NP size for efficient cellular uptake (Verma 
and Stellacci, 2010). In addition, they identified that spherical particles were 
taken up 500% more than rod-shaped particles of similar sizes. Cho et al found 
that NPs with a positive surface charge showed higher levels of endocytosis 
compared to both negatively and neutrally charged NPs (Cho et al., 2009), as 
they display the highest affinity for the negatively charged plasma membrane, 
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encouraging membrane invagination. A series of studies by Berry et al have 
reported differing NP-cell interactions depending on NP surface moiety. For 
example, AuNPs aggregated if functionalised with tiopronin, induced endocytosis 
if functionalised with ethylenediamine, and adhered to cells if functionalised 
with PEG (De La Fuente et al., 2006b). In a separate study, NPs functionalised 
with dextran induced deleterious alterations in cell behaviour and morphology, 
such as apoptosis and decreased cell motility, believed to be due to the large 
chains used in the study as dextran is typically inert (Berry et al., 2004b). In 
another study, NPs functionalised with transferrin localised at the cell 
membrane, without instigating the expected receptor-mediated endocytosis, 
and produced positive increases in proliferation, cytoskelaton organisation, cell 
signaling and production of extracellular matrix (Berry et al., 2004a). In a 
further study, AuNPs functionalised with a Tat-protein-derived peptide sequence 
localised inside the nucleus (De La Fuente and Berry, 2005). This string of 
studies demonstrates the considerable influence of NP surface groups on their 
uptake and intracellular processing.  
 
The fact that Berry et al achieved NP localisation in the nucleus suggests that 
those NPs must have escaped the endo-lysosomal pathway. However, there are 
currently no reliable and well-understood methods to achieve this essential feat, 
and therefore endosomal escape remains a large hurdle preventing the success 
of NP-mediated siRNA delivery (Nativo et al., 2008). Nativo et al investigated 
this problem by conducting a transmission electron microscopy (TEM) study of 
the uptake of 16nm surface-modified AuNPs into human fibroblast cells (Nativo 
et al., 2008). They reported that the endosomal route of cellular uptake could 
be bypassed by delivering the NPs via 2 uptake strategies: 1) liposome delivery, 
and 2) functionalisation with cell penetrating peptides (CPPs). Both of these 
uptake strategies resulted in the presence of free NPs within the cytosol. NPs 
delivered in liposomes appeared to enter the cytosol either by caveolar-clathrin-
dependent pathways, or directly across the plasma membrane. NPs 
functionalised with CPPs appeared to enter the cytosol either by endosomal 
escape, or directly through the plasma membrane. The observation that CPP-
functionalised NPs allow endosomal escape was supported by the fact that NPs 
within the cytosol were found in association with membrane-like structures that 
the authors believed could be destroyed endosome. It should also be noted that 
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the observation that CPP-functionalised NPs directly cross the plasma membrane 
could possibly be an artefact of cell fixation. This is in relation to a study by 
Richard et al, which reported that cell fixation can lead to the artificial uptake 
of CPPs (Richard et al., 2003).  
 
Nativo et al concluded that further studies will be needed to optimise particle 
delivery. They believe that this optimisation will involve finding the ideal 
composition of NP surface moieties in order to facilitate therapeutic RNAi. It is 
essential that this optimisation strategy involves nanotoxicity testing of the 
functionalised NPs, in order to avoid the induction of deleterious cell responses, 
and to ensure NP safety for human administration. 
1.4.6 Nanotoxicology 
In 2004, The Royal Society and The Royal Academy of Engineering published a 
report on the opportunities and uncertainties regarding nanoscience and 
nanotechnologies. This report concluded that NPs should be treated as new 
chemicals from a risk point of view, as they can overcome the body’s normal 
protective barrier due to their small size (Royalsociety, 2004). This type of 
cautious perspective has led to the emergence of nanotoxicology, a new 
discipline that aims to investigate the safety of nanotechnologies. This includes 
assessment of the risks involved with exposure to nanomaterials, investigations 
into the routes of NP entry into organisms, and studies into the molecular 
mechanisms of NP toxicity (Fischer and Chan, 2007; Oberdorster et al., 2005). 
There is currently a huge demand for nanotoxicological studies to be completed 
as NP research is rapidly translating into clinical use. This demand is amplified 
by growing public concern and awareness regarding NPs in everyday life (e.g. in 
sunscreens and cosmetics) and their impact on human health (Miller, 2006). 
Sanvicens and Marco acknowledge that the few risk-evaluating studies that have 
been performed with NPs to date have yielded inconclusive results; reporting 
effects at the cellular, subcellular, protein and gene levels (Sanvicens and 
Marco, 2008). For example, Sayes et al found that nano-C60 particles disrupted 
the plasma membrane (Sayes et al., 2005), whereas Lovric et al found that 
unmodified QDs damaged the plasma membrane, mitochondria and nucleus 
(Lovric et al., 2005). In contrast to these studies, Qian et al reported no toxicity 
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or physiological complications when PEGylated AuNPs were administered to nude 
mice (Qian et al., 2008). However, Su et al reported a dose-dependent toxic 
effect when Au-nanoshells were administered to BALBc mice (Su et al., 2007). 
Conner et al have voiced concerns that due to the size similarity of AuNPs to 
biological matters, they could be disguised against cellular barriers and gain 
unintended entry into cells, leading to toxic side effects (Connor et al., 2005). In 
relation to this idea, Pan et al have reported that AuNP cytotoxicity is size 
dependent (Pan et al., 2007). This latter study systematically investigated the 
effect of AuNP size on four cell lines: HeLa cervix carcinoma epithelial cells, Sk-
Mel-28 melanoma cells, L929 mouse fibroblast, and J774A11 mouse 
monocytic/macrophage cells. They found that AuNPs 1-2nm in size displayed cell 
type dependent cytotoxicity, whereas in another study, AuNPs 15nm in size did 
not (Chen Pc, 2008). Other investigations have suggested that NP toxicity is 
related to various factors, including cationic side chain attachment (Goodman et 
al., 2004), concentration (Kirchner et al., 2005), geometry (Cui et al., 2005) and 
surface modifications (Hoshino et al., 2007). In relation to AuNPs, Conner et al 
have concluded that their toxicity varies depending on the nature of the NP 
surface coating (Connor et al., 2005; Sanvicens and Marco, 2008). Sanvicens et 
al conclude that NPs must be analysed on a particle-to-particle basis using a 
strategy that tests adsorption, distribution, metabolism and excretion, together 
with physiochemical and toxicological in vitro and in vivo studies (Sanvicens and 
Marco, 2008). Crosera et al conclude that the classic investigation protocols 
must be adapted and re-standardised to the new nanosized compounds (Crosera 
et al., 2009). 
1.4.7 3D Research 
During the past decade, the majority of nanotoxicology research has focused on 
2D cell culture systems (Fischer and Chan, 2007). However, Fischer et al suggest 
that the data from these studies could be misleading and will require 
verification from animal studies (Fischer and Chan, 2007). This is because 2D cell 
systems do not adequately mimic the 3D environment of healthy and tumour 
tissues (Balis, 2002). It is becoming apparent that understanding the relationship 
between the nanostructure and its in vivo behaviour are essential when 
assessing, and predicting nanotoxicity (Fischer and Chan, 2007). An elegant 
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solution to this requirement of lengthy and expensive in vivo nanotoxicity testing 
is to use human tissue equivalents as an alternative to animal testing. An 
established example of this strategy is the use of fibroblast-seeded collagen 
gels. Bell et al first published the use of fibroblast-seeded collagen gels in 1979, 
demonstrating the cell-mediated contraction of the matrix into a denser, 
‘tissue-like’ structure (Bell et al., 1979). Since then, many researchers have 
replicated these findings, including R.A. Brown (Hadjipanayi et al., 2009; 
Marenzana et al., 2002), M. Eastwood (Eastwood et al., 1998), F. Grinnell 
(Grinnell et al., 1999b; Grinnell et al., 2003; Grinnell et al., 1999a; Grinnell, 
2003) and C.C. Berry (Berry et al., 2003; Berry et al., 2009b). It is only very 
recently, however, that such cell-seeded collagen gels have been adopted for 
use in nanotoxicity testing. For example, Mertsching et al, have developed a 3D 
skin equivalent model that is physiologically comparable to natural skin 
(Mertsching et al., 2008) and suitable for toxicity studies. This model is 
composed of primary human keratinocytes on a collagen substrate containing 
human dermal fibroblasts. It is grown at the air-liquid interface, facilitating 
complete epidermal stratification and epidermal-dermal interactions to occur. 
The authors state that this in vitro skin equivalent will be an excellent model for 
toxicity testing, tumor modeling, infection testing, and wound healing 
(Mertsching et al., 2008). 
1.5 Future Perspective 
With the advent of RNAi, gene replacement therapy and a host of new small 
molecule drugs, achieving the correct delivery of these novel therapeutics to 
diseased cells within a patient’s body still remains a major hurdle to achieving 
targeted disease treatment. NPs are set to facilitate this delivery, since they 
provide inherent protection, tailored multifunctionality, multivalency and 
theranostics. These qualities are allowing the development of very complex and 
clever NP designs for systemic delivery, which can protect therapeutic cargo 
from degradation during circulation within the bloodstream, recognise the 
correct disease cells via the binding of targeting moieties, facilitate cell uptake 
by CPPs, provide imaging by dyes or MRI, induce thermal ablation of tumours by 
NIR, and promote drug release once inside diseased cells. Needless to say, the 
design of NP-delivery systems is progressing well. These designs now need to 
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undergo extensive testing within human cell lines and suitable in vivo models, to 
ensure they function as intended. Before NP-mediated delivery of novel 
therapeutics (such as siRNA) can be routinely performed in the clinic, much 
more needs to be learnt about the cellular interactions of NPs in terms of 
toxicity, uptake, drug efficiency and effect of treatment on disease progression. 
Once these issues are resolved, widescale NP-mediated targeted disease 
treatment will no doubt become a reality. 
1.6 Aims 
This PhD has involved two separate projects, each investigating a different NP 
delivery system in order to assess their potential to be used for in vivo drug 
delivery. The first project focused on iron mNP delivery in 3D, and the second 
project focused on AuNPs for c-myc knockdown by RNAi. 
 
Aims of Project 1: Iron mNP Delivery in 3D 
• To develop and characterise cell-seeded Type 1 collagen gels as a tissue-
equivalent 3D cell culture system for the testing of NP delivery into 
tissue.  
• To determine if a magnetic field and the CPP penetratin can be used to 
increase the delivery of 100 and 200nm iron oxide mNPs to cells growing 
within 3D collagen gels. 
 
Aims of Project 2: AuNPs for c-myc Knockdown by RNAi 
• To assess the therapeutic potential of a range of AuNP formulations, 
featuring stepwise addition of PEG, Tat and c-myc siRNA, as were 
synthesised by grant partners. AuNPs were assessed in 2D monolayer cell 
culture on the basis of 4 main criteria; cellular toxicity, cellular uptake, 
c-myc knockdown and effect on the cell cycle. 
 
 
 
 
 
 
                                                                                                                           41 
2 Materials and Methods 
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2.1 Materials 
2.1.1 Atomic Force Microscopy (AFM) 
Silica microsphere 4.8!m     Microparticles GmbH, Berlin 
Tipless silicon nitride cantilever    Arrow-TL1, NanoWorld 
UV curable glue      Loctite 349 
AFM, NanoWizard II Bio      JPK Instruments, Berlin 
2.1.2 Antibodies 
Primary Antibodies 
• Anti-c-myc antibody [9E10]  Abcam 
 ChIP Grade (ab32) (murine)        
Used in Western blot at 1:500 
  
• Anti-GAPDH Rabbit Monoclonal  Epitomics 
      antibody (clone EPR6256) 
Used in Western blot at 1:10,000 
 
• Amersham Monoclonal anti-  GE Healthcare 
        Bromo-deoxyuridine  
     (clone BU-1) (murine) 
 Used to detect BrdU at 1:100        
 
Secondary Antibodies 
• Goat anti-mouse IgG-HRP (sc-2032) Santa Cruz Biotechnology 
Used in Western blot (c-myc) at 1:4000  
 
• Goat anti-rabbit IgG-HRP (sc-2030) Santa Cruz Biotechnology 
Used in Western blot (GAPDH) at 1:4000  
 
• Biotinylated anti-mouse    Vector Laboratories, Inc 
Used in BrdU assay at 1:50  
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Tertiary Antibodies 
• Streptavidin-FITC    Vector Laboratories, Inc 
Used in BrdU assay at 1:50   
2.1.3 Cell Culture  
Trypsin      Sigma 
Versine      (made in house) 
Fetal Bovine Serum (FBS)    Lonza      
10x DMEM      Sigma 
Type 1 collagen      First Link UK Ltd  
0.1M NaOH (liquid)     Sigma 
Needle (1.2mm x 40mm)    BD Microlance 3    
13mm glass coverslips    (from stores) 
Incubator (CO2 water jacketed incubator) Forma Scientific  
Dulbeco’s Modified Eagle Medium (DMEM) Sigma 
Medium 199       Sigma 
L-Glutamine 200mM (100x) liquid   Invitrogen    
Sodium pyruvate     Life Technologies, UK 
Penicillin streptomycin    Sigma 
Opti-MEM® I Reduced Serum Media   Invitrogen 
2.1.4 Electron Microscopy (EM) 
Thermanox coverslips     Thermo Scientific 
Gluteraldehyde (25% aqu Pure, EM Grade) Sigma 
Sodium cacodylate      Agar Scientific Ltd UK 
Osmium tetroxide     Agar Scientific Ltd UK 
Phosphate buffer      VWR International Ltd 
Uranyl acetate      Agar Scientific Ltd UK 
Propylene oxide     VWR International Ltd 
Resin (812 Kit E202)      TAAB Lab Equipment Ltd UK  
Methanol      Sigma 
Reynolds lead citrate    Agar Scientific Ltd UK 
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Alcohol increments (30-100% (dry))   AnalaR NORMAPUR, VWR BDH  
Molecular sieve     Sigma 
Hexamethyl-disilazane     TAAB Lab Equipment Ltd. UK 
Carbon coated grids    Agar Scientific Ltd UK   
2.1.5 General Reagents 
5-Bromo-2’-deoxyridine (BrdU)    Calbiochem 
DMSO        Sigma 
Ethanol absolute      AnalaR NORMAPUR, VWR  
Lipofectamine 2000     Invitrogen 
LIVE/DEAD® Viability/Cytotoxicity kit  Invitrogen 
Methanol, analytical reagent grade   Fisher Scientific 
MTT        Sigma 
Nitric acid (70%), analytical reagent grade Fisher Scientific 
Rhodamine phalloidin     Invitrogen Molecular Probes 
siRNA (c-myc and nonsense)   Thermo Scientific Dharmacon 
PBS tablets      Sigma 
Sucrose      Fisher Scientific 
NaCl       AnalaR NORMAPUR 
MgCl2 (hexahydrae)     AnalaR NORMAPUR 
Hepes       Fisher Scientific 
Triton® X-100     Sigma     
Formaldehyde (40%)    Fisher Scientific  
BSA (Albumin, from Bovine serum)  Sigma 
Tween® 20      Sigma 
Sodium deoxycholate     Sigma 
Sodium Dodecyl Sulphate (SDS)   BDH 
Protease inhibitor (10X)     Roche 
Phosphatase inhibitor (10X)   Roche 
ß-mercaptoethanol     BDH AnalaR 
Powdered milk  (dried, skimmed)  Marvel 
Glycine      BDH 
KCl       BDH AnalaR 
D-Glucose      Fisher Scientific  
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EDTA       Sigma   
Phenol red      Sigma 
NaOH  (powder)     Fisher Scientific 
TRIZMA® base     Sigma 
2.1.6 Histology 
Paraffin wax      Leica UK 
Polysine coated slides     CellPath, UK  
Oven       Thermo, UK 
Xylene      Genta Medical, UK 
Graded alcohols (100%, 70%)    Genta Medical, UK 
Haematoxylin & Eosin (H&E) 
 - Haem     CellPath, UK  
 - Eosin     Sigma    
Martius Scarlet Blue (MSB)    TCS Biosciences 
Perls Prussian blue      Leica Microsystems 
2.1.7 Iron Nanoparticles (mNPs) 
100 and 200nm, nano-screenMAG/G-PEA Chemicell GmbH 
MagnetoFACTOR-96 device    Chemicell GmbH 
2.1.8 Microscopes 
Axiovert 25 light microscope    Zeiss 
Axiophot fluorescence microscope  Zeiss 
Leitz DMRB fluorescence microscope  Leica  
Observer A1 inverted optical microscope Zeiss 
LSM 510 META confocal microscope   Zeiss 
Leo 912 AB TEM     Zeiss 
Jeol 6400 SEM     Jeol Ltd 
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2.1.9 Quantitative Real-Time PCR (qRT-PCR) 
RNeasy® Micro kit      Qiagen 
QuantiTect® Reverse Transcription kit   Qiagen 
Taqman® master mix     Applied Biosystems 
Primers and Probes     Eurofins MWG Operon 
Abi Prism 96-well plates     Applied Biosystems 
Real-time PCR, 7500 System    Applied Biosystems 
2.1.10 Scientific Instruments 
ICP-MS       THERMO X Series II 
NanoDrop-1000 V3.7.1    Thermo Scientific 
Plate reader       Dynatech MR7000 
Rheometer       CSL500 Carri-Med Rheometer 
Vortex       Fisions Whirlimixer 
Zetasizer      Malvern 
2.1.11 Western Blot 
Medical X-ray film     Kodak 
Light-proof cassette    Harper LONDON 
Sponge pads      Invitrogen 
Filter paper       Whatman 
Transfer membrane     Immobilon  
NuPAGE® 4-12% Bis-Tris gels   Invitrogen 
NuPAGE® LDS Sample Buffer (4X)   Invitrogen 
NuPAGE® Transfer buffer (20x)   Invitrogen 
NuPAGE® MOPS SDS Running Buffer (20X) Invitrogen 
NuPAGE® Antioxidant     Invitrogen 
SeeBlue® Plus2 Prestained Standard   Invitrogen 
Immobilon™ Western chemiluminescent  Millipore 
HRP Substrate 
Novex Mini Cell tank apparatus   Invitrogen 
Power pack      PowerEase 500 
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Heating block      Techne Dri-Block DB.2A 
X-Omat Processor      Kodak 
Scanner, Perfection V500 Photo   Epson 
Shaker, Vibramax 100    Heidolph Instruments    
2.2 General Solutions 
PBS 
1 x PBS tablet dissolved in 200ml H2O 
 
Permeabilising buffer 
100ml PBS 
10.3g sucrose 
0.292g NaCL 
0.06g MgCl2 (hexahydrae) 
0.476g Hepes 
pH adjusted to 7.2, followed by the addition of 0.5ml Triton X 
 
Fixative 
90ml PBS 
10ml (38%) formaldehyde 
2g sucrose 
 
PBS/BSA 
100ml PBS 
1g BSA 
 
PBS/Tween 
100ml PBS 
0.5ml Tween 20 
 
RIPA buffer 
45ml H2O 
150mM NaCl 
50mM TRIZMA® base 
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0.5ml Triton 1% (t-Octyl phenoxy polyethoxy ethanol) 
0.5g Sodium deoxycholate 1% 
0.05g SDS 1% (Sodium Dodecyl Sulphate) 
Make up to 50ml with H2O 
 
Protein Extraction Buffer (PEB) 
1ml RIPA buffer 
100!l Protease inhibitor (10X stock) 
100!l Phosphatase inhibitor (10X stock) 
 
Sample Loading Buffer 
950!l NuPAGE® LDS Sample Buffer (4X)  
50!l ß-mercaptoethanol 
 
Running buffer 
50ml 20X NuPAGE® MOPS SDS Running Buffer 
950ml H2O 
 
Transfer buffer 
50ml 20X NuPAGE® Transfer buffer 
100ml methanol 
850ml H2O 
1ml NuPAGE® antioxidant 
 
PBS-Tween 
5x PBS tablets 
1L H2O 
1ml Tween 20 
 
Blocking buffer 
30ml PBS-Tween 
1.5g Marvel milk  
 
Stripping buffer 
25mM Glycine, pH 2.5 
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Versine 
1L H2O 
8g NaCl 
0.4g KCl 
1g glucose 
2.38g Hepes 
0.2g EDTA 
2ml 0.5% phenol red 
Adjusted to pH 7.5 with 5M NaOH 
Dispensed into 20ml aliquots and autoclaved 
Stored at 4°C 
 
Electron Microscopy fixative (EM fixative) 
1.5% gluteraldehyde in 0.1M sodium cacodylate 
2.3 Cell Culture 
2.3.1 Human Cell Lines 
Fibroblasts 
• h-TERT-BJ1 cells   Clontech Laboratories, Inc. 
Breast Cancer 
• MCF-7 cells    Sigma   
Cervical carcinoma 
• HeLa cells    Gifted from Prof Gwyn Gould   
     (The University of Glasgow) 
 
2.3.2 Media 
Bj5-ta, h-TERT and MCF-7 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM), supplemented with 17.5% Medium 199, 10% FBS, 0.5% 100mM 
sodium pyruvate, and 1% penicillin streptomycin. 
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HeLa cells were grown in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with 10% FBS and 2mM glutamine. 
 
Cells were grown in T75 flasks in complete medium and passaged by 
trypsinization when confluent. Cells were cultured at 37°C with 5% CO2.  
2.4 General Methods 
2.4.1 NP Characterisation 
A 2µl aliquot of each NP sample (0.1mg/ml in MilliQ H2O) was dried onto a 
carbon-coated grid and viewed under the TEM at 120kV, at 40,000x 
magnification. In addition, NP size and charge were characterised by dynamic 
light scattering (DLS) and zeta potential respectively on a Malvern Zetasizer 
following manufacturers guidelines. 
2.4.2 Toxicity Testing (MTT Assay) 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a yellow 
tetrazole. The MTT assay is a colorimetric assay for measuring the activity of 
enzymes that reduce MTT to formazan dyes, producing a purple colour. The 
strength of this enzymatic activity and resulting purple colour can be used as an 
indication of cellular viability, and used to check for any cytotoxicity caused by 
a test substance, such as NPs. Cells were seeded at 1 x 104 cells per well in a 96 
well plate and allowed to adhere overnight. AuNP treatments were added (75µl 
at various test concentrations) and incubated with the cells for 24, 48 or 72 
hours (control cells were incubated with media instead). After treatment 
incubation, cells were washed with warmed PBS; 100µl MTT solution was added 
per well (0.5mg/ml MTT powder in PBS) and cells were incubated for 1.5 h at 
37°C. MTT solution was removed, and replaced with 100µl DMSO. Cells were left 
for 10 min at room temperature and then the absorbance (Abs) was read at 
550nm using a plate reader. 
 
MTT data analysis: Percentage viability was calculated using the following 
equation: (Abs NP-treated cells / Abs control cells) x 100 = % viability) [n=3]  
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2.4.3 Uptake Analysis 
2.4.3.1 Transmission Electron Microscopy (TEM) 
Cells were seeded at 1 x 105 cells per well on Thermanox coverslips in a 24 well 
plate and allowed to adhere overnight. NP treatments were added to 
coverslips/gels (500µl at 0.2mg/ml) and incubated for 1, 18, 24 or 48 hours 
(control cells were incubated with media instead).  
 
TEM processing of 2D/3D cell cultures 
Coverslips/gels were covered in 1ml EM fixative and left at 4°C for 30 min, then 
post fixed in 1% osmium tetroxide in phosphate buffer for 1 h, followed by 0.5% 
uranyl acetate for 1 h and then dehydrated through a series of alcohol 
increments (30 – 100%) and left in propylene oxide Epon 812 resin mix (1:1) 
overnight. Samples were put into pure resin and kept in an oven for 24 h to cure. 
Blocks were then cut into ultrathin sections, stained with 2% methanolic uranyl 
acetate and Reynolds lead citrate, and viewed under the TEM at 120kV. 
2.4.3.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
• Background 
ICP-MS, also known as element analysis, is a branch of mass spectrometry that 
can measure and quantify trace levels of a specified element. It is a popular 
choice commonly used to analyse the levels of NP cellular uptake; its main 
advantage being that it is highly quantitative compared to microscopy. The most 
commonly published method for ICP-MS analysis of NP cellular uptake is to 
measure the NP-element level in the cells after they have been incubated with 
the NP treatment. This involves removing the cell monolayer from the NP 
treatment, degrading all cellular organic matter with a strong acid and 
measuring the remaining amount of NP-element present in each sample. It 
follows that if more NPs have been taken up into the cell monolayer, then more 
NP-element will be present in the end sample.  
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A modified version of this method was used in this PhD to analyse the levels of; 
 
1) mNP (iron) uptake into 3D gels (results presented in Figure 3-8) 
2) mNP (iron) uptake into 2D cell monolayers (results presented in Figure 3-9) 
3) AuNP (gold) uptake into 2D cell monolayers (results presented in Figure 4-11B) 
 
To facilitate this work, a collaboration was set up with the chemistry 
department at the University of the West of Scotland (UWS) in Paisley.  
It was realised that acidic degradation of 3D collagen gels could not be 
performed as effectively as acidic degradation of 2D cell monolayers. Therefore, 
the original published method described above had to be modified; particularly 
since the introduction of any organic matter resulting from partially-degraded 
gel debris to the mass spec may prove detrimental.  
 
• Modified ICP-MS Method 
An alternative method was therefore introduced and applied to both 2D and 3D 
cell cultures (in the following description, ‘cell culture’ is used to refer to both 
2D cell monolayers and 3D cell cultures). 
 
The level of NP-element found in the spent media after incubation with the cell 
culture was analysed by ICP-MS. In addition, the amount of NP-element found in 
the neat NP-treatment (incubated without the cell culture) was also measured. 
These values were used in the following equation to calculate the amount of NP-
element uptake into the cell culture; 
 
Element uptake = (element level after incubated without cell culture) - 
(element level after incubated with cell culture) 
 
• Cell Culture Procedures 
 
2D Cell Monolayer  
Cells were seeded at 1 x 104 in a 96 well plate and allowed to adhere overnight. 
Media was replaced with NP treatments (75µl at 0.1mg/ml in DMEM). In an 
identical manner, each NP treatment was also incubated without cells, for 
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comparison (graphed as 0 hour time point). Incubation was performed for 1 or 18 
hours.  
 
3D Gel Culture 
Gel media was replaced with NP treatments (75µl at 0.1mg/ml in DMEM). In an 
identical manner, each NP sample was also incubated without gels, for 
comparison (graphed as 0 hour time point). Incubation was performed for 1 or 18 
hours.  
 
• ICP-MS Sample Processing 
After incubation, the treatment media from each sample was removed and 
added to 1ml of H2O, together with 100µl H2O that had been use to wash the 
cells and wells. Samples were treated with 1ml of 70% nitric acid and then 
heated in a water bath at 70°C overnight. After heating, samples were cooled 
and then diluted to 50ml with H2O (MilliQ H2O used throughout). Samples were 
analysed using ICP-MS at the UWS.  
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3.1 Introduction 
Disease treatments, such as chemotherapy, currently lack specificity (Parveen 
and Sahoo, 2008; Sawant and Torchilin, 2010), thus cytotoxicity is a common 
problem as the drugs administered attack both healthy and diseased cells alike. 
It is hoped that NPs can be used to solve this problem by carrying and delivering 
drugs specifically into diseased cells, thereby preventing the attack of healthy 
cells and improving drug efficacy (Ahmad et al., 2010; Berry and Curtis, 2003). 
In addition, it is anticipated that NP-mediated delivery of nucleic acids will 
enable the long-awaited clinical use of gene therapy. Two of the biggest 
problems currently facing NP-mediated drug delivery are the site-specific 
targeting and subsequent cellular uptake of NPs within the body (e.g. into 
cancerous cells within a tumour).  
 
One favourable method to improve NP targeting is to distally control their 
movement within the body through the application of an external magnetic field 
(MF) (Widder et al., 1978b). Magnetic nanoparticles (mNPs), such as those 
composed of iron oxide, are ideal for use in this targeting strategy since they 
display good biocompatibility (Jain et al., 2008), strong magnetism (Corchero 
and Villaverde, 2009), useful imaging properties (such as MRI) (Wu et al., 2010), 
ease of functionalisation and have been extensively researched in vitro (Dobson, 
2006a). The effectiveness of mNP-mediated magnetic targeting has already been 
exemplified in vitro by its widescale use as a research tool for gene 
transfection, this popular technique being coined ‘magnetofection’ (Plank et al., 
2003; Mah et al., 2000; Pickard and Chari, 2010). In light of the efficiency of 
mNP-targeting already seen in vitro it is hoped that a MF can be used in the 
same way in vivo to successfully target mNPs to the site of disease within a 
human body.  
 
Once at the site of disease, NPs face the second problem of cellular uptake; an 
essential feat required for delivery of their therapeutic payload. NP 
functionalisation with cell penetrating peptides (CPPs) is a promising solution to 
this hurdle (Berry, 2008). CPPs, such as Tat and penetratin, are short, highly 
basic, peptide sequences (<20 amino acids), able to promote conjugated cargo 
transport across the plasma membrane (Schwarze and Dowdy, 2000; Derossi et 
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al., 1994). Their ability to promote cellular uptake of NPs was first reported in 
1999 when Josephson et al demonstrated a 100-fold increase in Tat-
functionalised mNP uptake as compared to plain NPs (Josephson et al., 1999). 
Since then, increased cellular uptake of NPs functionalised with CPPs has been 
repeated in numerous in vitro studies (Smith et al.; De La Fuente and Berry, 
2005; Berry et al., 2009a). However, despite such encouraging findings, CPPs are 
not receptor-dependent and thus, not cell-specific (Deshayes et al., 2005). 
Therefore, to enable site-specific drug delivery they will need to be used in 
conjunction with a targeting strategy, such as a MF.   
 
This chapter has investigated the combined use of a 280mT MF with a CPP 
(penetratin) in order to simultaneously improve both targeting and uptake of 
mNPs to human fibroblasts in 3D. Previous theoretical studies have calculated 
that in order to facilitate in vivo magnetic targeting of mNPs, the magnetic flux 
density (field strength) at the target site must be in the order of 200-700mT in 
order to efficiently capture particles flowing in the blood stream (Voltairas et 
al., 2002; Pankhurst et al., 2003; Mykhaylyk et al., 2008; Dobson, 2006a). This 
suggests that the 280mT MF used in this study is of a suitable strength to induce 
movement of mNPs through a 3D tissue. The majority of magnetofection studies 
described in the literature have also used MF strengths within this recommended 
range of 200-700mT. For example Alexiou et al used a 400mT MF to pull mNPs 
into HeLa cells (Alexiou et al., 2005), Lamkowsky et al used a 367mT MF to pull 
mNPs into astrocytes ((Lamkowsky et al., 2012), Ang et al used a 130mT MF to 
transfect COS-7 cells (Ang et al., 2011b), del Pino et al used a 130-240mT MF to 
deliver siRNA to HeLa and H441 epithelial cells (Del Pino et al., 2010) and Darton 
et al used a 500mT MF to capture mNPs in flow (Darton et al., 2008).  
 
In comparison, the numerous studies into magnetic delivery of mNPs to 2D cell 
monolayers performed by Christian Plank’s group have used a stronger MF of 
1080-1150mT (Scherer et al., 2002; Plank et al., 2003; Gersting et al., 2004), 
which is similar to the 1-1.2T magnetic field produced by magnetic plates from 
Oz Biosciences, which have been used in numerous 2D magnetofection studies 
(Buerli et al., 2007; Mykhaylyk et al., 2007).  
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It would appear that although some groups are using higher MF strengths of 
around 1T for 2D magnetofection (being comparable to the high MF strength of 
1.5T required for conventional MRI scanners), lower strength MFs within the 
recommended range of 200-700mT are perfectly sufficient for magnetic 
targeting of mNPs. Evidence for this statement is that upon comparison of MF 
strengths of up to 250mT, Ang et al found that 130mT was an optimal MF 
strength to achieve maximum transfection efficiency in 2D in vitro cell cultures 
(Ang et al., 2011a). In addition, an important in vivo study by Kumar et al found 
that a relatively weak MF of only 2.5mT (~460x weaker than that used in Plank’s 
2D studies) was sufficient to target mNPs in the heart and kidneys of rats after 
intravenous injection into the tail (Kumar et al., 2010), bringing into question 
the need for higher-strength MFs to achieve in vivo magnetic targeting, and 
highlighting the useful information that can be gained from testing delivery 
strategies in vivo. 
 
The novelty of the work presented in this chapter lies in the use of a well 
established 3D tissue-equivalent model whereby cells are cultured within a type-
1 collagen gel matrix (Bell et al., 1979). The use of this 3D model provides a cell 
culture environment that is more comparable to in vivo tissue than are 
traditional 2D monolayer cultures. This is important, since research in 2D 
monolayer cell cultures may not reliably predict later-stage clinical responses to 
therapeutic NPs (Zhang et al., 2010). This is because in the latter scenario cells 
are surrounded by and interact with the extracellular matrix (ECM), which can 
produce phenotypic differences - altering behaviour to that observed in 
monolayer cell culture. Therefore, 2D testing of NP-delivery systems is 
ultimately of limited use as NP behaviour may be very different once introduced 
into a living system. The 3D study reported in this chapter therefore provides a 
more accurate prediction of how a MF and a CPP (in this case penetratin) could 
be used to deliver drug- loaded mNPs to diseased cells inside the human body.  
 
Results demonstrated that while a MF increased the rate and depth of mNP 
uptake into the gel, penetratin encouraged cell-NP association and subsequent 
cellular uptake. Thus a combination of both techniques would be recommended 
for therapeutic drug delivery in vivo.  This study represents an important 
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stepping-stone in the journey from traditional 2D research towards the 
development of a NP-based drug delivery system for clinical use.   
3.2 Aims 
The aim of this study was to investigate if an external MF and/or penetratin can 
be used to improve mNP-delivery to cells growing in a 3D environment, as they 
have previously been demonstrated to do in 2D monolayer cell culture. As such, 
this study provides a more realistic assessment of how these techniques might 
perform in future clinical settings.  
3.3 Methods 
3.3.1 mNP Design and Synthesis 
The mNPs used in this project were commercially sourced in two different sizes; 
100 and 200nm. The design of these commercial mNPs involved a magnetic iron 
oxide core encased by two outer molecular shells containing green-lipophilic 
fluorescent dye and a polysaccharide matrix. After purchase from Chemicell, 
aliquots of 100 and 200nm mNPs were sent to grant partners in Spain, who 
further functionalised them with the CPP penetratin. This provided a total of 
four mNP samples for use in this project; 100nm plain, 100nm penetratin, 200nm 
plain and 200nm penetratin (Figure 3-1). 
 
 
Figure 3-1 Schematic outline of the mNP design 
This figure demonstrates the main design features of the mNPs used in this project. As 
bought from Chemicell, the mNPs have a magnetic iron oxide core surrounded by a 
fluorescent dye and a polysaccharide matrix. Grant partners attached the CPP penetratin. 
This mNP design was bought in two sizes; 100 and 200nm, and each was functionalised 
with penetratin. Therefore this chapter involves a total of four mNP samples; 100nm plain, 
100nm penetratin, 200nm plain and 200nm penetratin. 
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3.3.1.1 mNP Functionalisation with Penetratin (provided by grant 
partners) 
Iron oxide magnetic green-fluorescence nanoparticles (100 and 200nm, nano-
screenMAG/G-PEA) were bought from Chemicell GmbH (article no. 4417). The 
amine groups of each mNP sample were activated with sulfosuccinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (sulfo-SMCC) for further 
functionalisation with the peptide penetratin. The amount of penetratin added 
aimed to derivatise 1000 of the activated amino groups on the 100nm mNPs, and 
7800 on the 200nm mNPs. This difference was to allow for the difference in 
surface area between the two sizes of mNPs. Therefore, supposing that the  
sulfo-SMCC activation and the peptide coupling worked 100%, the mNP to 
penetratin molar ratio is [1:1000] for the 100nm size, and [1:7800] for the 
200nm size. Both sizes were prepared to a final concentration of 1mg/ml of 
mNPs in H2O.   
3.3.1.2 Reaction Details (provided by grant partners) 
Ice cold buffer was prepared (100mM 2-(N-morpholino)ethanesulfonic acid (MES), 
150mM NaCl, pH 7.2) containing 500!g of sulfo-SMCC (article no. 22322 from 
Pierce)). 335!l from a 30mg/ml stock solution of 100nm mNPs was added to 
165!l buffer and 290!l from a 35mg/ml stock solution of 200nm mNPs was added 
to 210!l of buffer, to permit functionalisation of the 100nm and 200nm mNPs 
respectively. The two reaction mixtures were incubated for 30 minutes at room 
temperature and then 15!l from a 5mg/ml solution of activated Penetratin 1 
(cat. no. PENA0500 from MP Biomedicals) was added to each. The reaction 
mixtures were incubated overnight at 4° C. The functionalised nanoparticles 
were washed by magnetic precipitation with the previously used buffer to 
remove excess of sulfo-SMCC and peptide. Their final volume was adjusted to 
1ml (Table 3-1).   
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mNP size mNP concentration ~Molar ratio Penetratin 
added 
~Molar ratio 
(nm) (mg/ml)  (mM) (mNP:sulfoSMCC)  (mM) (mNP:added 
penetratin) 
 
100 
 
10 
 
30 x 10-3 
 
[1.38 x 103] 
 
29 
 
[1:1 x 103] 
 
200 
 
10 
 
3.7 x 10-3 
 
[1.310 x 103] 
 
29 
 
[1:7.8 x 103] 
Table 3-1 Chemical description of mNPs after functionalisation with penetratin 
The concentration of mNPs in each 1ml sample is displayed in both mg and molarity. The 
molar ratio of mNPs to sulfo-SMCC used for amine activation is shown. The concentration 
of penetratin in each 1ml sample and the molar ratio of mNPs to penetratin is also shown.  
3.3.2 MagnetoFACTOR Plate 
A MagnetoFACTOR plate was purchased from Chemicell for use with the mNPs. 
The plate is designed to be positioned underneath a 96-well cell culture plate, 
and exerts a 280mT strength magnetic field through the plate, in order to pull 
nanoparticles through any cell culture systems being grown inside the plate. In 
this project, gels were synthesised in 24 well plates, so that when fully 
contracted, they were small enough to fit inside the wells of a 96-well plate, 
which could then be placed on top of the MagnetoFACTOR plate, as shown in 
Figure 3-2. N.B [Calculations performed by Furlani and Xue confirm that the MF 
used can cover the whole thickness of 3D gels (Furlani and Xue, 2012).] 
 
Figure 3-2 MagnetoFACTOR plate 
This photograph shows the MagnetoFACTOR plate purchased from Chemicell (bottom right) 
that was placed underneath 96-well cell culture plates (top left) in order to exert a 280mT 
magnetic field through 3D collagen gels placed inside wells within the 96-well plate. This 
acted to pull mNPs through the gel, towards the underlying magnets. 
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3.3.3 Cell Seeded Collagen Gel Synthesis 
Gels were made in batches of 6 by mixing (on ice) 0.5ml FBS, 0.5ml 10x DMEM, 1 
x 106 human fibroblast cells (h-TERT BJ-1) suspended in 0.5ml complete 
medium, 2.5ml Type 1 collagen (2mg/ml) and 3.5ml 0.1M NaOH (to neutralise 
and solidify collagen). Gel mixture was vortexed, pipetted into a 24 well plate 
(1ml per well) and incubated at 37°C overnight to solidify. A needle was run 
around the edge of each solid gel to detach it from the plastic. Fresh media was 
added and changed daily. Following diameter measurements, gels were used in 
experiments four days after detachment to allow full gel contraction. The 
diameter measurements recorded for a typical gel are presented in Figure 3-3. 
 
 
Figure 3-3 Gel contraction 
Photographs of 3 gels made within a 12-well cell culture plate are shown in A (each well has 
a diameter of 22mm). The top three images were taken immediately after detachment of gels 
from plastic using a needle, and the bottom three images were taken 48 hours later, when 
the gels had contracted to roughly half their original size. Diameter measurements of a 
typical gel were recorded using a ruler every 24 hours for a 144 hour period, and are 
presented graphically in B. [N.B. For experiments gels were made to a smaller size within 24 
well plates in order to fit on the magnetoFACTOR plate. The same pattern of contraction 
was displayed, with gels reducing to half their original diameter after 48 hours.] 
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3.3.4 Gel Characterisation 
3.3.4.1 Rheology 
Rheology was used to measure the elastic modulus (G!) and viscous modulus (G") 
of the gels in order to verify their mechanical properties and gauge their 
elasticity/stiffness. This was performed to assess if the composition of the gel 
was suitably comparable to the stiffness of natural human tissue in order to be a 
reliable tissue-equivalent model. Dynamic frequency sweep experiments were 
carried out on a strain-controlled rheometer using a parallel-plate geometry 
(20mm diameter). The experiments were performed at 25°C and this 
temperature was controlled throughout the experiment using an integrated 
electrical heater. Extra precautions were taken to minimize solvent evaporation 
and to keep the sample hydrated by using a solvent trap and by saturating the 
internal atmosphere with H2O. To ensure the measurements were made in the 
linear viscoelastic region, an amplitude sweep was performed and the results 
showed no variation in elastic modulus (G!) and viscous modulus (G") up to a 
strain of 0.01%. The dynamic modulus of the gel was measured as a frequency 
function where the frequency sweeps were carried out between 1 and 40Hz. 
Measurements were repeated at least three times to ensure reproducibility. Gels 
were not fixed before use. 
3.3.4.2 Atomic Force Microscopy (AFM) 
AFM was used to measure the Young’s modulus of the gels in order to compare 
their elasticity/stiffness to that of human tissue. Analysis was carried out with a 
NanoWizard II Bio AFM mounted on a Zeiss Observer A1 inverted optical 
microscope. The complete set-up was acoustically isolated in order to reduce 
the interference of ambient noise during the measurements. The probes used for 
the indentations were prepared in-house by attaching a 4.8!m silica microsphere 
to a tipless silicon nitride cantilever using a UV curable glue. Before any 
measurements were recorded the spring constant of the modified cantilever was 
determined using the thermal calibration method according to the AFM user 
manual. The value was 0.121 N/m. Force-indentation curves were carried out at 
10!m/sec with a 10!m Z-ramp until a maximum force of 5nN was reached. 
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Three positions spread evenly across the surface of the gel were selected for 
indentation measurements. Gels were not fixed before use. 
3.3.4.3 Scanning Electron Microscopy (SEM) 
SEM was used to image the gel surface in order to investigate cellular 
morphology and the structure of the collagen fibres and pores. Gels were fixed 
in 1.5% gluteraldehyde in 0.1M sodium cacodylate at 4°C for 1.5 hours then 
postfixed in 1% osmium tetroxide for 1 hour. Samples were subsequently stained 
with 0.5% uranyl acetate and dehydrated through a series of alcohol increments 
(30%, 50%, 70%, 90%, 100%, 100% (dry)) and hexamethyl-disilazane. After 
dehydration gels were then air dried and viewed on a Jeol 6400 SEM at an 
accelerating voltage of 6kV, at 1000 or 3000x magnification. 
3.3.4.4 Histology  
Histology was used to obtain a cross-sectional view of the gels, thus allowing 
observation of both collagen and cell density and dispersal in the gel structure. 
Gels were fixed in 4% formaldehyde/PBS with 1% sucrose at 37°C for 15 min, 
submerged in 1ml permeabilisation buffer at 4°C for 15 min and embedded in 
paraffin wax. Sections of 4µm thickness were cut from the gel centre onto 
polysine coated slides and baked at 60°C overnight. Sections were then de-
waxed in xylene for 5 min and rehydrated through graded alcohols (100%, 70%) 
before rinsing with H2O for 5mins. After rinsing, sections were stained with 
Haematoxylin & Eosin (H&E) to display general structures present, or Martius 
Scarlet Blue (MSB) to display fibrin/connective tissue. After staining, sections 
were dehydrated through graded alcohols (70%, 100%), placed in xylene for 1 
min, mounted and imaged on a Zeiss Axiovert 25 light microscope at 10x 
magnification. Histology staining was performed at The Beatson West of Scotland 
Cancer Centre. 
3.3.4.5 Cell Viability 
Cell viability in the 3D gel model was assessed after 96 hours using a live/dead 
staining kit. Gels were incubated at 37°C for 1 hour in 600µl of Calcein AM and 
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ethidium homodimer (1µl/ml in DMEM). Images were taken on a Leica Leitz 
DMRB fluorescence microscope at 10x magnification.  
3.3.4.6 Cell Cytoskeleton F-actin Immunofluorescence 
Immunofluorescent staining was performed to visualise cellular F-actin in order 
to determine cell structure within the gel. Gels were fixed as per section 3.3.4.4 
and then incubated with rhodamine phalloidin (1:50 in PBS/BSA) at 37°C for 1 
hour. Gels were rinsed twice with PBS between each step. Images were taken on 
a Leica Leitz DMRB fluorescence microscope at 20x magnification.  
3.3.5 Uptake Analysis 
For all uptake experiments, contracted gels were transferred to a 96-well plate 
and incubated with 75µl of the mNP solution (0.1mg/ml in DMEM). Control gels 
were incubated with 75µl of DMEM. A static MF was applied by sitting the 96-
well plates on top of a MagnetoFACTOR-96 magnetic plate, which exposed the 
wells to a 280mT magnetic field. Gel-mNP incubation was performed in this 
manner at 37°C for the time periods indicated in each experiment.  
3.3.5.1 Histology  
To identify mNPs in the cell seeded gels, gel-mNP incubation was performed 
with all four mNP species (100nm plain/penetratin, 200nm plain/penetratin) +/- 
a MF, for 18 hours and, following washing in PBS, processed for histology as in 
3.3.4.4. Sections were stained with Perls Prussian blue (stains iron) to visualise 
the mNPs and imaged on a Zeiss Axiovert 25 light microscope at 10 and 40x 
magnification.  
3.3.5.2 Fluorescence Microscopy  
To assess any possible surface localisation of 100nm mNPs, gels were incubated 
with 100nm plain/penetratin mNPs, +/- a MF for 18 hours. Gels were then 
washed twice in PBS and the gel surface was imaged on a Zeiss Axiophot 
fluorescence microscope at 10x magnification.   
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3.3.5.3 Confocal Microscopy  
To assess the depth of 100nm penetratin mNP uptake, gels were incubated with 
100nm penetratin mNPs, +/- a MF, for 1 or 22 hours. After incubation, gels were 
washed twice in PBS and fixed in 4% formaldehyde/PBS with 1% sucrose for 
25mins. A Zeiss LSM 510 META confocal microscope (at 10x magnification) was 
then used to produce a z-stack of each gel composed of sequential images taken 
1µm apart. Each compressed z-stack was analysed from the first image 
downwards through the gel and the depth of mNP penetration was recorded. 
These distances were then averaged (n=3) and used for statistical analysis and 
graphical representation (Figure 3-11).  
3.3.5.4 Transmission Electron Microscopy (TEM)  
To visualise the cellular interaction of 100nm penetratin mNPs, gels were 
incubated with 100nm penetratin mNPs, +/- a MF for 18 hours. Gels were 
sectioned into quarters (to a size which permitted viewing under the 
microscope) and processed as per section 2.4.3.1.  
3.3.5.5 Statistics  
Statistical analysis was performed in SPSS. The ICP-MS data for each size of mNP 
(100 or 200nm) for each time point (1 or 18 hours) was analysed by 1-way ANOVA 
with Dunnett’s test. The confocal data was analysed by 1-way ANOVA with 
Tukey’s test. For the rheology, ICP-MS and confocal data, n=3. In all figures * = 
p<0.05, ** = p<0.01 and *** = p<0.001.  
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3.4 Results 
3.4.1 NP Characterisation  
TEM allowed visualisation of the four mNP species (Figure 3-4). Whilst the sizes 
of the mNPs are described as 100 and 200nm by Chemicell, in TEM both  
species appeared much smaller as only the electron- dense core is visible. Since 
the aggregation seen here could have been caused by the TEM processing, 
additional characterisation was performed using a Malvern Zetasizer. Analysis of 
particle size by dynamic light scattering (DLS) confirmed that the 100nm species 
were not aggregated, but that the 200nm species were slightly aggregated into 
groups of 5-10 particles. This was also reflected in the zeta potential values, as 
the 200nm mNPs had a lower zeta potential than the 100nm mNPs, indicating 
that aggregation was more likely to occur in these samples due to less steric 
repulsion between particles. In addition, an increase in particle negativity as 
measured by zeta potential confirmed the successful attachment of penetratin 
(Table 3-2).   
 
Figure 3-4 TEM images of the four mNP species 
Images represent plain 100nm mNPs (A), 100nm with penetratin (B), plain 200nm mNPs (C) 
and 200nm with penetratin (D). Please note that the polysaccharide matrix, the fluorescent 
dye and the penetratin peptide (16 amino acids) surrounding the mNPs cannot be seen by 
TEM.  Hence this figure shows only the electron-dense iron core of each mNP [scale bar = 
50nm].  
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mNP sample Size (nm) Zeta potential (mV) 
100nm plain 183.2     + 0.7 -27.3    + 0.6 
100nm penetratin 205.5     + 8.1 -31.8    + 0.8 
200nm plain 1902      + 334.5 -8.6      + 0.2 
200nm penetratin 2006.7   + 403 -12.1    + 0.2 
Table 3-2 Zetasizer analysis of mNPs 
Dynamic light scattering (DLS) measured the hydrodynamic diameter of each of the four 
mNPs. These size measurements are larger than those advertised by Chemicell (100nm and 
200nm), however taken together with the TEM images (Figure 3-4) it is clear that this 
difference is not due to larger individual particle size but rather due to slight particle 
aggregation. Please note that the non-aggregated 100nm samples were the main focus of 
this chapter. Furthermore it is noted that (i) the attachment of penetratin does not 
significantly increase particle size, and (ii) the zeta potential increases in negativity with the 
attachment of penetratin, as expected, and confirms peptide attachment.  
3.4.2 Gel Characterisation  
3.4.2.1 Atomic Force Microscopy (AFM) & Rheology   
The Young’s modulus (stiffness) of the gel (fully contracted) was found to be 
2kPa + 1.7 (mean + SD) as measured by AFM, being comparable to the Young’s 
modulus of human fibroblast cells, which is reported as 2- 60kPa as measured by 
AFM (Alonso and Goldmann, 2003). 
 
Rheology is a method of measuring a material’s elasticity (termed it’s elastic 
modulus) through the application of force. In this case, the elastic modulus of 
the gel was found to be between 1-10kPa (Figure 3-5) as measured by rheology, 
being comparable to the elastic modulus of human adipose tissue as tested by 
rheology (3-6kPa) (Discher et al., 2009). The AFM and rheology results presented 
here both demonstrate that the gels have a consistency similar to human tissue, 
highlighting the suitability of this cell culture model for use in realistic 3D 
studies. 
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Figure 3-5 Gel stiffness 
The elastic modulus (G’) and the viscous modulus (G’’) of the gel as measured by rheology 
indicated that G’ lies between 1 and 10kPa - a stiffness in line with human tissue (error bars 
are SD, n=3).  
3.4.2.2 Microscopy Characterisation 
Gels were further analysed to determine cell distribution and viability in the 3D 
construct (Figure 3-6). SEM images showed cells growing in a confluent, parallel 
sheet over the top surface of the gel (Figure 3-6A) with collagen fibres visible 
between the cells (Figure 3-6B). These fibres appeared as a dense, random 
network with pores of less than 5µm in diameter with the cellular extensions 
interacting and probing the collagen fibrous network. Histology cross-sections 
showed cells distributed uniformly throughout the gel (Figure 3-6C and D). The 
surface layer of cells, as was noted in the SEM, was again observable here, 
running along the top edge of the section. The MSB stain indicated that the 
collagen was fibrous in appearance and homogeneous throughout the gel (Figure 
3-6D). The gel thus structurally presented as a dense, tissue-equivalent model.  
 
Cell viability staining demonstrated viable cells both in the centre and at the 
edge of the gel after 96 hours of culture (Figure 3-6E and F respectively). No 
dead cells were observed. A higher density of cells was visible at the gel 
periphery due to radial gel contraction condensing this area. Cellular F-actin 
immunofluorescence indicated a dense concentration of cells growing in a 
parallel fashion on the gel surface (Figure 3-6G), in agreement with SEM and 
histological analysis. Cells at the edge of the gel were observed growing in line 
with the contour of the gel (Figure 3-6H).    
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Figure 3-6 Microscopy gel characterisation 
SEM images of gel surface structure (A and B, scale bars 5µm) indicated cells growing over 
the gel surface (A, 1000x magnification) with a magnified area between the cells showing 
the collagen fibre network in the gel, typically with pores less then 5!m (B, 3000x 
magnification). Gel histology cross-sections (C and D, scale bar 50µm) demonstrated 
uniform cell and collagen distribution throughout the gel. H&E depicts cells as red (C), MSB 
depicts collagen as blue (D). Viability staining (E and F, scale bar 100µm) showed viable 
cells at both the gel centre (E) and the gel edge (F). Cellular F-actin immunofluorescence (G 
and H, scale bar 50µm) indicated cells at the gel centre growing in a parallel direction (G, 
white arrow denotes cell orientation), and cells at the gel edge growing in line with the 
contour of the gel (H, white arrow denotes cell orientation). This figure demonstrated that 
the gel is a good tissue-equivalent model.  
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3.4.3 Uptake Analysis  
3.4.3.1 Histology  
An initial qualitative assessment of mNP-gel interaction was obtained by staining 
histology cross-sections of the gel (1cm length x 0.5cm width, cut to a thickness 
of 4!m) with Perls Prussian blue to visualise the iron mNPs. All four mNP species 
(100nm plain/penetratin, 200nm plain/penetratin) were investigated + MF for 18 
hours. Results demonstrated that all four mNP species could become associated 
with the gel, being seen as dark blue/black clusters (Figure 3-7). Since individual 
mNPs are not visible at this low magnification, assessment of total uptake level 
was not possible. However, this figure does clearly show that groups of mNPs 
were abundant on the gel surface (upwards pointing arrows). These surface 
particles may either be particles interacting with cells on the top layer of the 
gel, or perhaps larger aggregates that have remained attached to the gel 
surface, being too large to fit between the collagen fibres. In addition, clusters 
of both 100nm plain and 100nm penetratin mNPs were noted inside the gel 
(downwards pointing arrows) demonstrating successful gel penetration. 
Following this initial proof of gel-mNP association, further quantitative 
techniques were employed to assess the effect of a MF and penetratin on gel-
mNP uptake.  
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Figure 3-7 Histology sections of gels stained with Perls Prussian blue to visualise iron 
mNPs after incubation in a magnetic field for 18 hours  
Images refer to 100nm mNPs (A-C), 200nm mNPs (D-E) and control sample (F, no mNPs). 
Plain mNPs are shown in A and D whilst penetratin functionalised mNPs are shown in B and 
E. Figure 4C refers to penetratin functionalised 100nm mNPs at a higher magnification. This 
figure demonstrated that mNPs became associated with the gel surface (upwards pointing 
arrows) and were also seen within the gel itself (downwards pointing arrows) [scale bars 
50µm].  
 
3.4.3.2 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
The amount of gel-mNP uptake was quantified by ICP-MS analysis of iron after 
each of the four mNP species (100nm plain/penetratin, 200nm plain/penetratin) 
had been incubated with the gel, +/- a MF, for either 1 or 18 hours (Figure 3-8). 
The term ‘uptake’ is used to describe any mNP association with the gel that was 
not removed by washing (penetratin NPs, being positively charged, naturally 
repel positively charged collagen, thus no cross association was assumed). 
Results demonstrated that after 1 hour, uptake of 100nm mNPs was dramatically 
increased on average 103% by a MF (p<0.01), and 162% by penetratin (p<0.001). 
Similarly, uptake of 200nm mNPs was increased on average 103% by a MF (no 
significance), and 243% by penetratin (p<0.01) Figure 3-8B. Interestingly, at 18 
hours, uptake levels were comparable, irrespective of a MF or penetratin (with 
the exception of 200nm penetratin without MF). Combining both a MF and 
penetratin simultaneously had a slightly attenuating effect on uptake of 100nm 
mNPs after 1 hour. After 18 hours, no significant attenuating effect was seen for 
either size. It is apparent from these results that the application of a MF and the 
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presence of penetratin both increased the speed of gel mNP-uptake, with 
penetratin being the fastest. It was interesting to compare the effect of a MF 
between plain and penetratin mNPs. To do this plain mNPs without a MF was 
considered the base rate of standard, "unaided" mNP-gel uptake. This 
comparison showed that a MF was required to increase plain mNP uptake, 
whereas when penetratin was attached, this requirement no longer existed - 
penetratin mNPs were able to reach the maximal level of uptake after 1 hour 
without a MF. There was little to no difference between the uptake levels 
induced by a MF and by penetratin. A MF had no additional effect on the level of 
penetratin mNP-gel uptake.  
 
In a side-experiment, ICP-MS was also used to quantify the level of uptake of the 
same four mNP species into h-TERT cells grown in 2D monolayer cell culture 
(Figure 3-9). This provided a useful comparison to the data obtained for the 3D 
gel system presented in Figure 3-8. Interestingly, the results showed that the 
pattern of uptake in the 3D system followed a similar trend to the pattern of 
uptake in the 2D system. The main conclusion that can be drawn from this 
finding is that the uptake observed in 3D was definitely cell-dependant, rather 
than simply diffusion into the gel.  
 
N.B [Since results were similar for both sizes of mNPs, and a smaller size is 
deemed optimal for dense tissue penetration, only the 100nm mNPs were used 
in all further investigations.]
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Figure 3-8 Iron uptake into 3D cell cultures as assessed by ICP-MS 
Graph A is the raw ICP-MS data showing the levels of iron that remained in the culture 
media after incubation. Graph B is the converted data showing the levels of iron uptake into 
the 3D collagen gels after incubation. 100nm mNPs are represented in the left hand side of 
these graphs by red (1 hour) and yellow (18 hours) bars. 200nm mNPs are represented in 
the right hand side of these graphs by orange (1 hour) and blue (18 hours) bars. The x-axis 
refers to plain or penetratin functionalised mNPs samples (indicated by plain or pen 
respectively) treated without or with a magnetic field (indicated by -MF or +MF respectively). 
This figure shows that a MF and penetratin both increased the speed of mNP uptake into 3D 
cell cultures. (* = p<0.05, ** = p<0.01 and *** = p<0.001 as analysed by one-way ANOVA with 
Dunnett’s test in SPSS. Error bars are SD, n=3.)  
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Figure 3-9 Iron uptake into 2D cell cultures as assessed by ICP-MS 
Graph A is the raw ICP-MS data showing the levels of iron that remained in the culture 
media after incubation. Graph B is the converted data showing the levels of iron uptake into 
the 2D monolayer cell cultures after incubation. 100nm mNPs are represented in the left 
hand side of these graphs by red (1 hour) and yellow (18 hours) bars. 200nm mNPs are 
represented in the right hand side of these graphs by orange (1 hour) and blue (18 hours) 
bars. The x-axis refers to plain or penetratin functionalised mNPs samples (indicated by 
plain or pen respectively) treated without or with a magnetic field (indicated by -MF or +MF 
respectively). This figure shows that a MF and penetratin both increased the speed of mNP 
uptake into 2D cell cultures. (The four bars denoted with *** were found to have p<0.001 
compared to all three other bars within that colour group (red, yellow, orange or blue), as 
analysed by one-way ANOVA with Dunnett’s test in SPSS. Error bars are SD n=3.) 
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3.4.3.3 Fluorescence Microscopy  
In order to visualise the possible interaction of 100nm mNPs with the surface 
layer of the gel, gels were imaged on a fluorescence microscope after 18 hours 
of incubation with plain or penetratin 100nm mNPs, +/- a MF. Results indicated 
that a high number of both plain and penetratin mNPs became associated with 
the surface of the gel in all conditions (Figure 3-10), an observation confirmed 
by analysis using Image J. From these images it is suggested that without a MF 
there were more penetratin mNPs on the surface of the gel (Figure 3-10E) than 
there were plain mNPs (Figure 3-10C). This reflected the ability of penetratin to 
enable the mNPs to become cell-associated on the surface of the gel. While this 
technique was useful to visualise mNP interaction on the gel surface, the depth 
of gel uptake of 100nm penetratin mNPs was subsequently assessed using 
confocal microscopy (Figure 3-11).
Hannah W. Child, 2012                                                                        Chapter 3, 76 
 
 
Figure 3-10 Gel surface localisation of 100nm mNPs after 18 hour incubation 
Control gels had no mNPs present (A, B). Plain mNPs (C, D) and penetratin mNPs (E, F) were both clearly evident on the gel surface after incubation. A, C, 
and E were incubated without a magnetic field (-MF), whereas B, D, and F were incubated with a magnetic field (+MF). The fluorescence signal in images C-
F was quantified via Image J and expressed graphically (G) [scale bar = 50µm].
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3.4.3.4 Confocal Microscopy  
To assess the depth of 100nm penetratin mNP uptake, gels (with a total depth of 
3mm) were imaged on a confocal microscope, +/- a MF, after 1 and 22 hours 
incubation. This allowed visualisation of the fluorescent mNPs within the gel 
through the z-axis, and consequent measurement of the depth to which they had 
penetrated +/- a MF (Figure 3-11). The Z-stacks showed that 1 hour incubation 
+/-MF, and also 22 hour incubation -MF resulted in a shallow penetration depth 
with no significant difference between groups. Thus, 100nm penetratin mNPs 
were only able to penetrate the gel to a very minimal depth, which was not 
increased with longer incubation. However, when a MF was applied, after a 22 
hour incubation mNP uptake distance was increased on average by 503% 
(p<0.01), to a depth of 728µm, at a rate of 33µm h-1. This experiment 
demonstrated that penetratin alone did not facilitate mNP movement in 3D, but 
if aided by a MF and incubated for enough time, functionalised mNPs can be 
pulled to a considerable depth within the gel. These results are in agreement 
with the findings of fluorescence microscopy, which indicated that there was a 
higher density of penetratin mNPs evident on the gel surface without a MF 
(Figure 3-10E) as compared to with a MF (Figure 3-10F). N.B [The accuracy of 
confocal microscopy depended on the starting plane height of each gel, which 
inevitably varied very slightly between each individual gel. This could explain 
the insignificant variation in results between 1 and 22 hours, without a MF.] 
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Figure 3-11 Gel uptake depth of 100nm penetratin mNPs  
This figure shows the uptake depth of 100nm penetratin-functionalised mNPs into 3D 
collagen gels as assessed by confocal microscopy. On the x-axis, samples treated without 
or with a magnetic field (MF) are indicated by – MF or + MF respectively. Red or yellow bars 
refer to 1 or 22 hours of incubation respectively. This figure indicates that after 22 hours a 
MF significantly increased the depth of gel-uptake of 100nm penetratin mNPs. (* p<0.05, ** 
p<0.01 as analysed by one-way ANOVA with Tukey’s test in SPSS. Error bars are SD, n=3.)   
 
3.4.3.5 Transmission Electron Microscopy (TEM)  
Confocal microscopy results demonstrated that a MF was able to pull mNPs into 
the gel. However it was also important to identify if these functionalised mNPs 
were being taken up by cells at this depth; a requirement for in vivo drug 
delivery. To answer this question, TEM was used to image gels after incubation 
with 100nm penetratin mNPs for 18 hours, +/- a MF (Figure 3-12). TEM results 
showed that 100nm penetratin mNPs localised within cells at a gel depth of 
around 500µm, when treated with a MF (Figure 3-12C and D). For comparison, 
images were taken of 100nm penetratin mNPs inside cells grown in 2D monolayer 
cell culture (Figure 3-12 A and B). This experiment supported the confocal 
results, demonstrating that a MF was able to pull functionalised mNPs through 
the gel structure, where cells growing within it can internalise them. This 
cellular uptake is most likely aided by penetratin attachment, since the mNPs 
observed were not located in cellular vesicles, resulting from the fact that CPPs 
are reported to facilitate direct translocation across the plasma membrane, 
thereby avoiding the endo-lysosomal pathway (Jarver and Langel, 2006).   
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Figure 3-12 Uptake of 100nm penetratin mNPs into cells grown in 2D and 3D 
A and B show mNPs inside a cell grown in 2D monolayer in the presence of a magnetic field 
(MF). C and D show mNPs (indicated by white arrows) inside a cell grown in a 3D collagen 
gel in the presence of a MF at a depth of around 500µm into the gel. D is a magnified section 
of C. E is a control gel (no mNPs). This figure demonstrates that the combination of a CPP 
with a MF can facilitate the delivery of mNPs to cells growing in 3D [scale bars = 200nm].  
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3.5 Summary  
This study has utilised fibroblast-seeded collagen gels to investigate whether a 
MF and NP- functionalisation with the CPP penetratin could be used to enhance 
the delivery of mNPs to cells grown in 3D, in order to assess the potential of 
these techniques for in vivo drug delivery. Gel-mNP uptake analysis showed that 
on average a MF doubled the speed of gel-mNP uptake, and caused a 5-fold 
increase in the depth of gel-mNP uptake, occurring at a rate of 33µm h-1. 
Penetratin, however, more than doubled the speed of 100nm gel uptake, more 
than tripled the speed of 200nm mNP gel uptake, increased the localisation of 
mNPs to cells on the gel surface, but had no effect on the depth of gel-mNP 
uptake. 
3.6 Discussion 
3.6.1 Characterisation of the 3D Model  
The characterisation results suggested that the 3D cell-seeded collagen gels used 
in this project were a realistic tissue-equivalent model suitable for the 
assessment of NP delivery. The gels were shown to have an elasticity similar to 
that of human tissue, and to contain viable cells that were well dispersed 
throughout the collagen matrix. Previous 3D models that have been used to test 
NP delivery include acellular gels and multicellular spheroids. These 3D systems 
are not ideal and it is believed that collagen gels overcome some of the 
disadvantages associated with these types of earlier models. 
 
Acellular Gels 
The use of acellular gels was demonstrated by Kim et al, who used acellular 2% 
agarose gels with pore sizes of 100nm to assess the therapeutic potential of 
drug-loaded worm micelles composed of polylactic acid (PLA) and amphiphiles. 
This agarose gel model was used to measure the 3D permeation abilities of the 
fluorescently tagged worm micelles, and demonstrated that their elongated 
shape provided a physical advantage to deliver drugs deep into tissue (Kim et 
al., 2005). A second example of the use of acellular gels is a study by Valentine 
et al, who used 3D biopolymer networks composed of fibrin or actin to assess 
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the effect of different microsphere surface modifications on particle mobility. 
Results showed that the attachment of PEG reduced protein adsorbtion, and 
thereby increased particle movement within the 3D biopolymer network, as 
would be a desirable attribute to achieve targeted drug delivery in vivo 
(Valentine et al., 2004).  
 
The main advantage of using acellular gels is that they mimic some of the types 
of extracellular hindrances to NP delivery that exist in vivo, which are not 
present in 2D monolayer cell culture, including small pore size and the ECM. 
However, their main shortcoming is an inability to accurately predict cell 
responses to NPs. In comparison to my work, although acellular gels do represent 
a step forward from 2D monolayer cell culture, cell-seeded collagen gels are a 
better choice since they are more comparable to natural tissue due to the 
inclusion of cells. Results presented in this chapter have demonstrated that cells 
were evenly distributed throughout the collagen gel, and remained viable at 
both the gel centre and edge, indicating that this 3D model suitably mimics the 
in vivo cellular environment and therefore acts as a good tissue-equivalent 
model for testing NP delivery. 
 
Multicellular Spheroids 
Multicellular spheroid growth can be initiated by growing cell cultures in a 
spinner flask or on agar-coated culture plates (Nederman and Twentyman, 1984) 
Their use was demonstrated by Goodman et al who used SiHa cervical carcinoma 
cell spheroids as a 3D tumour model to investigate the penetration of 
carboxylated polystyrene NPs. This study reported that NPs functionalised with 
ECM degrading enzymes such as collagenase, displayed a 4-fold increase in 
penetration into the spheroid (Goodman et al., 2007).  
 
Multicellular spheroids are considered to be a good 3D tumour model due to the 
fact that they mimic properties of avascular regions of solid tumours, including 
regions of proliferation, quiescence and a necrotic core (Waleh et al., 1994). 
However, their main disadvantage is a lack of ECM proteins and outside forces 
such as mechanical stress (Goodman et al., 2008). In comparison to my work, 
the main difference between the two models is cell density; in multicellular 
spheroids the cells are arranged in very dense, compact clusters, whereas in the 
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collagen gels the cells are more spread out and interspersed with the collagen 
matrix, which provides them with a more realistic ECM. Most likely, the cell 
density of real tissue is somewhere in-between these two models, although the 
spheroids may be more representative of the high density environment within a 
tumour since a necrotic core was not visualised within the collagen gels, where 
cells remained viable throughout. (This core viability was most likely due to the 
fact that matrix pore sizes of 5!m allowed for free diffusion of nutrients to the 
centre of the gel.) In addition to the benefits of high cellular viability and the 
provision of an ECM, cells grown within collagen gels aligned in a striated 
fashion, indicative of inherent cell-mediated gel tensile forces (Eastwood et al., 
1998), which do not exist to such an extent in multicellular spheroids. 
Therefore, although multicellular spheroids are a more realistic 3D model than 
acellular gels, collagen gels are deemed to be a better choice since they provide 
a suitable ECM matrix and tensile forces, such as the cells would experience in 
natural in vivo tissue. 
3.6.2 ICP-MS 
The trends observed with the ICP-MS data were the same for both 100 and 
200nm mNPs. The only notable difference was that penetratin (-MF) resulted in 
a greater increase in the gel uptake of 200nm mNPs compared with the 100nm 
mNPs. This difference could be an artefact because since the 200nm mNPs have 
a larger hydrodynamic diameter they contain more iron (i.e. the volume ratio of 
100nm:200nm mNPs is 1:8.2). This means that even though the level of iron 
uptake was different the number of particles taken up may actually be the same 
However, it is likely that the difference in penetratin-induced uptake was 
caused by the 200nm mNPs carrying more penetratin molecules per particle than 
the 100nm mNPs (Table 3-1), resulting in increased cell uptake. As smaller NPs 
were considered to be better drug delivery candidates (due to cell accessibility 
in the tight collagen matrix and their larger surface area to volume ratio) the 
100nm mNPs were used in all further investigations.   
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It is useful to clarify that ‘increased speed of uptake’, refers to the fact that the 
level of gel-mNP uptake that occurred under the influence of a MF/penetratin, 
was higher than that of the control mNPs (no MF/penetratin) after 1 hour, but 
became equal to that of the control mNPs after 18hours.  
 
We know that the mNP sample added did not expire, thereby preventing any 
further uptake, as the level of uptake reached after 18 hours always remained 
lower than the total level of sample that the gels were challenged with (Figure 
3-8A). Therefore it seems more likely that, for some reason, the gels have a 
maximum threshold level of gel-mNP uptake, which was reached much faster 
than normal under the influence of a MF/penetratin, but once reached it could 
not be increased any further. This uptake threshold was evident in both the 2D 
and 3D data, suggesting that the effect is cell- rather than gel-dependent, and is 
most likely due to cell uptake saturation. The idea that cells have a natural 
threshold level for NP uptake is supported by numerous publications reporting a 
NP ‘uptake plateau’ after a certain length of time. For example, in a 2D 
magnetofection study, Plank et al showed that a MF increased the amount of 
mNP uptake after 10mins, but did not increase the amount of uptake achieved 
after 4 hours, suggesting that the cells reached their threshold level of mNP 
uptake which could not be bypassed once it had been reached (Plank et al., 
2003). In addition, Harush-Frenkel et al used fluorescence-activated cell sorting 
(FACs) analysis to quantify the uptake of PLA fluorescent NPs into HeLa cells, 
and found that NP uptake plateaued within 45-60mins. The authors postulated 
that this indicated possible NP recycling and or binding saturation, which might 
have resulted in an inability to internalise additional NPs (Harush-Frenkel et al., 
2007). Similarly, Zaki et al used fluorimetry to quantify the uptake of 
hyaluronic-acid (HA)-coated chitosan NPs into macrophages, and found that NP 
uptake plateaued after 6 hours. The authors postulated that this plateau effect 
indicated that NP-uptake is dependent on receptor-mediated endocytosis, and 
that this apparent saturation may have been caused by the kinetics of recycling 
of the HA receptors. This idea is based on the fact that for soluble HA, the 
receptors are internalised with their ligands and require a significant time to be 
transported back to the cell surface, during which time the internalisation 
capacity of the cell is reduced (Zaki et al., 2011).  
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This list of 2D studies reporting NP uptake plateaus supports my ICP-MS data, 
which suggests that a cellular threshold level of NP uptake exists. However, my 
work is one of the first to exemplify that this phenomenon also effects NP 
uptake in 3D, an important aspect to consider for NP delivery in vivo. 
3.6.3 Effect of the Magnetic Field (MF)  
MFs are commonly used to attract mNPs into cells grown in 2D. The confocal 
data presented in this chapter demonstrated that a MF was also able to pull 
mNPs into a 3D system; pulling 100nm penetratin mNPs to an average depth of 
728µm, at a rate of 33µm h-1. Similar 3D studies by Kuhn et al have reported 
that under the influence of a static MF, 145nm mNPs travelled through a 
hydrogel at 1.5mm h-1 (Kuhn et al., 2006b) and travelled through a collagen-
supplemented gel at 90µm h-1 when functionalized with the enzyme collagenase 
(Kuhn et al., 2006a). For both of these studies, the MF strength was 100-500mT, 
which is comparable to the 280mT used in my experiments on collagen gels. The 
NP travel-rate of 1.5mm h-1 achieved by Kuhn et al is much faster than my NP 
travel-rate of 33µm h-1. However, this difference can be explained by the fact 
that Kuhn et al were using a hydrogel that does not contain the same resistance 
to NP-travel as that of a gel composed of collagen fibres. Indeed, the hindrance 
to NP-travel caused by the presence of collagen is exemplified by the fact that 
Kuhn’s rate of NP-travel was significantly reduced to 90µm h-1 upon the 
introduction of collagen into the 3D model. Collagen is one of the main 
components of the ECM (Di Lullo et al., 2002) and these comparative studies 
demonstrate that the presence of this protein significantly increases resistance 
to mNP movement. This highlights the importance of testing NP delivery in a 3D 
model that realistically represents the in vivo barriers to NP delivery posed by 
the ECM. The results in this chapter demonstrate that a MF caused on average a 
5-fold increase in the depth of gel-mNP uptake, and the literature suggests that 
mNP functionalisation with a proteolytic enzyme such as collagenase could 
increase this depth even further.  
 
One of the best comparisons to the work presented in this chapter is a recent 
study by Zhang et al, who used a very similar 3D fibroblast seeded collagen gel 
model to achieve 3D magnetic delivery of 30nm mNPs conjugated to siRNA, 
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resulting in up to 82% silencing efficiencies (Zhang et al., 2010). As a proof-of-
concept, the authors demonstrated that traditional transfection agents (such as 
Lipofectamine and FuGene), which displayed transfection efficiencies of 90-95% 
in 2D, did not work at all in 3D due to a lack of permeation into the collagen 
matrix (exemplifying the uselessness of these transfection agents in vivo). The 
authors found that collagen gel transfection efficiencies could be improved to 5% 
using 250nm mNPs, and to 64% using 30nm mNPs (in both cases using a 1.2T MF). 
This highlights the potential of using magnetically guided NPs to overcome the 
barriers associated with 3D tissue transfection. It also demonstrates the fact 
that larger mNPs find it more difficult to permeate the tight collagen matrix 
than smaller mNPs, even under an external MF, which supports my decision to 
choose 100nm mNPs over 200nm mNPs for optimal delivery in my collagen gel 
model. Interestingly, the authors also noted that 3D transfection reached a 
maximum at 3 hours, supporting my previously discussed finding that 3D collagen 
gels displayed a maximum threshold for mNP-delivery. Interestingly, the authors 
also demonstrated the effectiveness of using collagen gels to quickly and easily 
screen shRNA plasmids for toxicity (some of which were shown to cause up to 
51% cell death), which I think will be an important aspect of pre-clinical 3D 
screening if therapeutic gene therapy is to be made widely available. 
3.6.4 Effect of the CPP  
This chapter confirms previous findings from our lab that the CPP penetratin can 
increase the uptake of mNPs into fibroblast cells (Dejardin et al., 2011). This 
penetratin-induced increase in NP cellular uptake has also been reported by 
Nativo et al, who found that penetratin-conjugated gold NPs displayed increased 
endocytosis in Hela cells after 2 hours as assessed by TEM (Nativo et al., 2008). 
In addition, Petersen et al found that the attachment of penetratin doubled the 
amount of AuNP uptake in endothelial cells after 2 hours as assessed by laser 
scanning confocal microscopy (Petersen et al., 2011). Tseng et al reported that 
there was a 1 hour peak of penetratin-induced cellular uptake of liposomes, 
after which time uptake declined (Tseng et al., 2002). This could relate to the 
pattern of penetratin-induced uptake reported in this chapter, since ICP-MS 
showed that maximal mNP uptake was also achieved after a 1 hour incubation.  
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As described, it is well reported that CPPs increase cellular uptake of associated 
NPs in 2D cell systems. However, no other studies can be found on the effects of 
penetratin on NP delivery to cells in 3D, highlighting the novelty of this chapter, 
which allows for fresh insights to be gained about how this CPP may perform in 
vivo.  
 
ICP-MS results showed that penetratin increased the speed of mNP uptake into 
the 3D gel. In this 3D model system, a cell layer was observed on the gel 
surface, most likely due to the initial gel contraction, causing a concentration of 
cells at the periphery. Penetratin-induced gel-mNP uptake is thus most likely 
caused by the increased uptake of mNPs into this surface layer of cells. The 
confocal data confirmed that penetratin mNPs did not move deeply into the gel 
and away from this surface layer without a MF. This lack of movement is in fact 
one of the main problems when trying to target functionalised NPs to a diseased 
tissue in vivo (Prijic and Sersa, 2011) (Dobson, 2006b) and is explained by the 
fact that CPPs cannot independently travel through the collagen gel matrix. 
Therefore it is imperative that CPPs be used in conjunction with a targeting 
technique, such as a MF, to enable mNPs to reach and subsequently enter target 
cells, in order to facilitate drug delivery. While CPPs and magnetic fields have 
been used in conjunction in a select few 2D studies ((Smith et al., 2010; Song et 
al., 2010) this is the first use of this combined approach in a 3D model. It was 
proved successful since TEM images showed that following magnetically induced 
movement through the gel, the 100nm penetratin mNPs were able to achieve 
cellular uptake at this increased depth within the gel. Due to the fact that these 
mNPs were seen free in the cytoplasm, it is possible that they translocated 
directly across the plasma membrane, facilitated by the attached CPP, thus 
supporting the hypothesis that CPPs can be used to prevent degradation by the 
endo-lysosomal pathway (Jarver and Langel, 2006). This work has demonstrated 
that if used together, a MF and CPPs show huge potential to facilitate targeted 
drug-delivery in vivo.  
 
Although it is hard to directly compare it against additional CPPs, in terms of 
increasing cell uptake of NPs in 2D and 3D, penetratin appears to be one of the 
most effective CPPs currently presented in the literature. Interestingly, a recent 
study by Maniti et al investigated the mechanism by which penetratin works to 
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increase cellular uptake, and concluded that the CPP induces direct 
translocation across the plasma membrane. The authors also discovered that 
penetratin induces a second mechanism termed ‘physical endocytosis’, whereby 
the creation of endocytotic membrane invaginations is driven by the peptide’s 
self-capacity to induce negative curvature rather than through the use of 
metabolic energy (Maniti et al., 2012). This leads to speculation that penetratin 
may hold additional benefits compared to other CPPs, such as Tat, since its 
unique lack of cellular energy requirement could be considered less disruptive to 
normal cellular function. This metabolic energy-independent mechanism of 
action, together with its herein proven ability to increase cellular uptake in 3D, 
suggest that penetratin is an excellent CPP candidate to be taken further into in 
vivo studies of drug delivery. 
3.7 Conclusion  
This study has been the first to investigate the combined effects of a MF and a 
CPP on the delivery of mNPs to cells growing in a 3D environment. This proof-of-
concept study has shown that a MF significantly enhanced the movement of 
mNPs though the tissue-equivalent model, while a CPP facilitated cell uptake at 
this increased depth. These results suggest that the best strategy for site-
specific drug delivery in vivo will be to use these techniques together thereby 
providing both targeting and cellular uptake of drug- loaded mNPs.  
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4.1 Introduction 
Cancer is caused by the incorrect expression of genes that control the cell cycle. 
One such gene is c-myc, a positive regulator of the cell cycle found to be 
overexpressed in the majority of cancers (Pelengaris and Khan, 2003; Aulmann 
et al., 2006; Beroukhim et al., 2010b; Borg et al., 1992; Bourhis et al., 1990; 
Deming et al., 2000; Kozma et al., 1994). Modern research aims to develop a 
therapy whereby this incorrect gene expression associated with cancer can be 
rectified at the molecular level, as a method of disease treatment. One way that 
incorrect gene expression can be reduced is through RNA interference (RNAi), a 
natural cellular mechanism discovered by Fire and Mello in 1998 (Fire et al., 
1998). This mechanism enables a target gene to be silenced via the destruction 
of its mRNA, by the introduction of a short interfering RNA (siRNA) with 
complementarity to the target mRNA (Ameres et al., 2007). The siRNA gets 
incorporated into the enzymatic RISC complex found in the cytoplasm, activating 
RISC to find and destroy the complementary endogenous target mRNA (Rand et 
al., 2004), preventing its translation into protein. 
 
Since Tuschl et al first demonstrated that artificial siRNA, 21nt in length, can be 
used to silence mRNA in mammalian cells (Elbashir et al., 2001), RNAi has 
become a prominent research tool used for gene knockdown studies (Gondi and 
Rao, 2009; Kurreck, 2009). Currently, the most difficult task in performing RNAi 
is the cellular uptake of negatively charged siRNA, as it cannot naturally cross 
the cell membrane (Akhtar et al., 1991; Wittung et al., 1995). For research 
purposes, the transfection agent Lipofectamine and electroporation are used to 
promote cellular uptake of siRNA for RNAi. However, due to toxicity issues and 
lack of specificity, these techniques would be unsuitable to deliver siRNA for 
RNAi in vivo. In addition, naked siRNA suffers from degradation if injected 
directly into the bloodstream, as it is unprotected from nucleases (Dykxhoorn 
and Lieberman, 2005). Therefore, in order for RNAi to be used in a clinical 
setting, a delivery vehicle must be found to enable siRNA entry into diseased 
cells within the body (Huang et al., 2008; Whitehead et al., 2009). Nanoparticles 
(NPs) present as a very promising candidate for this delivery task (Juliano et al., 
2008). Firstly, because they can have numerous cargos and functional molecules 
attached to their surface (Song et al., 2005; Derfus et al., 2007; Paciotti et al., 
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2006), and secondly because they provide the cargo with protection against 
degradation as it is carried through the body to the target cells requiring RNAi 
therapy (e.g. to cancer cells within a tumor) (Lee et al., 2009b).  
 
While many different types of NPs are currently under development, gold NPs 
(AuNPs) are a very popular choice for the development of a therapeutic delivery 
vehicle (Huang et al., 2007; Sanvicens and Marco, 2008). Reasons for this include 
its low toxicity (Connor et al., 2005), good optical properties and ease of 
functionalisation (Lee et al., 2009c; Chen Pc, 2008). Many studies have shown 
that AuNPs can be internalised by cells, and that this process can be increased 
by functionalisation with CPPs, such as Tat (Berry, 2008; Braun et al., 2009; 
Smith et al.). Furthermore, AuNPs have proven popular for the delivery of siRNA, 
although to date the majority of AuNP knockdown studies have used siRNA 
targeted to reported genes such as luciferase or GFP, instead of an actual gene. 
The second project of this PhD (as presented in chapters 4 and 5) has aimed to 
take the next step and use AuNPs to deliver siRNA directed against the c-myc 
oncogene.  
4.1.1 The Nanotruck Project 
The Nanotruck project was a European Union funded project with the vision of 
developing nanoparticle-mediated therapeutic RNAi as a method of cancer 
treatment. This PhD formed part of the collaborative Nanotruck project aiming 
to design, develop and test an optimal AuNP species to silence the c-myc 
oncogene by RNAi, via the delivery of complementary siRNA, thus slowing 
cancerous cell proliferation and growth. The collaborative side of the project 
involved five separate academic institutes. The AuNP synthesis was carried out 
by inorganic chemists in Zaragoza, Spain, whereby the particles were designed 
and functionalised, resulting in a library of different AuNP formulations. The 
AuNPs were subsequently forwarded to labs in Glasgow, Naples and Munich, for 
testing/screening with in vitro human cell lines, and in vivo invertebrate 
(freshwater polyp Hydra) and vertebrate (mouse) models respectively, thus 
allowing for robust testing of c-myc silencing efficiency. 
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4.1.1.1 Aims 
The aim of the Glasgow lab, and this section of the PhD project, were to test 11 
AuNP species synthesised by grant partners (Figure 4-2) in human cell lines in 
order to develop an optimal AuNP design for the delivery of siRNA to silence the 
c-myc oncogene by RNAi, as a method of cancer treatment. At the outset, the 
main screening objectives were investigation of AuNP performance in the 
following four criteria; 
 
1) potential cell toxicity  
2) cellular uptake 
3) c-myc knockdown 
4) effect on the cell cycle 
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4.2 Materials and Methods 
4.2.1 AuNP Design and Synthesis 
The AuNPs were synthesised by the citrate reduction method described by Lee 
and Meisel (Lee and Meisel, 1982), producing a NP composed of a gold core 
surrounded by a layer of citrate. These core particles were then functionalised 
with various different molecular attachments. First, a layer of thiolated-
poly(ethylene glycol) (PEG) was attached to the AuNP core, facilitated by direct 
gold-sulphur bonding between the sulphur atoms in the thiol molecules and Au 
atoms in the particle core. Two types of PEG molecules were used, ending with 
either carboxylic acid (COOH) or azide (N3) functional groups. The PEG layer 
therefore played two main roles; 1) increasing AuNP therapeutic efficiency due 
to the many previously demonstrated benefits (i.e. to guarantee NP stability & 
avoid nonspecific interactions), and 2) providing a platform for the attachment 
of additional molecules that could be conjugated to the COOH/N3 PEG end 
groups. PEG-COOH was used to attach molecules that contained NH2 groups 
(such as amino acids/peptides) via the EDC reaction, where COOH and NH2 are 
bound together producing a peptide bond with the expulsion of water.  
 
Figure 4-1 The EDC reaction 
This figure illustrates the EDC reaction that was used to bind peptides, such as Tat and the 
R4N group, to PEG-COOH chains on the AuNPs (image provided by grant partners).  
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The EDC reaction was used to attach the Tat peptide and the positively charged 
R4N group to PEG-COOH on the AuNP. N.B [The R4N group is a 5 amino acid long 
peptide composed of 1 asparagine residue (N) and 4 positively charged arginine 
residues (R). The purpose of the R4N group was to provide a positive charge in 
order to ionically bind negatively charged siRNA to the AuNP]. The second type 
of PEG used, PEG-N3, was intended to be used to attach molecules via click 
chemistry, however synthesis proved difficult.  
 
Two strategies were employed for siRNA attachment to the AuNP 1) the covalent 
approach, and 2) the ionic approach. The covalent approach involved thiolating 
the siRNA molecules and using gold-sulphur bonding to bind the siRNA covalently 
to the gold core of the particles. Alternatively, in the ionic approach, siRNA was 
attached ionically to the positively charged R4N group (which was attached to 
PEG-COOH via the EDC reaction). The principles of the ionic approach were 
based on the fact that the R4N group is positively charged at all pH values and 
has a great affinity for the negatively charged siRNA (because of its phosphate 
backbone). The ionic attachment was performed in DEPC-treated water with a 
pH around 6.5-7. Great care was taken to perform the ionic attachment at a pH 
where the siRNA was stable and in water instead of buffer to prevent 
electrolytes from weakening the bond between nanoparticles and siRNA since 
electrolytes also form ionic interactions with charged species.  
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During the process of developing the optimal AuNP species for c-myc RNAi, 11 
different AuNP species were created by the chemists for testing/screening. 
These 11 samples were divided into three main classification groups; 
 
1) Primary Samples – This group involved three samples; (i) the initial gold-
citrate core produced after citrate reduction (pAu_citrate), (ii) a sample with a 
layer of PEG-COOH (pAu_COOH) and (iii) a sample with a layer of PEG-N3 
(pAu_N3). 
 
2) Covalent Approach – This group involved four samples (all of which had a 
mixed PEG layer including both PEG-COOH and PEG-N3); (i) a sample with no 
attachments other than PEG (cAu_plain), (ii) a sample with Tat (cAu_Tat), (iii) a 
sample with thiolated c-myc siRNA covalently bound to the gold core 
(cAu_siRNA), and (iv) a sample with Tat and thiolated c-myc siRNA covalently 
bound to the gold core (cAu_Tat, siRNA).  
 
3) Ionic Approach – This group involved four samples (all of which had a mixed 
PEG layer including both PEG-COOH and PEG-N3, and the R4N group attached to 
PEG-COOH); (i) a sample with no attachments other than PEG and R4N (iAu-
plain); (ii) a sample with Tat (iAu_Tat), (iii) a sample with c-myc siRNA ionically 
bound to the R4N group (iAu_siRNA), and (iv) a sample with Tat and c-myc siRNA 
ionically bound to the R4N group (iAu_Tat, siRNA) (see Figure 4-2). 
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 Primary Samples       Covalent Approach                   Ionic Approach 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2 Description of the 11 different AuNPs employed in this chapter 
Schematic representations of each sample (A) with a corresponding descriptive table (B). 
The 11 AuNP samples were divided into three classification groups; primary (green), 
covalent (violet) and ionic (orange). The various molecular attachments on each AuNP 
species have been displayed in a simplified manner. Yellow is the gold core, grey is the 
PEG layer, the red ladder is siRNA (complementary to c-myc mRNA), and turquoise boxes 
are peptides (showing the 1-letter code of each amino acid present). The 16-amino acid 
peptide is the cell penetrating peptide (CPP) Tat. The shorter, 4-amino acid peptide is the 
positively charged R4N group used to ionically attach siRNA to the particle in the ionic 
samples (schematics not drawn to scale). 
Sample 
Number 
Sample 
Group 
Sample 
Acronym 
siRNA 
(strands/NP) 
1 primary pAu_citrate - 
2 primary pAu_COOH - 
3 primary pAu_N3 - 
4 covalent cAu_plain - 
5 covalent cAu_Tat - 
6 covalent cAu_siRNA 41 
7 covalent cAu_Tat, siRNA 48 
8 ionic iAu_plain - 
9 ionic iAu_Tat - 
10 ionic iAu_siRNA 79 
11 ionic iAu_Tat, siRNA 78 
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4.2.1.1 Experimental Details of AuNP Synthesis (provided by 
grant partners) 
Synthesis of PEG Heterofunctional Surfaces. A mixture of 0.5 mg/ml of the 
citrate AuNP, 0.028 % SDS and 0.03 mg/ml SH-EG(7)-CH2-COOH (Iris-Biotech) and 
0.015 mg/ml SH-CH2-CH2-CONH-EG(6)-CH2-N3 for NP-ionic and 0.015 mg/ml SH-
EG(7)-CH2-COOH (Iris-Biotech) and 0.015 mg/ml SH-CH2-CH2-CONH-EG(6)-CH2-
N3 for NP-covalent were prepared. NaOH was further added to a final 
concentration of 25 mM and the mixture was incubated for 16 hours at room 
temperature. The excess of PEG chains was removed by centrifugation at 14000 
rpm for 30 minutes at 4°C and the supernatant was discarded. This washing 
process was repeated three times and the pellet with AuNPs was dissolved in 
pure water.  
 
AuNP Functionalisation with Tat Peptides and Quaternary Ammonium Groups 
by EDC/NHS Coupling Reactions. 1 mg/ml NP-ionic/covalent were incubated in 
1.25 mg/ml sulfo-NHS and in 25 mM MES (2-(N-morpholino)ethanesulfonic acid) 
buffer pH 6.1. For NP-ionic, 6.6 mg/ml of quaternary ammonium groups (R4N+) 
were added to the mixture, EDC (1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide) was added at a final concentration of 150 !g/ml and the mixture 
incubated for 20 min. Tat peptide was added at a final concentration of 0.8 
!g/ml and the mixture incubated at room temperature for 16 hours. For NP-
covalent EDC was added at a final concentration of 150 !g/ml, the Tat was 
added at a final concentration of 0.8 !g/ml and the mixture incubated at room 
temperature for 16 hours. After this period of time, the PEGylated AuNPs were 
centrifuged at 14000 rpm for 30 minutes at 4ºC to remove the excess of the Tat 
peptide and the supernatants were recovered and tested for protein 
concentration by the Bradford assay. 
 
AuNP Functionalisation with siRNA. For NP-ionic the unmodified siRNAs, at a 
constant concentration of 5 nmol/ml, were incubated with RNase-free solution 
of the NP-ion@R4N+@TAT (0.5 mg/ml) during 16 hours at 4ºC. For NP-covalent, 
the purified SH-siRNAs, at a constant concentration of 5 nmol/ml, were 
incubated with RNase-free solution of the NP-cov@Tat (0.5 mg/ml) containing 
0.028 % SDS. Subsequently, the salt concentration was increased to 0.1M NaCl 
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with brief ultrasonication following each addition to increase the coverage of 
oligonucleotides on the nanoparticle surface. After functionalisation during 16 
hours at 4ºC, the particles were purified by centrifugation at (13000 rpm, 20 
mins) at 4°C, and re-suspended in DEPC-water. This process was repeated 3 
times. The number of siRNA per gold nanoparticle was determined by using a 
nucleic acid intercalculator – GelRed. Briefly, the supernatants were incubated 
with GelRed 100" and TBE 0.5" and fluorescence was measured using a 
fluorometer Perkin Elmer LS55 with emission at 602 nm and compared to a 
standard curve.  
4.3 Results 
4.3.1 AuNP Characterisation 
4.3.1.1 TEM 
TEM was used to visualise each of the 11 AuNP species to provide information 
regarding their physical size and morphology. Images demonstrated that all 11 
samples maintain a uniform particle size of ~20nm and a circular morphology. 
However, the TEM also indicated that a considerable variation in aggregation 
state existed between samples (as summarised in Table 4-1). Representative 
TEM images of the primary samples are shown in Figure 4-3 and the covalent and 
ionic samples are shown in Figure 4-4.  
 
 
 
 
 
 
 
 
 
 
 
 
Hannah W. Child, 2012                                                                      Chapter 4, 98 
 
 
 
 
AuNP Aggregation state 
Low Medium High 
pAu_citrate pAu_COOH pAu_N3 
cAu_siRNA iAu_plain cAu_plain 
cAu_Tat, siRNA iAu_Tat cAu_Tat 
iAu_siRNA 
iAu_Tat, siRNA 
Table 4-1 Summary of AuNP aggregation state as assessed by TEM 
Each of the 11 AuNP species was categorised as having low, medium or high levels of 
particle aggregation. Samples with ‘low aggregation’ contained free particles in single form 
that were not attached to any neighbouring particles. Samples with ‘medium aggregation’ 
contained particles that were slightly associated with each other, with some space 
remaining between each particle. Samples with ‘high aggregation’ contained particles that 
were clumped together into dense groups, with no space remaining between each particle. 
(This table has been colour-coordinated with Figure 4-2, where primary samples are 
displayed in green, covalent samples in violet and ionic samples in orange.) 
 
 
 
 
 
 
Figure 4-3 TEM images of the three primary AuNP samples 
TEM images show the three primary AuNP samples at both high and low magnification (as 
indicated by the left hand side labels). Particles appeared uniform in size (~20nm) and 
circular in shape. Images show that a difference in aggregation state existed between 
samples. pAu_citrate appeared as single particles, pAu_COOH was slightly aggregated, and 
pAu_N3 was highly aggregated into dense clumps [scale bars = 100nm].  
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Figure 4-4 TEM images of the eight covalent and ionic AuNP samples 
TEM images show the eight AuNP species at both high and low magnification (as indicated 
by the left hand side labels). Particles appeared uniform in size (~20nm) and circular in 
shape. Images show that a difference in aggregation state existed between samples. Those 
with siRNA attached appeared as single particles, whereas those without siRNA attached 
appear to be clumped together into aggregates [scale bars = 100nm]. 
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4.3.1.2 Zetasizer Analysis 
A Malvern Zetasizer was used to measure particle size by dynamic light 
scattering (DLS), and particle zeta potential, which gives an indication of sample 
charge and corresponding colloidal stability. DLS results showed that the size of 
cAu_plain, and all four of the ionic samples measured at the predicted diameter 
of ~20nm, as was observed by TEM. The remaining three covalent samples 
measured slightly higher, with reported sizes of up to ~80nm. The zeta potential 
results measured all samples to have charges between -20 and -55mV.  
 
 
Figure 4-5 Zetasizer analysis of the eight covalent and ionic AuNP samples 
The AuNP species in the covalent and ionic groups were analysed using dynamic light 
scattering (DLS) to measure particle size (A). A dotted line has been drawn at 20nm, which 
is assumed to be the true diameter of the AuNPs (as advised by the NP synthesis chemists 
and observed in TEM). In addition, zeta potential analysis was used to measure particle 
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charge (B). A dotted line has been drawn at -30mV since this is the minimal negative charge 
that indicates NP stability (as recommended in the Malvern Zetasizer manufacturers 
guidelines). (Error bars are SD, n=3.) 
 
 
4.3.1.3 Toxicity Screening (MTT Assay) 
 
In order to test the toxicity of the AuNPs used in this project, the MTT assay was 
used to measure cell viability after incubation with AuNP samples. The toxicity 
of the three primary samples was initially screened in the h-TERT BJ1 human 
fibroblast cell line after 24, 48 and 72 hours incubation with the cells to 
determine any obvious issues (Figure 4-6). Subsequently, the toxicity of the 
covalent and ionic AuNP samples was screened in the more relevant MCF-7 
breast cancer cell line after 24, 48, and 72 hours incubation with the cells 
(Figure 4-7). Results showed that the nine AuNP samples tested were not toxic 
to any cells up to 72 hours incubation.  
 
N.B [Due to synthesis issues with the cAu_siRNA and cAu_Tat, siRNA these two 
covalent samples were not included in this toxicity screening. However they 
were later included in further MTT analyses using HeLa cells (presented in 
chapter 5, Figure 5-2) with no associated toxicity]. 
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Figure 4-6 AuNP MTT toxicity screening in h-TERT cells 
The MTT assay was used to determine the toxicity of the three primary AuNPs samples in h-
TERT human fibroblast cells after 24 (A), 48 (B) or 72 hours (C). In this experiment, AuNPs 
were screened at concentrations of 1, 0.1 and 0.01mg.ml (error bars are SD, n=3). 
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Figure 4-7 AuNP MTT toxicity screening in MCF-7 cells 
The MTT assay was used to determine the toxicity of AuNPs from the covalent and ionic 
groups in MCF-7 human breast cancer cells after 24 (A), 48 (B) or 72 hours (C). In this 
experiment AuNP were screened at concentrations of 0.1, 0.01 and 0.001mg.ml (error bars 
are SD, n=3). 
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4.3.2 Uptake Analysis 
Visualising cells by TEM following incubation with AuNPs allowed investigation of 
the (i) uptake level, (ii) time scale, and (iii) endocytotic method of particle 
uptake. TEM also allowed visualisation of any intracellular processing of particles 
after they had successfully traversed the cell membrane and gained entry into 
the cytoplasm.  
4.3.2.1 TEM Experiment 1: Cell Uptake at 1 Hour (h-TERT) 
The first TEM experiment performed was a 1 hour incubation of h-TERT human 
fibroblast cells with two of the primary AuNP samples; pAu_COOH and pAu_N3 
(Figure 4-8). Results showed that after 1 hour high levels of each sample were 
cell-associated, with AuNPs mainly observed at the cell periphery, with few 
AuNPs actually being seen inside the cell membrane. This suggested early stage 
endocytosis at 1 hour. Notably, the difference in aggregation state previously 
illustrated between these two samples was again evident here, with pAu_COOH 
existing in a single-particle composition, and pAu_N3 existing as large aggregates 
of clumped particles. Endocytotic events, facilitating cellular internalisation of 
the samples, were captured for both AuNP species. In the case of pAu_COOH, 
membrane pits were observed forming and enclosing a small number of the 
single particles before transporting them internally within endocytotic vesicles 
(Figure 4-8 A). In contrast, pAu_N3, which contained aggregates too large to be 
internalised within pits, was observed being engulfed by larger membrane 
invaginations (Figure 4-8 D). 
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Figure 4-8 Uptake of pAu_COOH and pAu_N3 into h-TERT cells after 1 hour 
TEM images after 1 hour incubation with two of the primary AuNP species, pAu_COOH (A-C) 
and pAu_N3 (D-F).  From these images it can be seen that pAu_N3 was aggregated into 
clumps, whereas pAu_COOH remained as single particles. At this 1 hour point, AuNPs were 
located at the cell surface in the early stages of endocytosis, a process captured in A and D 
[scale bars = 100nm]. 
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4.3.2.2 TEM Experiment 2: Cell Uptake at 18 Hours (h-TERT) 
Following the observation that endocytosis was in the early stage at 1 hour, 
subsequent TEM processing investigated the interaction of these two primary 
samples (pAu_COOH and pAu_N3) in h-TERT cells after a longer incubation time  
of 18 hours (Figure 4-9). Results showed that high levels of each sample were 
cell-associated, with pAu_COOH being mainly confined inside the cell, having 
traversed the membrane. This suggested 18 hours as an optimal time point to 
observe the AuNPs intracellularly, and was thus adopted for further 
experiments. At 18 hours, single particles of pAu_COOH were extensively noted 
inside membrane-enclosed vesicles within the cytoplasm (Figure 4-9 A-E). In 
addition, single particles of pAu_COOH were also seen out with any vesicular 
structure, appearing to be free in the cytoplasm (Figure 4-9 F). This may be 
explained by the fact that some vesicles full of single particles were observed to 
be bursting, releasing the particles within into the cytoplasm (Figure 4-9 D and 
E). In contrast, the aggregates of pAu_N3 were rarely seen inside the cell, 
suggesting that their larger size inhibited the process of endocytosis. Therefore, 
the pAu_N3 AuNP species was not deemed a suitable candidate to achieve the 
project goal of NP-mediated delivery of siRNA.  
 
The TEM observations of pAu_COOH, (i.e. uptake into pits, subsequent 
internalisation, particle grouping in vesicles followed by bursting of these 
vesicles to release the particles into the cytoplasm) represents an ideal situation 
for NP-mediated delivery of siRNA, particularly since if NPs are free inside the 
cytoplasm, out with any endocytotic/lysosomic vesicle, it follows that their 
siRNA payload would be available to interact with the cytoplasmic RISC complex 
to induce silencing of the target gene. 
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Figure 4-9 Uptake of pAu_COOH and pAu_N3 into h-TERT cells after 18 hours 
TEM images after 18 hour incubation with two of the primary AuNP species; pAu_COOH (A-
F) and pAu_N3 (G-L).  The difference in sample aggregation-state is evident in these images, 
with pAu_N3 being highly aggregated and pAu_COOH remaining as single particles. 
pAu_N3 was mainly located at the cell surface, rarely being seen within the cytoplasm, 
indicating poor cellular uptake after 18 hours. Alternatively, pAu_COOH was mainly located 
inside the cytoplasm, either inside vesicles or free inside the cytosol, indicating very high 
cellular uptake after 18 hours, proving suitability to facilitate RNAi [scale bars = 100nm]. 
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4.3.2.3 TEM Experiment 3: Cell Uptake of Ionic Samples at 1 & 48 
Hours (MCF-7 Cancer Cells) 
Following initial investigations into the cellular uptake of the primary AuNP 
samples (pAu_COOH and pAu_N3) into h-TERT fibroblasts, three AuNP samples 
from the ionic group were tested in MCF-7 breast cancer cells after 1 and 48 
hours incubation (Figure 4-10), with similar results expected. However, TEM 
images in this case showed that no uptake of the ionic samples had occurred in 
MCF-7 cells after 1 or 48 hours (Figure 4-10). No cell-associated particles were 
seen, either on the surface or inside the cell. This experiment had involved a 
change of three variables in comparison to the previous TEM Experiment 2 
(different cell type, AuNP samples and longer incubation time), thus it was not 
known what had caused the lack of uptake observed. Efforts now focused on 
elucidating which was the contributing factor. 
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Figure 4-10 No uptake of ionic AuNPs into MCF-7 cells after 1 or 48 hours 
TEM images after 1 or 48 hour incubation with three of the ionic AuNP species; iAu_Tat (A 
and D), iAu_siRNA (B and E) and iAu_Tat, siRNA (C and F).  No AuNPs were seen in 
association with cells in any of the three treatment groups, indicating that no cellular uptake 
had occurred [scale bars = 100nm]. 
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4.3.2.4 TEM Experiment 4: Cell Uptake of Ionic samples at 18 
Hours (h-TERT & MCF-7) 
In order to determine if cell type was a contributory factor, a comparison of the 
uptake levels of pAu_COOH and iAu_siRNA in both h-TERT and MCF-7 cells after 
18 hours was carried out. Results showed that pAu_COOH was heavily uptaken 
into both cell types, whereas iAu_siRNA was poorly uptaken into both cell types 
(Figure 4-11A). This recommended that the lack of uptake seen in TEM 
Experiment 3 was in fact due to the new AuNP samples, rather than the new cell 
type, and suggested that the new ionic samples may have an inherent inability 
to be endocytosed into either cell type tested.  
 
In addition to TEM analysis, ICP-MS was used to quantify the level of uptake of 
10 different AuNP samples (the entire AuNP library, except from pAu_citrate) in 
both h-TERT and MCF-7 cells for comparison with the TEM results. The ICP-MS 
data supported results from TEM Experiment 4, and showed that pAu-COOH 
displayed much higher levels of uptake than iAu_siRNA in both cell types. The 
ICP-MS results also showed that the extremely high level of uptake displayed by 
pAu_COOH was significantly higher than all 8 members of the ionic and covalent 
groups, even those with Tat attached (Figure 4-11B).  
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Figure 4-11 Uptake of pAu_COOH compared to covalent (cAu) and ionic (iAu) samples in h-
TERT and MCF-7 cells after 18 hours (TEM and ICP-MS) 
Figure A: TEM images of MCF-7 cells and h-TERT cells after 18 hours incubation with 
pAu_COOH (A, B, E and F) or iAu_siRNA (C, D, G and H). In accordance with previous TEM 
results, pAu_COOH displayed very high uptake in both h-TERT and MCF-7 cell types, with 
single particles being seen free inside the cytoplasm. In contrast, iAu_siRNA displayed very 
poor uptake in both cell types, and cell-associated particles were rarely observed [scale bar 
= 100nm]. Graph B: ICP-MS analysis of the cellular uptake of 10 AuNP species after 18 
hours incubation with h-TERT and MCF-7 cells. The ICP-MS results supported the TEM, 
since pAu_COOH displayed a ~5-fold higher level of uptake compared to iAu_siRNA in both 
cell types (pAu_COOH and iAu_siRNA have been outlined in red in the ICP-MS graph for 
easy comparison to the TEM images in A.) (In Graph B, error bars are SD, n=3.)  
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4.3.2.5 TEM Experiment 5: Cell Uptake into HeLa Cells at 18 Hours 
(pAu-COOH, cAu_siRNA and cAu_Tat, siRNA) 
Following literature reviews and collaborative work with other members of the 
Nanotruck project, HeLa cervical cancer cells were suggested for use as a cancer 
cell model to test c–myc RNAi. A final TEM assessment was carried out to 
determine the uptake of pAu-COOH, cAu_siRNA and cAu_Tat, siRNA into HeLa 
cells after 18 hours incubation. Results showed that all three AuNPs were heavily 
endocytosed into HeLa cells, being seen mainly within vesicles inside the 
cytoplasm (Figure 4-12). This very promising result suggested that it was feasible 
to hypothesise that covalent and ionic siRNA-functionalised AuNPs would be able 
to induce RNAi in HeLa cells, as the AuNPs were endocytosed. HeLa cells were 
thus selected as the optimal model cancerous cell type in which to test the c-
myc knockdown capabilities of the siRNA-functionalised AuNPs involved in this 
project, as presented in chapter 5.    
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Figure 4-12 Uptake of pAu_COOH compared to cAu_siRNA (+/- Tat) in HeLa cells after 18 
hours 
TEM images after 18 hour incubation with pAu_COOH (A and D), cAu_siRNA (B and E) or 
cAu_Tat, siRNA (C and F). Results showed that all three AuNP species displayed very high 
uptake in HeLa cells [scale bars = 100nm].  
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4.4 Summary and Discussion 
This chapter was mainly concerned with the initial experimental design for 
achieving RNAi in a cancer cell line and has outlined results from the initial 
biological screening of a group of 11 different AuNP samples. The performance 
of these samples in terms of NP characterisation, toxicity screening and cellular 
uptake was used to aid the design of functional optimal AuNP species for 
therapeutic RNAi.  
4.4.1 AuNP Characterisation 
The characterisation results showed that a significant difference in extent of 
particle aggregation existed between samples, ranging from samples composed 
of single, free AuNPs (cAu_siRNA), to samples composed of particles that were 
completely aggregated together into dense clumps (pAu_N3). This difference 
was most likely due to surface chemistry variations. The most obvious example 
of surface chemistry impacting particle aggregation would be the observation 
that samples carrying siRNA were in distinct single-particle form, whereas their 
control counterparts without siRNA suffered from aggregation. Therefore, it is 
conceivable that the negative charge given to particles through the attachment 
of negatively charged siRNA caused steric repulsion between particles, resulting 
in the low state of aggregation as observed by TEM. However, particles of 
pAu_citrate also appeared in the same single-particle format, and so this state is 
not exclusive to the involvement of the siRNA. Perhaps pAu_citrate also 
contained a charge strong enough to cause a similar state of steric repulsion 
between particles. To explain why some of the other samples became very 
heavily aggregated (pAu_N3), perhaps they lacked a charge strong enough to 
induce steric repulsion, or alternatively, it is feasible that some chemical 
surface groups provided attractive forces, causing a ‘sticky’ effect between 
particles.  
 
In theory, using a Malvern Zetasizer is an ideal way to measure the size and zeta 
potential of NPs. However, there are some important technical factors that must 
be taken into careful consideration in order to correctly interpret the results. 
Firstly, the Zetasizer measures NP diameter through the use of dynamic light 
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scattering (DLS), which will read the size of the largest ‘particle’ in the 
suspension. Therefore, in a sample containing 20nm NPs aggregated into 100nm 
clumps, the Zetasizer will incorrectly record the NP diameter as being 100nm. 
Thus, in my opinion, DLS is only useful for measuring suspensions that you are 
either a) entirely sure are in a single particle state, with no aggregation and you 
are using DLS to measure single NP size, or b) you already know the single NP 
size of your suspension (e.g. via TEM), and you are using DLS to determine if any 
particle aggregation has occurred. In this case, TEM had confirmed NP size as 
20nm. In comparison, DLS correctly measured the single NP size of all four ionic 
samples, and cAu_plain, to be 20nm. However, DLS also measured the single NP 
size of the other three covalent samples to be higher (up to 80nm for 
cAu_siRNA). This does not support the TEM images, as the two ionic samples 
without siRNA were aggregated, thus should have had a higher DLS size reading, 
and the covalent samples with siRNA attached appeared dispersed and therefore 
should have had a lower DLS size reading. The fact that the TEM and DLS results 
do not tie up exactly could be due to the temperamentality of using a Zetasizer, 
and also the danger that a TEM image may not be representative of the entire 
NP sample. On a more optimistic note, all eight of the covalent and ionic AuNP 
samples measured under 100nm in diameter by DLS, which is quite relatively 
accurate. Secondly, the format of the NP characterisation by TEM was given 
credibility due to the fact that samples consistently appeared in a similar size 
and state whenever they were investigated in the subsequent TEM cell uptake 
experiments. 
 
In addition to size, the Zetasizer also measured the zeta potential of the eight 
covalent and ionic AuNPs, reporting samples to be between -20 and -50mV. 
Quite frequently in the field, a NP’s zeta potential gets misconstrued to be a 
direct measurement of its electrical charge. However, this is not the case, and 
the main purpose of the zeta potential is to indicate a sample’s colloidal 
stability. This is based on the rule that if a sample has a zeta potential higher 
than 30mV or lower than -30mV, it is considered stable, as the strength of these 
charges will cause steric repulsion of the individual particles, preventing them 
from aggregating out of solution. On the other hand, if a sample has a zeta 
potential between 30 and -30mV, it is considered unstable, as this strength of 
charge is not enough to repel individual particles away from each other in 
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solution, leading to particle aggregation. Assuming this rule, only two out of the 
eight AuNP samples tested had zeta potentials strong enough (below -30mV) to 
classify them as being ‘colloidally stable’ (cAu_plain, and cAu_Tat). This does 
not reflect the aggregation states reported by TEM, as cAu_plain and cAu_Tat 
were not the least aggregated samples tested, and those that were the least 
aggregated (cAu_siRNA and iAu_siRNA) were measured to have zeta potentials in 
the ‘unstable’ region of between 30 and -30mV.  
4.4.2 Toxicity Testing 
MTT toxicity testing did not report any significant reduction in viability in either 
cell type (h-TERT and MCF-7) after incubation with the nine different AuNP 
samples. Significant levels of toxicity are generally considered to correspond to 
the production of # 80% cell viability. Following treatment with the three 
primary AuNP samples, the minimum observed cell viability was 60% at 24 hours, 
and 80% at 48 and 72 hours. Following treatment with the covalent and ionic 
samples, the minimum observed cell viability was 80% for 24 and 48 hours, and 
70% for 72 hours. In conclusion, the majority of the MTT data suggests that the 
AuNP design used in this project can be considered non-toxic to these cell types, 
up to 72 hours. Interestingly there were some data points reporting cell viability 
over 100% after AuNP-treatment. This could have been an indicator of AuNP-
induced cell proliferation, but this was disproved by doing a detailed cell 
counting experiment using Coomassie blue, which showed that there was no 
difference in cell number between control and AuNP-treated cells (results not 
shown). In addition, it was confirmed that the AuNPs themselves were not being 
detected in the colorimetric MTT assay (thereby increasing readings of cell 
viability). It is more likely that viability readings over 100% represent an increase 
in cellular metabolic activity, stimulated as the cells begin to endocytose the 
AuNPs in the surrounding media.  
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4.4.3 Uptake Analysis 
The five separate TEM experiments outlined in this chapter were crucial in 
determining the complex story of AuNP cell uptake. There are two main 
conclusions to be drawn from this work. The first is that pAu-COOH was superior 
to all other samples with regards to cell uptake levels, in all cell lines tested (h-
TERT, MCF-7 and HeLa). The second conclusion is that HeLa cells were advanced 
at taking up siRNA-functionalised AuNPs compared to h-TERT and MCF-7 cells. 
Whilst further studies need to be carried out to provide definite answers to 
explain both of these observations, they do lead to the following considerations. 
1) COOH could play an important role in endocytosis, possibly being able to 
promote binding to certain receptors or docking molecules commonly present on 
the membranes of various different cell lines. Therefore, functionalising NPs 
with COOH may be a useful strategy in order to increase cell uptake in a range 
of different cell types. 2) The fact that siRNA-functionalised AuNPs in this case 
could only be taken up into HeLa cells and not h-TERT or MCF-7 cells highlights 
the fact that NP-uptake is largely cell type-specific. This idea has been 
previously reported, and resonates the importance of testing new NP designs on 
a particle-by-particle basis, in a variety of different cell lines.  
4.4.3.1 COOH  
In comparison to other studies, increased cell uptake mediated by COOH is a 
poorly understood phenomenon that has been reported by a handful of other 
research groups. For example, Jiang et al found that carboxyl-functionalised NPs 
internalised more rapidly and accumulated to a much higher level than plain NPs 
in mesenchymal stem cells (MSCs) (Jiang et al., 2011). This study used 
endocytosis inhibitors to elucidate that carboxyl NPs were internalised by the 
clathrin-mediated mechanism, whereas plain NPs were internalised by 
macropinocytosis. The authors concluded that NP uptake mediated by carboxyl-
functionalisation indicated a specific interaction of the carboxyl group with 
receptors on the cell surface. In addition, Zhang et al reported that carboxylic 
coated quantum dots (QDs) were taken up in greater amounts than either PEG- 
or PEG-amine coated QDs in human epidermal keratinocytes (HEK) (Zhang and 
Monteiro-Riviere, 2009). However, in contrast to Jiang et al, endocytosis 
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inhibitors showed that carboxylic QDs were recognized by lipid rafts but not by 
clathrin or caveolae in HEK cells. Another study into QDs by Xiao et al reported 
that carboxylic QDs were internalised quickly and with large amount in both 
MCF-10A (human mammary non-tumourigenic) and MCF-7 (carcinoma) cells, 
whereas no detectable intracellular uptake was observed for either PEG- and 
PEG-amine QDs in the same cell types (Xiao et al., 2010). The authors concluded 
that the endocytosis of carboxylic QDs was probably assisted by receptors 
specific to ligands with negative charges (such as COOH). Finally, Clift et al 
reported that COOH QDs displayed higher uptake levels than both organic- and 
NH2 (PEG) QDs in J774.A1 (murine ‘macrophage-like’) cells (Clift et al., 2008).  
 
These studies support my data that COOH functionalisation increases cell uptake 
of NPs. As a whole, this body of research dispels the logical and widely believed 
idea that NPs with positively charged surface groups should display better 
endocytosis than NPs with negatively charged surface groups, due to 
electrostatic interactions with the negatively charged cell membrane. In 
contrast, negatively charged COOH seems to provide the highest levels of 
endocytosis, even over positively charged surface groups, such as amine. This 
implies that the process of endocytosis is much more complex than previously 
thought, where negatively charged COOH may have an ability to bind to specific 
cell surface receptors to mediate NP internalisation. However, such COOH-
specific receptors have yet to be identified.  
4.4.3.2 Cell Type 
The second conclusion derived from the TEM experiments presented in this 
chapter (i.e. that siRNA-functionalised AuNPs were taken up into HeLa cells, but 
not h-TERT or MCF-7 cells), is more difficult to directly compare to similar 
studies due to the huge variety in study design present in the literature. In 
contrast to my data, some studies have reported NP uptake to be possible across 
multiple cell types. For example, Siu et al found that amphiphilic core-shell NPs 
consisting of a poly(methyl methacrylate) core with a branched PEI shell could 
transfect MCF-7, BEL 7404, C6, CHO-K1 and HeLa cells successfully (Siu et al., 
2012). Conversely, in a recent study into the uptake of two different NP 
formulations into three different cell types, Lunov et al reported that the (i) 
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extent of NP internalisation, (ii) kinetics of particle uptake, and (iii) particle 
uptake mechanism may grossly differ between cell types (Lunov et al., 2011).  
 
In contrast to the results of this chapter, MCF-7 cells have been successfully 
transfected with siRNA via NP-mediated delivery in other studies. This included  
Huang et al, who reported that PEG-PCL-PEI copolymeric NPs could be used to 
transfect MCF-7 cells with siRNA, which resulted in significant silencing of the 
firefly luciferase gene (as was previously transfected into the cells) (Huang et 
al., 2011). Furthermore, Kean et al found that chitosans with positive charges 
displayed increased uptake in MCF-7 cells compared to PEI, although this 
transfection preference of a positive charge was not observed in COS-7 cells 
(Kean et al., 2005). These studies exemplify that transfection and NP-mediated 
siRNA delivery is possible in MCF-7 cells, although they shed little light on why 
this cell type would not internalise the siRNA-functionalised AuNPs presented in 
this chapter.  
 
In my opinion, differences in surface receptor expression is one of the most 
likely explanations as to why uptake of siRNA-functionalised AuNPs differed 
between cell types in this chapter. This theory is supported by numerous studies 
that have demonstrated the heterogeneity of receptor expression on the surface 
of different cell lines. For example, a study by Li et al investigated the 
expression of the folate receptor across 25 different cancer cell lines. Results 
showed that receptor expression was extremely variable across different cell 
types, and that out of the 25 tested, MCF-7 and HeLa cells were identified to 
have the highest levels of folate receptors compared to the other cell type, and 
were thus selected for siRNA delivery mediated by folate-functionalised NPs (Li 
et al., 2009). In addition, McNamara II et al showed that chimeric RNAs could be 
targeted to certain cell types due to the differential expression of the cell-
surface receptor PSMA across cell types. The authors reported that cell types 
lacking PSMA, such as PC-3 cells could not bind to the chimeric RNAs, whereas 
cell types that did express PSMA, such as LNCaP cells could bind and internalise 
the chimeric RNAs, which induced gene silencing by RNAi (Mcnamara et al., 
2006).  
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Certainly, in the studies by Li et al and Mcnamara et al, cell-specific uptake had 
been anticipated by including ligands for the target receptors in the NP design 
(folate and a PSMA-binding aptamer respectively), whereas in this chapter, cell-
specific uptake was an unexpected result. However, these studies are a good 
example of the heterogeneity of cell surface receptor expression observed 
across different cell types, which lends feasibility to the idea that in this 
chapter, HeLa cells may have expressed some as-yet unidentified cell surface 
receptor that facilitated siRNA-functionalised AuNP uptake, and was not 
expressed in either h-TERT or MCF-7 cells explaining their lack of uptake. Rather 
than being detrimental to a goal of universal siRNA delivery across all cell types, 
Kean et al state that the differences in transfection ability observed between 
cell lines may prove to be an asset allowing researchers to preferentially 
transfect desired cell types with appropriate vectors (Kean et al., 2005). This 
suggests that the HeLa cell specific uptake of siRNA-functionalised AuNPs 
reported in this chapter could in fact be an asset, possibly allowing selective 
targeting of cervical cancer cells.  
4.4.3.3 Tat 
The TEM and ICP-MS data both showed that the CPP Tat did not increase the 
cellular uptake of AuNPs, as it had been expected to do. Prior to speculation on 
the reasoning for this, several issues need to be resolved, including confirmation 
that the Tat remained bound to the NP during the uptake process. Some doubt 
was cast over this as the attachment of a CPP normally results in an increase in 
zeta potential negativity (as demonstrated for the CPP penetratin in chapter 3). 
This increase was not observed with the Tat-functionalised AuNP samples, and so 
testing should be carried out to confirm that the CPP did not become detached 
or denatured/inactivated in some way. Overall, however, the inability of Tat to 
enhance uptake was sidelined since AuNPs without Tat proved perfectly capable 
of being heavily endocytosed into cells (pAu_COOH in to all cell types, and all 
samples into HeLa).  
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4.5 Conclusion 
In conclusion, due to their superior AuNP-uptake capabilities, HeLa cells were 
selected as a model cell line in which to test the c-myc knockdown capabilities 
of the covalent and ionic AuNP samples. 
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5 c-myc Knockdown in HeLa Cells 
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5.1 Introduction 
One of the biggest barriers to NP-mediated delivery of siRNA for therapeutic 
RNAi is the cellular uptake of siRNA-functionalised NPs. As reported in Chapter 
4, HeLa cells presented as an optimal cell line in which to test RNAi delivery 
vehicles, due to the fact that they endocytosed the siRNA-functionalised AuNPs 
more successfully than other cell types (h-TERT and MCF-7). This chapter uses 
HeLa cells to address the two remaining objectives of this part of the Nanotruck 
project; the c-myc knockdown capabilities of the covalent and ionic siRNA-
functionalised AuNPs and the effect of c-myc knockdown on the cell cycle.  
 
In order for NP-mediated RNAi to be achieved, siRNA-functionalised NPs must be 
able to cross the cell membrane and gain access to the cytoplasm. Once in the 
cytosol, the NP’s siRNA payload can interact with the RISC complex, become 
incorporated and thus cause the destruction of endogenous mRNA molecules 
with complementarity to the NP-delivered siRNA. The destruction of the target 
mRNA in this manner prevents its translation into protein, effectively silencing 
gene expression. In the case of this project, a reduction in c-myc expression in 
cancer cells was intended to normalise the balance of the cell cycle. This intent 
was based on the role c-myc plays as a transcription factor to regulate the 
expression of many other genes involved in controlling the cell cycle (Dang, 
2012; Luescher and Vervoorts, 2012). Since the overexpression of c-myc is a 
contributing factor in oncogenesis, reducing its expression via the destruction of 
its mRNA by RNAi was expected to normalise oncogene expression, returning the 
cell cycle to a healthy rate (Ponzielli et al., 2005; Wang et al., 2005).  
 
The performance of the covalent and ionic siRNA-functionalised AuNPs was 
assessed in terms of their c-myc knockdown capability using the following three 
approaches; 
 
(1) monitor the level of target mRNA by qRT-PCR 
 
(2) measure the level of c-myc protein resulting from translation of target 
mRNA. If NP-mediated RNAi has been successful, levels of the target mRNA and 
protein should be significantly reduced. 
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(3) This is frequently where knockdown assessment ends, but a third important 
factor to assess is the cellular effect of the RNAi-induced target mRNA and 
protein knockdown. In this case, the desired effect of c-myc knockdown was to 
decrease the number of cancer cells entering S phase in the cell cycle, thus to 
decrease cell proliferation. A recommended technique was used to measure cell 
proliferation, which involved the substitution of thymidine with labeled uridine 
(BrdU) during the DNA replication stage in the cell cycle. Once BrdU had been 
incorporated, it was immunodetected with an anti-BrdU antibody. This allowed 
dividing cells to be fluorescently distinguished in cell populations.  
 
During assessment of the c-myc knockdown capability of siRNA-functionalised 
AuNPs, a range of controls were introduced into experiments for comparison. 
These were primarily the use of Lipofectamine to deliver c-myc and nonsense 
siRNA to HeLa cells, as it is one of the most effective in vitro transfection agents 
currently available (not for clinical use due to high toxicity) and acts as a good 
positive control. Furthermore, naked c-myc and nonsense siRNA was applied to 
HeLa cells in order to compare the knockdown potential of siRNA when it is used 
without any suitable delivery vehicle (such as NPs or Lipofectamine).  
5.2 Aims 
This chapter aimed to knockdown the c-myc oncogene in HeLa cervical cancer 
cells, through the delivery of siRNA by AuNPs. Knockdown was assessed at the 
levels of mRNA, protein and effect on the cell cycle by qRT-PCR, Western blot 
and BrdU staining respectively. This completes the third and forth objectives of 
this project, as outlined at the beginning of Chapter 4. 
 
1) potential cell toxicity 
2) cellular uptake 
3) c-myc knockdown 
4) effect on cell cycle 
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5.3 Methods      
5.3.1 qRT-PCR 
HeLa cells were grown at 1 x 105 cells per well in a 24 well plate and allowed to 
adhere overnight. AuNP treatments were added (500µl at 0.2mg/ml) and 
incubated with the cells for 48 hours (control cells were incubated with media 
instead). Lipofectamine 2000 was used according to the protocol for HeLa cells 
supplied by Invitrogen (Form No. 18057N). For siRNA delivery by Lipofectamine 
and direct (naked) delivery, siRNA was used at 25 pmol per well. Due to their 
toxicity, Lipofectamine-siRNA complexes were removed after 6 hours and then 
the cells were allowed to complete the 48 hour incubation in culture media. 
Naked siRNA and all AuNP treatments were left in contact with the cells for the 
full 48 hour incubation period. After 48 hours, treatments were removed and 
RNA was extracted using an RNeasy Mini Kit. Reverse transcription was 
performed using a QuantiTect Rev. Transcription kit. Each qRT-PCR reaction 
contained 10ng of cDNA. Three technical replicas were used for each of three 
biological replicas. A 7500 Real-time PCR System was used with Taqman master 
mix and Abi Prism 96-well plates as supplied by Applied Biosystems. Primers and 
probes for c-myc and GAPDH were supplied by Eurofins MWG Operon and their 
sequences are listed in Table 5-1, together with the c-myc siRNA sequence that 
was used in this project to induce RNAi. The binding sites of the c-myc siRNA and 
the c-myc qRT-PCR primers and probes are highlighted within the c-myc mRNA 
transcript displayed in Figure 5-1.  
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Name Sequence 
c-myc siRNA GCGAGGATATCTGGAAGAAAT 
c-myc forward TCAAGAGGTGCCACGTCTCC 
c-myc reverse TCTTGGCAGCAGGATAGTCCTT 
c-myc probe FAM-CAGCACAACTACGCAGCGCCTCC-TAMRA 
GAPDH forward GAAGGTGAAGGTCGGAGTC 
GAPDH reverse GAAGATGGTGATGGGATTTC 
GAPDH probe VIC-CAAGCTTCCCGTTCTCAGCC-TAMRA 
Table 5-1 Sequences of c-myc siRNA and Taqman qRT-PCR primers and probes  
This table lists the sequences of the c-myc siRNA and the qRT-PCR probes and primers for 
c-myc and GAPDH. The colours correspond to binding sites within the c-myc mRNA 
transcript as shown in Figure 5-1. 
 
ORIGIN 
        1 gacccccgag ctgtgctgct cgcggccgcc accgccgggc cccggccgtc cctggctccc 
       61 ctcctgcctc gagaagggca gggcttctca gaggcttggc gggaaaaaga acggagggag 
      121 ggatcgcgct gagtataaaa gccggttttc ggggctttat ctaactcgct gtagtaattc 
      181 cagcgagagg cagagggagc gagcgggcgg ccggctaggg tggaagagcc gggcgagcag 
      241 agctgcgctg cgggcgtcct gggaagggag atccggagcg aatagggggc ttcgcctctg 
      301 gcccagccct cccgctgatc ccccagccag cggtccgcaa cccttgccgc atccacgaaa 
      361 ctttgcccat agcagcgggc gggcactttg cactggaact tacaacaccc gagcaaggac 
      421 gcgactctcc cgacgcgggg aggctattct gcccatttgg ggacacttcc ccgccgctgc 
      481 caggacccgc ttctctgaaa ggctctcctt gcagctgctt agacgctgga tttttttcgg 
      541 gtagtggaaa accagcagcc tcccgcgacg atgcccctca acgttagctt caccaacagg 
      601 aactatgacc tcgactacga ctcggtgcag ccgtatttct actgcgacga ggaggagaac 
      661 ttctaccagc agcagcagca gagcgagctg cagcccccgg cgcccagcga ggatatctgg 
      721 aagaaattcg agctgctgcc caccccgccc ctgtccccta gccgccgctc cgggctctgc 
      781 tcgccctcct acgttgcggt cacacccttc tcccttcggg gagacaacga cggcggtggc 
      841 gggagcttct ccacggccga ccagctggag atggtgaccg agctgctggg aggagacatg 
      901 gtgaaccaga gtttcatctg cgacccggac gacgagacct tcatcaaaaa catcatcatc 
      961 caggactgta tgtggagcgg cttctcggcc gccgccaagc tcgtctcaga gaagctggcc 
     1021 tcctaccagg ctgcgcgcaa agacagcggc agcccgaacc ccgcccgcgg ccacagcgtc 
     1081 tgctccacct ccagcttgta cctgcaggat ctgagcgccg ccgcctcaga gtgcatcgac 
     1141 ccctcggtgg tcttccccta ccctctcaac gacagcagct cgcccaagtc ctgcgcctcg 
     1201 caagactcca gcgccttctc tccgtcctcg gattctctgc tctcctcgac ggagtcctcc 
     1261 ccgcagggca gccccgagcc cctggtgctc catgaggaga caccgcccac caccagcagc 
     1321 gactctgagg aggaacaaga agatgaggaa gaaatcgatg ttgtttctgt ggaaaagagg 
     1381 caggctcctg gcaaaaggtc agagtctgga tcaccttctg ctggaggcca cagcaaacct 
     1441 cctcacagcc cactggtcct caagaggtgc cacgtctcca cacatcagca caactacgca 
     1501 gcgcctccct ccactcggaa ggactatcct gctgccaaga gggtcaagtt ggacagtgtc 
     1561 agagtcctga gacagatcag caacaaccga aaatgcacca gccccaggtc ctcggacacc 
     1621 gaggagaatg tcaagaggcg aacacacaac gtcttggagc gccagaggag gaacgagcta 
     1681 aaacggagct tttttgccct gcgtgaccag atcccggagt tggaaaacaa tgaaaaggcc 
     1741 cccaaggtag ttatccttaa aaaagccaca gcatacatcc tgtccgtcca agcagaggag 
     1801 caaaagctca tttctgaaga ggacttgttg cggaaacgac gagaacagtt gaaacacaaa 
     1861 cttgaacagc tacggaactc ttgtgcgtaa ggaaaagtaa ggaaaacgat tccttctaac 
     1921 agaaatgtcc tgagcaatca cctatgaact tgtttcaaat gcatgatcaa atgcaacctc 
     1981 acaaccttgg ctgagtcttg agactgaaag atttagccat aatgtaaact gcctcaaatt 
     2041 ggactttggg cataaaagaa cttttttatg cttaccatct tttttttttc tttaacagat 
     2101 ttgtatttaa gaattgtttt taaaaaattt taagatttac acaatgtttc tctgtaaata 
     2161 ttgccattaa atgtaaataa ctttaataaa acgtttatag cagttacaca gaatttcaat 
     2221 cctagtatat agtacctagt attataggta ctataaaccc taattttttt tatttaagta 
     2281 cattttgctt tttaaagttg atttttttct attgttttta gaaaaaataa aataactggc 
     2341 aaatatatca ttgagccaaa tcttaaaaaa aaaaaaaaa 
Figure 5-1 Human c-myc mRNA sequence 
Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) transcript is 
a 2379bp linear mRNA. The c-myc siRNA sequence used in this project is highlighted in 
yellow. The c-myc forward primer, reverse primer and probe used for qRT-PCR are 
highlighted in blue, grey and green respectively. (These c-myc siRNA and qRT-PCR 
sequences are listed in Table 5-1.) The c-myc mRNA transcript contains four exons as 
defined by the four different colours of text. Blue, green, red and black text indicates exons 
1-4 respectively. 
Hannah W. Child, 2012                                                                      Chapter 5, 127 
 
5.3.2 Protein Extraction 
Cell culture and the addition of AuNPs/Lipofectamine was performed as in 5.3.1. 
After a 48 hour incubation the treatment media was removed, cells were 
trypsinised and pelleted by centrifugation. Cell pellets were resuspended in 50µl 
protein extraction buffer, left on ice for 15 min and then ultracentrifuged for 10 
min at 14,000 rpm (4°C). The supernatant was transferred to a fresh eppendorf 
and stored at -80°C until ready to use. NB (A frozen protein pellet from Burkitts 
lymphoma Rayj cells (EBV+) was gifted from Joanna Wilson at the University of 
Glasgow for use as a c-myc positive control in Western blots.) 
5.3.3 SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was used to separate proteins on the basis of size. SDS-PAGE was 
performed using Invitrogen Novex Mini Cell tank apparatus, and a PowerEase 500 
power pack. Proteins were separated using NuPAGE 4-12% Bis-Tris gels (1.0mm x 
15 well).  
 
The total protein concentration of samples was quantified using a 
spectrophotometer (NanoDrop-1000 V3.7.1) following manufacturer’s 
instructions. Samples were diluted to equal amounts of total protein (60ng for 
Hela cell samples and 10ng for Rayj EBV+ cell sample) and made up to 20µl with 
protein extraction buffer (with no inhibitors added). 7µl sample loading buffer 
was added and samples were incubated on a preheated heating block for 10 min 
at 70°C to denature proteins. During heating, the gel tank apparatus was 
assembled. The inner chamber was filled with inner chamber running buffer and 
the outer section of the tank was filled with normal running buffer. Combs were 
removed from the gel and empty wells were flushed with running buffer to 
remove any residual oils before sample loading. After heating, the total volume 
of each sample (27µl) was loaded onto the gel. 10µl protein ladder was loaded 
into the first lane of gel. Gel was run at 200V, 120mA, and 25W until the colour 
of the sample-loading buffer had reached the bottom of the gel.  
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5.3.4 Western Blotting 
Following SDS-PAGE, proteins were transferred onto a nitrocellulose membrane 
for immunodetection. The gel was removed from plastic cassette and the wedge 
at the bottom edge of the gel was cut off. Gel was immersed in cold transfer 
buffer while transfer apparatus was assembled. Membrane was soaked in 
methanol for 10 sec, distilled water for 5 min and transfer buffer for 5 min. The 
rest of the transfer apparatus (pads and filter paper) was also soaked in transfer 
buffer and the transfer system was assembled in the following order, from 
cathode to anode: 2x sponge pads, 3x filter paper, gel containing proteins, 
transfer membrane, 3x filter paper, 3x sponge pads. The transfer cassette was 
completed with its lid, put into the tank and clamped into place. The tank was 
sat on ice, filled with transfer buffer, and proteins were transferred onto the 
nitrocellulose membrane at 25V, 120mA, and 3W for 1 hour.  
5.3.5 Immunodetection of Proteins 
Following Western blotting, proteins were visualised by enhanced chemical 
luminescence (ECL). Nitrocellulose membranes were removed from the transfer 
cassette and placed in a small container. To block non-specific binding sites 
membranes were incubated in blocking buffer for 1 hour on a plate shaker at 
room temperature, or overnight at 4°C. Primary antibodies were diluted in 5% 
(w/v) dried milk/ PBS-T to an appropriate dilution. Membranes were incubated 
in primary antibody on shaker for 1 hour at room temperature, or overnight at 
4°C. Membranes received 3 x 10 min washes in PBS-T on shaker. Secondary IgG 
horseradish peroxidase-conjugated antibodies (HRP-conjugated IgG) were 
diluted in 5% (w/v) dried milk/ PBS-T to an appropriate dilution. Membranes 
were incubated in HRP-conjugated IgG for 1 hour at room temperature on 
shaker. Membranes received 3 x 10 min washes in PBS-T on shaker. 
 
HRP-immunolabelled proteins were visualised using the ECL system. ECL 
reagents were mixed in a 1:1 ratio and then poured over the nitrocellulose 
membrane. The membrane was incubated in this detection mix for 5 min in the 
dark. The membrane was then removed from container, excess detection mix 
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was removed and the membrane was exposed to Kodak X-ray film in a lightproof 
cassette and developed using an X-Omat Processor.   
5.3.6 Stripping of Nitrocellulose Membranes 
To strip nitrocellulose membranes of bound antibodies, membranes were 
immersed in transfer buffer, and then incubated in stripping buffer for 10 min at 
room temperature, on shaker. Membranes were then washed in PBS-T, and 
blocked and re-probed with primary antibody as required.  
5.3.7 Antibodies for Probing Nitrocellulose Membranes 
To detect the c-myc protein, the primary antibody was Anti-c-myc antibody, 
raised in mouse (Abcam), used at 1:500 dilution in 5% (w/v) milk in PBS-T. The 
secondary antibody was anti-mouse IgG-HRP, raised in goat (Santa Cruz Biotech), 
used at 1:4000 dilution in 5% (w/v) milk in PBS-T. 
 
To detect the GAPDH protein, the primary antibody was Anti-GAPDH antibody, 
raised in rabbit (Epitomics), used at 1:10,000 dilution in 5% (w/v) milk in PBS-T. 
The secondary antibody was anti-rabbit IgG-HRP, raised in goat (Santa Cruz 
Biotech), used at 1:4000 dilution in 5% (w/v) milk in PBS-T. 
5.3.8 BrdU Staining 
HeLa cells were seeded at 1 x 105 cells per well on glass coverslips in a 24 well 
plate and allowed to adhere overnight. AuNP/Lipofectamine treatments were 
added as in 5.3.1 and incubated for 48 hours (control cells were incubated with 
media alone). Cells were washed in PBS and incubated with 1ml of 100µM BrdU 
for 1.5 hours. Cells were washed in PBS, fixed in 4% formaldehyde, 
permeabilised, blocked in PBS/1%BSA and then incubated with anti-BrdU/DNase 
(1:100), followed by biotinylated anti-mouse secondary antibody (1:50), 
followed by streptavidin-FITC (1:50), in conjunction with rhodamine-phalloidin 
to stain actin. Cells were washed with PBS between each step. 
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5.3.9 Statistics 
Statistical analysis was performed in SPSS. For the qRT-PCR data, the covalent 
AuNP group, the ionic AuNP group and the lipo/naked control group were all 
analysed independently by one-way ANOVA with Dunnett’s test (n=3). For the 
BrdU data, the number of BrdU positive cells in 10 fields of view per treatment 
was quantified using Image J software, and analysed by one-way ANOVA with 
Dunnett’s test (n=10). In all figures, * = p < 0.05, ** = p < 0.01. *** = p < 0.001. 
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5.4 Results 
5.4.1 MTT Cell Toxicity Screening 
In order to assess any cellular toxicity caused by the AuNPs, the viability of HeLa 
cells after incubation with each AuNP for 48 hours was measured using the MTT 
assay. Results showed that the HeLa cells remained highly viable after a 48 hour 
incubation with each AuNP species (Figure 5-2). In the majority of cases, cells 
remained over 80% viable, which is considered to indicate a very low level of NP 
toxicity. Slightly higher toxicity was caused by AuNPs with ionically attached 
siRNA (iAu_siRNA and iAu_Tat, siRNA), which reduced cellular viability to ~70%. 
In comparison, AuNPs with covalently attached siRNA (cAu_siRNA and cAu_Tat, 
siRNA) retained over 90% cellular viability. This batch of eight AuNPs can be 
considered generally non-toxic to cells, with the covalent attachment of siRNA 
proving a less toxic design than the ionic attachment of siRNA.  
 
 
Figure 5-2 AuNP MTT toxicity screening in HeLa cells 
The eight AuNP samples were screened following a 48 hour incubation with Hela cells. 
Control cells, treated with only media, were taken to represent 100% viability, and the 
viability of the eight nanoparticle treated samples was expressed as the percentage viability 
relative to the control. A line has been drawn at 100% viability to aid easy comparison 
between the control and the eight nanoparticle treated samples.  
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5.4.2 qRT-PCR 
The level of c-myc mRNA was quantified by qRT-PCR after a 48 hour incubation 
with each of the eight AuNP species, in order to compare their c-myc knockdown 
capabilities. Results showed that the highest c-myc knockdown was achieved 
when the siRNA was covalently attached to the AuNP: cAu_siRNA caused a 39% 
knockdown, and cAu_Tat, siRNA caused a 42% knockdown. In comparison, when 
the siRNA was ionically attached to the AuNP, the c-myc knockdown was much 
lower: iAu_siRNA caused a 13% knockdown, and iAu_Tat, siRNA caused no 
knockdown at all. This suggested that covalent siRNA attachment was more 
effective than ionic siRNA attachment. In addition, results indicated that the 
inclusion of Tat did not significantly improve the knockdown efficiency of AuNPs. 
Due to the lack of requirement for Tat, it was concluded that out of the eight 
species investigated, cAu_siRNA was the optimal AuNP design for the delivery of 
c-myc siRNA to HeLa cells (Figure 5-3B). 
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Figure 5-3 c-myc mRNA knockdown in HeLa cells, as assessed by qRT-PCR 
This figure shows the level of c-myc mRNA (normalised to GAPDH) as assessed by Taqman 
quantitative real-time PCR (qRT-PCR). Graph A shows the level of c-myc mRNA after 
treatment with c-myc or nonsense (n.s) siRNA, either delivered directly onto the cells 
(naked), or delivered to the cells using Lipofectamine (lipo). Graph B shows the level of c-
myc mRNA after treatment with the eight AuNP species. In both graphs, the control 
represents cells treated with media alone. All treatments were incubated with the cells for 
48 hours. Please note that AuNPs with covalent siRNA attachment (red bars) produced a 
higher knockdown than AuNPs with ionic siRNA attachment (yellow bars). (* = p < 0.05,  
** = p < 0.01 as analysed by one-way ANOVA with Dunnett’s test in SPSS. Error bars are SD, 
n=3.) 
 
 
 
 
 
Hannah W. Child, 2012                                                                      Chapter 5, 134 
 
5.4.3 Western Blotting 
Cellular protein was investigated by Western blot in order to check if the 40% 
knockdown of c-myc mRNA induced by a 48 hour incubation with cAu_siRNA (as 
reported by qRT-PCR) was detectable at protein level. Only two AuNP species 
were selected for the Western blots; cAu_siRNA, and the corresponding negative 
control cAu_plain. These were compared against c-myc or nonsense (n.s) siRNA 
delivered to the cells by Lipofectamine. The density of the c-myc protein bands 
was normalised to the density of the GAPDH protein bands for each sample, and 
expressed graphically using Image J analysis. Results show that expression of the 
c-myc protein was reduced by 40% when c-myc siRNA was delivered by 
nanoparticles (cAu_siRNA) and by 80% when delivered by Lipofectamine (c-myc 
lipo). Expression of the c-myc protein was not effected by either of the two 
negative controls (cAu_plain or n.s lipo), supporting the fact that the c-myc 
knockdown is specific to the c-myc siRNA, and not caused by the presence of 
either AuNPs or Lipofectamine (Figure 5-4).  
 
 
 
N.B [During the optimisation of the Western blot procedure, protein from the 
Rayj EBV+ cell line (known to overexpress c-myc) was employed as a positive 
control to which the other HeLa samples could be compared.] 
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Figure 5-4 c-myc protein knockdown in HeLa cells, as assessed by Western blot 
HeLa cells were incubated with each treatment for 48 hours, after which the level of 
expressed c-myc protein was measured by Western blot. The density of each c-myc band 
was normalised to the density of the corresponding GAPDH band (to allow for any 
differences in loading volume) and results were expressed graphically as the percentage of 
c-myc protein expression relative to the control sample (control cells treated with media 
only). Results showed that cAu_siRNA produced a 40% knockdown in c-myc protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hannah W. Child, 2012                                                                      Chapter 5, 136 
 
5.4.4 BrdU Staining 
In order to determine if the 40% reduction in c-myc expression reported at both 
the mRNA and protein levels by qRT-PCR and Western blot respectively was 
having an effect on the speed of the cell cycle, BrdU staining was employed to 
fluorescently label dividing cells. The BrdU method allows 5-bromo2’-deoxy-
uridine (BrdU) to be incorporated into the DNA in place of thymidine, during the 
process of DNA replication occurring in dividing cells. This incorporation allows 
dividing cells to be fluorescently visualised by subsequent immunodetection 
using a monoclonal antibody against BrdU.  
 
As in the Western blot experiment, only two AuNP samples were investigated, 
cAu_siRNA and the corresponding negative control cAu_plain. These treatments 
were compared to c-myc or nonsense (n.s) siRNA delivered by Lipofectamine. 
Results show that a similar number of dividing cells were evident in the control 
cell culture and in those treated with the negative controls (cAu_plain and n.s 
lipo). In contrast, the number of dividing cells was significantly reduced in cell 
cultures when c-myc siRNA was delivered by nanoparticles (cAu_siRNA) and by 
Lipofectamine (c.m lipo) (Figure 5-5). This demonstrated that the reduction in 
the level of c-myc expression achieved by treatment with cAu_siRNA acted to 
inhibit cells entering the S phase of the cell cycle, thus decreasing cell 
proliferation. 
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Figure 5-5 Proliferation of HeLa cells as assessed by BrdU staining 
Cells treated with c-myc siRNA, either delivered by covalent attachment to AuNPs 
(cAu_siRNA) or by Lipofectamine (c-myc lipo) are presented in the right hand side of A (two 
images are provided for cAu_siRNA). Untreated cells (control), cells treated with AuNPs 
without any siRNA attached (cAu_plain) and cells treated with nonsense siRNA delivered by 
Lipofectamine (n.s lipo) are presented on the left hand side of A [scale bars = 100µm]. The 
number of BrdU positive cells in 10 fields of view per treatment was quantified in Image J 
and presented graphically (B). (*** = p < 0.001 as analysed by one-way ANOVA with 
Dunnett’s test in SPSS. Error bars are SD, n=10.) 
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5.4.5 TEM  
TEM was used to visualise the AuNPs inside HeLa cells to gain insight into the 
level and method of cellular uptake, and intracellular location of the 
internalised nanoparticles. AuNP samples with c-myc siRNA covalently attached, 
with and without Tat (cAu_siRNA and cAu_Tat, siRNA) were chosen for 
investigation by TEM as they produced the best c-myc knockdown as assessed by 
qRT-PCR. Furthermore, it was hoped that TEM would provide clarification as to 
the inclusion of Tat, as results to date suggested it was not enhancing uptake as 
originally expected. Results showed that both AuNP species were uptaken into 
HeLa cells, although from these images it appears that Tat did not increase 
uptake, and as such, was not necessary for inclusion in the nanoparticle design.  
 
 
Figure 5-6 Uptake of AuNPs into HeLa cells as assessed by TEM 
TEM images indicate AuNPs with siRNA covalently attached in HeLa cells after 18 hours 
incubation. The top two images show AuNPs without Tat, and the bottom two images show 
AuNPs with Tat. AuNPs were seen in the cytoplasm, where it is envisaged that their siRNA 
payload becomes incorporated into the RISC complex to cause gene silencing through RNA 
interference (RNAi) [scale bars = 500nm]. 
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5.5 Summary and Discussion 
This chapter has demonstrated knockdown of the c-myc oncogene in HeLa cells 
through RNAi, facilitated by the delivery of siRNA by AuNPs. Two alternative 
approaches for chemically attaching siRNA to AuNPs were investigated, and 
results conclude that the covalent attachment is favorable compared to the 
ionic attachment. The inclusion of Tat in the AuNP design did not significantly 
improve knockdown efficiency, and this is believed to be due to the fact that 
Tat did not appear to enhance cell uptake of AuNPs.  
 
The reason for the higher knockdown levels observed when siRNA was attached 
covalently rather than ionically may be due to the fact that the Au-S covalent 
bonds between the thiolated siRNA and the AuNP core are stronger than the 
electrostatic bonds between the siRNA and the positively charged R4N group on 
the outside of the particle. Therefore, due to weaker bonding, perhaps the 
ionically attached siRNA became dissociated from the AuNP before it could be 
successfully delivered to the cytoplasm to interact with RISC. Or alternatively, 
perhaps the presence of the positively charged R4N group inactivated RISC in 
some way, possibly by preventing correct siRNA loading into the enzymatic 
complex. 
5.5.1 The Unsuccessful Ionic Approach 
In comparison to the literature, Ghosh et al used a similar ionic design strategy 
whereby AuNPs were functionalised with the amino acid lysine in order to 
ionically bind DNA plasmids for delivery to monkey kidney cells (Cos-1) (Ghosh et 
al., 2008). This study utilised ionic binding between the positive charges of the 
amine groups within the lysine residues and the negatively charged DNA plasmid 
to achieve very high transfection efficiencies. The success of the ionic AuNP 
design demonstrated by Ghosh et al suggests that the similar positively charged 
R4N surface groups used in this thesis should also have facilitated successful 
delivery of siRNA. However, results in this chapter proved that the ionic design 
was unsuccessful with regards to c-myc knockdown by RNAi. There are a number 
of possible reasons to explain why ionic attachment to AuNPs should enable the 
delivery and expression of plasmid DNA but not the delivery of c-myc siRNA for 
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RNAi, including 1) the electrostatic interaction of siRNA largely differs from that 
of plasmid DNA (Patil et al., 2008; Gary et al., 2007), and 2) following delivery, 
plasmid DNA does not require any involvement with the RISC complex for 
molecular functionality. The study by Ghosh et al concluded that AuNPs 
functionalised with lysine were ~28 fold superior than polylysine in reporter gene 
expression, suggesting that NPs functionalised with cationic surface groups may 
be more successful than the use of cationic polymers for ionic delivery 
strategies. In contrast to this, and despite the poor performance reported for 
polylysine, cationic polymers are commonly used in polyplex formation for siRNA 
cellular delivery, which is useful for comparison to this chapter.  
 
The polyplex delivery strategy involves the formation of nanometer-sized ionic 
complexes (polyplexes) through noncovalent interaction between negatively 
charged siRNA and positively charged macromolecular vectors such as polymers, 
dendrimers and lipids (Salcher and Wagner, 2010). A recent polyplex study by 
Ornelas-Megiatto et al is relevant to this discussion of why ionic attachment of 
siRNA to the R4N (quaternary ammonium) surface group proved unsuccessful for 
c-myc knockdown in HeLa cells. Ornelas-Megiatto et al compared polyplexes 
composed of either ammonium or phosphonium positively charged polymers, for 
their ability to deliver siRNA to HeLa cells in order to silence the luciferase 
gene. Results showed that ammonium polymers achieved 25% knockdown with 
85% cell viability, whereas phosphonium polymers achieved 65% knockdown with 
100% viability (Ornelas-Megiatto et al., 2012). Based on these findings, the 
authors concluded that ammonium polymers were not the best choice of vector 
for siRNA delivery since they displayed higher toxicity and weaker nucleotide 
binding than other types of cationic polymers. In theory, these undesirable 
transfection properties associated with ammonium polymers could also hold true 
for the R4N group that was used to ionically attach siRNA to AuNPs species 
described in this thesis. If so, it supports the idea that the poor knockdown 
capabilities of the ionic AuNPs could indeed have been caused by weak binding 
strength between the R4N group and the siRNA, as previously suggested. 
However, in contrast to the findings of Ornelas-Megiatto et al, it seems unlikely 
that the R4N group was the cause of any toxicity associated with the ionic AuNP 
samples, since the MTT assay showed that iAu_plain and iAu_Tat displayed no 
toxicity despite also having the R4N group attached.  
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Aside from implicating weak binding and toxicity to explain the poor transfection 
properties of ammonium polymers, Ornelas-Megiatto et al did not consider that 
the cationic polymers used to bind siRNA could cause inhibition of the RISC 
complex. This lack of consideration is probably because the authors 
hypothesised that the siRNA payload became released from the cationic polymer 
upon entry into the cell, and therefore the two molecules would not be in 
contact during siRNA incorporation into RISC. Whether the R4N group interfered 
with RISC in this chapter remains to be determined. Learning from the findings 
of Ornelas-Megiatto et al, perhaps ionic siRNA attachment to NPs will be more 
successful if cationic surface groups based on phosphonium are used instead of 
the R4N quaternary ammonium group featured in this project, since they may 
provide stronger electrostatic interactions, thereby preventing the siRNA from 
becoming dissociated before it reaches the cell.  
5.5.2  The Successful Covalent Approach 
The particular type of covalent bond employed in this project, (i.e. the gold-
thiol interaction) is a far stronger attachment than ionic bonding (Pissuwan et 
al., 2011). In addition, it has been described as a dynamic bond allowing 
disassociation under reductive conditions such as the high glutathione 
concentrations in the cell cytoplasm (Lytton-Jean et al., 2011; Meister and 
Anderson, 1983). Therefore it seems likely that c-myc knockdown was achieved 
because covalent attachment of siRNA provided two main advantages to 
delivery; 1) extracellular strength, and 2) intracellular release.  
 
The c-myc knockdown achieved by the AuNPs with siRNA covalently attached 
echoes the success of previous studies that have achieved gene knockdown using 
functionalised NPs. For example, siRNA-delivering cationic NPs reduced the 
expression of Mcl-1 in carcinoma cells, causing an 81% reduction in cell viability 
(Chang et al., 2011). In addition, conjugated polymer NPs delivered siRNA to 
reduce the expression of actin by 94% in HeLa cells (Moon et al.). In 2004, Wang 
et al demonstrated 80% knockdown of c-myc in breast cancer cells after 
transfection with a siRNA-encoding plasmid, demonstrating an alternative 
approach to siRNA delivery, growing in popularity due to its longer lasting 
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silencing (Wang et al., 2005). In the example of Wang et al, Lipofectamine 
facilitated the plasmid transfection, although several more recent studies have 
used NPs to deliver siRNA-encoding plasmids for RNAi (Guo et al.; Mukerjee et 
al.). In comparison of this long-term plasmid approach, this chapter has shown 
that the knockdown produced by covalent AuNP siRNA delivery is in effect after 
48 hours, but how long it would last in vivo is an issue that remains to be 
determined. 
 
The majority of previous knockdown studies report a higher level of target gene 
knockdown than the 40% c-myc knockdown presented here, but this higher 
knockdown was often associated with a higher level of cellular toxicity (Chang et 
al., 2011). Obviously killing cancer cells by RNAi appears as a desirable end goal 
to siRNA delivery. However, this chapter has shown that a 40% oncogene 
knockdown is indeed sufficient to induce a significant reduction in cancer cell 
proliferation, whilst avoiding cell death. This suggests that complete silencing of 
oncogenes may not actually be necessary for successful cancer therapy. 
Therefore, perhaps the end goal in future RNAi therapy should instead be to 
normalise the abhorrent expression levels of oncogenes rather than to stop their 
expression completely. 
5.5.3 The Lack of Tat Influence 
The CPP Tat was included in the AuNP design strategy as it was expected to 
increase cell uptake of the particles, thereby increasing their c-myc knockdown 
efficiency. However, the qRT-PCR data revealed that the inclusion of Tat did not 
significantly increase the level of c-myc knockdown. Uptake analysis by TEM and 
ICP-MS indicated that this lack of effect is due to the fact that Tat did not 
actually enhance the cell uptake of AuNPs. This finding could be possibly due to 
inaccessibility or dissociation of Tat. To discuss the former, some studies have 
shown that if the PEG chains on a NP surface are longer than the functional 
molecules, the activity of the functional molecules can be reduced due to their 
inaccessibility to the cell since they are hidden within the PEG layer. This danger 
was highlighted in a review by (Lytton-Jean et al., 2011), which discussed that a 
study using AuNPs co-loaded with SH-PEG5000-PAMA7500 and SH-siRNA only 
achieved 65% luciferase knockdown in HuH-7 cells (Oishi et al., 2006), whereas a 
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study that used AuNPs co-loaded with much shorter SH-PEG400 and SH-siRNA 
achieved 70% luciferase knockdown in HeLa cells (Giljohann et al., 2009). 
Lytton-Jean et al suggested that the improvement in knockdown efficiency was 
due to the use of shorter PEG chains, since it allowed more of the siRNA 
molecules to be accessible to the cell for RISC interaction. In comparison to 
these similar studies using PEGylated AuNPs, the PEG8 chains used in this chapter 
were much smaller than either PEG5000-PAMA7500 or PEG400, making them less 
likely to hide adjacent functional molecules from cellular recognition.  
 
In this project, the 13 amino acid long Tat peptide was ~6.5nm in length, the 21 
nucleotide long siRNA was ~10.5nm in length and the 8 monomer long PEG 
polymer was ~3.5nm in length. Therefore, it is unlikely that Tat was inaccessible 
to the cells, due to the fact that 1) the PEG chains were smaller than Tat and 2) 
Tat was attached to the ends of the PEG molecules rather than to the NP core. 
Alternatively, the most likely theory to explain why Tat did not improve uptake 
is that it became dissociated from the AuNP during transit from grant partners. 
This theory was suggested in chapter 4, since the Zetasizer results showed no 
difference in zeta potential between particles with or without Tat.  
 
An interesting point worth discussing as to the use of Tat for enhancing siRNA 
delivery, is that it has recently emerged that infection with the HIV-1 Tat virus 
(from which the Tat CPP is derived) can inhibit RNAi in mammalian cells (Qian et 
al., 2009). Although Tat was not shown to inhibit RNAi in this project, it is an 
important consideration in the design of future CPP-mediated siRNA delivery 
strategies for RNAi; as are peptide dissociation, and cellular inaccessibility 
within large PEG layers. 
5.6 Conclusion 
This study has been the first to directly compare ionic vs. covalent attachment 
of siRNA to NPs for RNAi. Results have demonstrated that c-myc knockdown by 
RNAi can be achieved in HeLa cells through the delivery of siRNA covalently 
attached to AuNPs. This has proven to be a more effective design strategy than 
either a) ionically attached siRNA, or b) the inclusion of Tat. The novel AuNPs 
presented in this thesis demonstrated low cellular toxicity, facilitated c-myc 
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knockdown and as a result, reduced cell proliferation in cancerous HeLa cells (as 
summarised in Table 5-2). Therefore they exemplify the achievable potential of 
NP-mediated RNAi in future cancer therapy. 
 
Sample 
Acronym 
Main findings 
pAu_citrate Used only in toxicity testing (low toxicity) 
pAu_COOH • Sample with best cell uptake properties 
• Desplayed high uptake into all cell types tested 
(h-TERT, MCF-7 & HeLa) 
pAu_N3 • Aggregated 
cAu_plain Used only in toxicity testing (low toxicity) 
cAu_Tat • Low uptake in MCF-7 cells 
cAu_siRNA • Low uptake in h-TERT or MCF-7 cells 
• High uptake into HeLa cells 
• Sample with optimal knockdown properties 
• Produced 39% knockdown in c-myc mRNA 
• Produced 40% knockdown in c-myc protein 
• c-myc knockdown reduced cell proliferation 
cAu_Tat, siRNA • Low uptake in h-TERT or MCF-7 cells 
• High uptake into HeLa cells 
• Produced 40% knockdown in c-myc mRNA 
iAu_plain Used only in toxicity testing (low toxicity) 
iAu_Tat Used only in toxicity testing (low toxicity) 
iAu_siRNA • Low uptake into h-TERT or MCF-7 cells 
• High uptake into HeLa cells 
• Produced 13% knockdown in c-myc mRNA 
iAu_Tat, siRNA • Low uptake into h-TERT or MCF-7 cells 
• High uptake into HeLa cells 
• Knockdown unsuccessful (0%) 
Table 5-2 Summary of main findings 
This table summarises the main findings for each of the 11 AuNP species investigated in 
this thesis. The four main test criteria, as outlined at the start of chapter 4, were potential 
cell toxicity, cellular uptake, c-myc knockdown and effect on the cell cycle. Out of the 11 
samples, pAu_COOH was found to display the best cellular uptake properties, and 
cAu_siRNA was found to be the optimal sample for c-myc knockdown. (This table has been 
colour-coordinated with Figure 4-2, where primary samples are displayed in green, covalent 
samples are displayed in violet and ionic samples in orange.)
                                                                                                                         145 
6 Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hannah W. Child, 2012                                                                      Chapter 6, 146 
 
6.1 Introduction 
Advances in biomedicine have identified many novel types of therapeutic 
molecules that have the potential to cure disease. These include newly 
identified small molecule drugs, and oligonucleotides for gene replacement 
therapy and RNAi. However, at present systemic delivery remains the major 
hurdle to widescale clinical use of these therapeutics. It is proposed that NPs 
will over come this hurdle by acting as multifunctional delivery vehicles to 
transport molecular cargo into diseased cells within the body. This thesis has 
investigated two different NP design strategies to assess their potential for use 
as therapeutic delivery vehicles; 1) the use of a magnetic field (MF) and a CPP 
(penetratin) to increase the delivery of iron oxide magnetic NPs (mNPs) to cells 
grown in tissue-equivalent 3D collagen gels, and 2) gold NPs (AuNPs) for the 
delivery of siRNA to silence the c-myc oncogene for cancer treatment. The main 
conclusions from this work were that; 
 
• a MF facilitated movement of iron mNPs through 3D tissue-equivalent cell-
seeded collagen gels, targeting the mNPs to the embedded fibroblast 
cells, whilst the CPP penetratin enhanced the cellular uptake of mNPs 
within this 3D model. This led to the conclusion that synergistic use of 
both together (i.e. the MF and penetratin) could provide an excellent 
platform for NP mediated delivery in 3D tissues. 
 
• AuNPs delivered covalently attached siRNA to HeLa cells, mediating a 40% 
c-myc knockdown by RNAi. The COOH functional grouping was shown to 
significantly enhance cellular uptake, and the uptake of siRNA-
functionalised AuNPs displayed cell-type specificity. Covalent attachment 
of siRNA proved more effective than ionic attachment of siRNA for RNAi. 
 
This discussion will now consider how the findings from this thesis contribute 
towards the overall goal of achieving NP-mediated cancer treatment. 
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6.2 Selection of the Core NP Material 
This thesis has investigated NPs composed of either gold (AuNPs) or iron (mNPs).  
Results within have suggested that both materials were excellent candidates 
with regards to production of therapeutic NPs. Two main criteria when 
considering cellular delivery vehicles were met, in that both metals displayed 
low cellular toxicity and high cellular uptake. However, both NP systems have 
also demonstrated that they offer further potential benefits. The main 
advantage of using iron for NP synthesis is that it provides magnetism to the NP 
enabling targeting via an externally applied magnetic field, as was exemplified 
in chapter 3. In addition, iron provides excellent in vivo imaging capabilities 
through the use of MRI. Alternatively, the main advantage of using gold for NP 
synthesis is that it can be used to bind thiolated molecules by exploiting the 
unique covalent bond that forms between gold and sulphur atoms. Chapter 5 has 
shown that the gold-sulphur covalent bond is highly advantageous to NP-
mediated drug delivery, since it is stronger that other types of bonds, such as 
the electrostatic interactions involved in ionic attachment. The strength of this 
covalent gold-sulphur bond allows AuNPs to remain bound to their thiolated 
cargo up until and during cellular uptake, whereas in comparison weaker ionic 
bonds often become dissociated prior to cellular uptake. A further advantage of 
the gold-sulphur covalent bond is that it becomes dissociated within the 
reductive conditions of the intracellular environment, allowing for thiolated 
cargo molecules to become released from the AuNP once inside the cell. In 
addition, with regards to in vitro studies, during this project it was noticed that 
gold was more suitable for TEM since it is more electron dense than iron, 
whereas iron was more suitable for ICP-MS since it is more easily detectable than 
gold. 
 
In my opinion, the findings from this thesis suggest that both iron and gold have 
very desirable but distinct properties that are advantageous to therapeutic NPs. 
Therefore, I propose that an excellent idea would be to utilise all of these 
benefits by making a chimeric NP out of both metals. A NP with an iron core 
would enable magnetic targeting and imaging by MRI, and a gold surface coating 
would facilitate the use of gold-sulphur covalent bonding of thiolated molecules. 
The potential of hybrid NPs composed of two different metals has already been 
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realised by materials chemists, and in their 2006 review, Cozzoli et al state that 
grouping inorganic materials with different properties in the same particle has 
been devised by several research groups (Cozzoli et al., 2006). This review 
supports the use of such gold-iron chimeric NPs, concluding that providing a 
magnetically active core (e.g. iron) with a gold shell via a transmetalation 
reaction allows for the NP to display desirable magnetic properties (Park et al., 
2004), while simultaneously offering a suitable surface to which biomolecules 
can attach more easily (Cao et al., 2001). Additional studies into gold-iron 
chimeric NPs include Umut et al, who have described the synthesis of 
multifunctional hybrid magnetic nanoparticles (HNPs) (Umut et al., 2012) which 
conversely have a gold core and an iron shell. The authors state that iron 
provided the HNPs with magnetism whereas gold provided the HNPs with optical 
activities due to the fact that gold shows surface plasmon phenomena. Similarly, 
Bach et al have described the synthesis of NPs with an iron core and gold shell 
(Fe-Au/core-shell), stating that these hybrid metal NPs displayed 
superparamagnetic properties and could be functionalised by utilising gold-
sulphur covalent bonding (Bach et al., 2012).  
6.3 Method of Administration 
The literature suggests that NPs can be administered either locally or 
systemically. Local administration usually involves direct injection of NPs into 
the site of disease, (i.e. directly into a tumour), whereas systemic 
administration involves intravenous injection of NPs into the blood stream. It is 
understood that systemic delivery is necessary to treat disease sites deep within 
the body, and therefore this is the main goal of therapeutic NP delivery vehicles. 
To achieve systemic delivery, it is envisaged that after intravenous injection, 
NPs must circulate through the body within the blood stream until location of 
the disease site, upon which they should leave the blood stream via traversing 
the blood vessel wall and enter the surrounding tissue. Once at the disease 
target site, NPs must be able to selectively enter diseased cells and deliver their 
therapeutic payload intracellularly. 
 
In regards to systemically administered therapeutic NPs for cancer treatment, it 
would appear that gold-iron chimeric NPs show great potential, as a magnetic 
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field may be employed to attract the NPs towards the disease site. This could be 
used as an adjunct to the enhanced permeability and retention (EPR) effect 
associated with solid tumours, which occurs with the systemic delivery of any 
type of NP formulation (Matsumura and Maeda, 1986). Fang et al describe the 
EPR effect as a unique pathophysiological phenomenon of solid tumours that 
allows biocompatible macromolecules (>40kDa) to accumulate selectively in the 
tumour (Fang et al., 2012). The EPR effect is caused by the fact that tumours 
display increased vasculature, which is made permeable by (i) the presence of 
vascular mediators such as bradykinin and VEGF, (ii) the lack of a smooth muscle 
layer and (iii) large gaps between vascular endothelial cells. In addition, 
retention of macromolecules is mediated by impaired lymphatic clearance from 
the tumour interstitial space (Maeda et al., 2003). Therefore, the EPR effect 
provides circulating NPs with an increased chance of being able to leave the 
blood stream and accumulate at the tumour site. Results from chapter 3 
certainly suggest that this accumulation would be increased further through the 
use of a magnetic field as a relatively low field strength was shown to pull mNPs 
through the dense fibre network of the tissue-equivalent cell-seeded collagen 
gel model.  
6.4 Cellular Uptake 
Once at the target disease site, mediated by a combination of the EPR effect 
and magnetic targeting, therapeutic NPs must recognise and selectively enter 
diseased cells. TEM and ICP-MS results from chapter 4 have demonstrated that 
AuNPs displayed good cellular uptake properties, which was enhanced by the 
attachment of COOH and was cell-type specific if the AuNPs were functionalised 
with siRNA. The attachment of a CPP is still advisable, although this was not a 
necessary requirement to mediate cell uptake of AuNPs in this project. Despite 
the fact that Tat had no effect in this project, possibly due to molecular 
dissociation during transit, results from chapter 3 clearly demonstrated that the 
CPP penetratin was highly effective at enhancing the cell uptake of mNPs and is 
therefore recommended for use in future NP design strategies. 
 
This thesis did not involve the use of NP targeting moieties, although this is 
advisable in an optimal design strategy for in vivo systemic delivery. The most 
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popular choices presented in the literature are folate, and the RGD tripeptide, 
which act to attract NPs to cancer cells that over express receptors for these 
targeting peptides. As discussed in chapter 4, the siRNA-functionalised AuNPs 
investigated in this project displayed very distinct cell-specific targeting, being 
internalised into HeLa cells, but not h-TERT or MCF-7 cells. Further investigation 
is required to determine if this effect was due to cell-type specific expression of 
certain surface receptors, which could be used to ensure specific uptake into 
only the target diseased cell type.  
6.5 Therapy 
Chapter 5 of this thesis demonstrated the successful NP-mediated delivery of 
siRNA to HeLa cells, which resulted in silencing of the c-myc oncogene and 
reduced cell proliferation. Therefore, this work has proven that RNAi is a very 
promising method of cancer treatment. However, one of the main problems 
facing the treatment of cancer is that it can be caused by many different genes. 
As discussed by Weinstein, it is hoped that due to the ‘oncogene addiction’ of 
many tumours, treating cancer by reducing the expression of one key oncogene, 
such as c-myc, will be sufficient to reverse tumourigenesis (Weinstein, 2002). 
Nevertheless, the problem still exists that each individual cancer may not be 
addicted to exactly the same oncogene. Therefore, it seems necessary that for 
clinical cancer treatment by RNAi to become a reality, its use must be designed 
on a patient-to-patient basis, according to the genetic profile of each cancer. 
Indeed, this idea is beginning to become well known as personalised therapy, 
and genetic profiling of cancer patients is already carried out to identify 
patients who would be more likely to respond to drugs due to the nature of the 
individual cancer. For example, 95% of chronic myelogenous leukemias are 
characterised by mutations involving the BCR-ABL fusion gene, leading to the 
expression of a leukemia-specific hybrid tyrosine kinase. Patients who have this 
mutation respond well to the powerful tyrosine kinase inhibitor, Imatinib (Saglio 
et al., 2004). In addition, breast cancer patients are screened for abnormal 
expression of the HER2 gene, as cancers that are HER2+ are approved for 
treatment with Herceptin (Murphy and Fornier, 2010). Hopefully, if samples 
from tumour biopsies can be analysed by micro-array and compared against the 
patient’s normal tissue, an expression profile of the patient’s cancer genome 
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can be formed. This could then be used to identify any key oncogenes that are 
overexpressed, or alternatively, any tumour suppressor genes that are 
underexpressed. After screening in this manner, siRNA or expression plasmids 
could be selected for the identified abnormal genes, attached to a NP delivery 
vehicle and intravenously injected into the patient.  
 
It could be envisaged that in a future clinical setting, this screening could be 
made routine for cancer patients. Specialised NP synthesis labs could be made 
available containing libraries of all the necessary molecular attachments 
including siRNAs, expression plasmids, targeting moieties (e.g. RGD/folate), 
CPPs (e.g. Tat/penetratin) and additional cancer drugs (eg. Imatinib/Herceptin). 
Following the cancer screening report, a team of oncologists, molecular 
biologists, nanoscientists and toxicologists could create the optimal 
multifunctional NP design tailored to that individual cancer. For example, a 
screening report may identify a breast cancer with overexpression of cell surface 
folate receptors, expression of the (as yet unidentified) cell surface receptors 
for COOH, c-myc overexpression, p53 mutation, and overexpression of cell 
surface HER2 receptors. Thus, in this example, an Fe-Au core/shell NP could be 
functionalised with folate for selective targeting of cancer cells, COOH to 
facilitate cell uptake of NPs, c-myc siRNA and a p53 expression plasmid to 
normalise gene expression and regain genetic control over the cell cycle, and 
Herceptin to reduce cell signaling and cell proliferation. This multifunctional NP 
design could be intravenously injected, targeted to the tumour site by an 
externally applied magnetic field (aided by the EPR effect), and deliver its 
therapeutic payload to the cancer cells. The gold core could also facilitate 
thermal ablation of the tumour by heating under NIR light.  
6.6 The Consequence of Treatment 
It is important to consider what the effects of such a NP treatment may be. 
Pelengaris and Khan discuss that based on data received from transgenic mouse 
models of tumourigenesis, deactivation of an initiating oncogene, such as c-myc, 
can have three possible cellular outcomes; apoptosis, redifferentiation or escape  
(as described in Figure 6-1) (Pelengaris and Khan, 2003). In the first two cases, 
apoptosis and redifferentiation lead to tumor reversal, and are therefore the 
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intended aim of administering a therapeutic NP for RNAi as described. This 
desirable outcome was exemplified by Jain et al who, reported that inactivation 
of c-myc caused osteogenic sarcoma cells to differentiate into mature 
osteocytes (Jain et al., 2002). In light of this, perhaps the reduction in cell 
proliferation after c-myc RNAi reported in chapter 4 was mediated by 
redifferentiation of HeLa cells, although this was not determined. The less 
desirable third outcome is escape, where deactivation of the initiating oncogene 
has no effect on the cell and it escapes from treatment, resulting in no tumour 
reversal taking place. This can be explained by the fact that some cells within a 
tumour can gain lesions in additional oncogenes, lifting the previous addiction to 
the initiating oncogene. As some cancer cells may escape treatment in this 
manner, it lends further support to the benefits of NP multivalency, in order to 
attach siRNA molecules against a variety of different oncogenes to ensure 
tumour reversal (Paciotti et al., 2006). Perhaps in designing future NP 
treatments the top 5 overexpressed oncogenes identified in tumour biopsy 
micro-array screening should all be attached to the delivery NP in order to 
maximize the chance of achieving tumour reversal.  
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Figure 6-1 The possible outcomes of oncogene deactivation  
Deactivation of oncogenes can result in desirable outcomes of cellular apoptosis or 
redifferentiation, which lead to tumour reversal. However, escaper cells can defy treatment, 
leading to no tumour reversal after oncogene deactivation. These escaper cells are likely to 
have obtained additional lesions in other oncogenes, reducing their addiction to the 
initiating oncogene. Image modified from (Pelengaris and Khan, 2003).  
 
6.7 Dangers 
This futuristic and theoretical approach to NP-mediated cancer treatment tries 
to maximize the opportunity for tumour reversal, by making multifunctional NPs 
as potent as possible and potentially deadly to cancer cells. Thus it is imperative 
to ensure that cell specific targeting is tightly controlled in developing this 
clinical treatment, as the effects would be dire if these potent therapeutic NPs 
were to gain entry into healthy cells. At present, the laws that govern NP entry 
into different cell types are poorly understood, as was demonstrated in chapter 
4. NP cell uptake can occur in unexpected and unclear manners, such as the fact 
that COOH enhanced NP uptake and that the uptake of siRNA functionalised 
AuNPs was cell-type specific. Both of these findings were unexpected and as yet 
remain unexplained.  
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Considering the fact that the blood supply in the human body supplies over 200 
different cell types, more needs to be known about their interactions with NPs 
to ensure safety. However, it is likely that most of these healthy cells and 
tissues will not encounter NPs since they should not be able to leave the blood 
circulation without the tumour associated EPR effect and the applied magnetic 
force at the tumour site. However, in vivo studies into NP biodistribution in mice 
have shown that while circulating NPs predominantly accumulate in the liver and 
spleen (Mykhaylyk et al., 2001), reports have also suggested that the blood flow 
can take them to other organs such as the brain and heart (Jain et al., 2008; 
Prijic and Sersa, 2011). Therefore investigations into NP interactions and toxicity 
within these organs and cell types should be prioritised.  
 
It seems that the popular strategy of targeting NPs to cancer cells through the 
use of receptors that are overexpressed on cancer cells (e.g. the folate 
receptor) may not be advisable in vivo, since these receptor are also expressed 
on the surface of healthy cells, albeit to a lesser extent. This issue will have to 
be weighed up with consideration of how serious the effects would actually be 
of multifunctional NPs gaining low incident access into healthy cells.  
6.8 Future work 
Future work should now focus on clarifying some of the fundamental biological 
questions that remain unknown regarding the cellular interactions of NPs. This 
thesis has demonstrated the success of two different NP delivery design 
strategies in vitro, and whilst many of the observations discussed remain 
unexplained, they are well supported by the literature. In my opinion, the main 
areas to focus on are; 
  
• clearly defining the mechanisms of NP endocytosis. This will include the 
identification of cell surface receptors responsible for unexplained cell 
uptake such as that induced by COOH, and comparison of the expression 
of these cell surface receptors across different cell types, to aid better 
prediction of cell-type specific NP uptake. 
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• Identifying new ways to tightly control the specificity of NP uptake into 
diseased cells, since perhaps overexpressed surface receptors, the EPR 
effect and magnetic targeting will not be enough to ensure the necessary 
100% specificity of potent therapeutic NPs. 
 
• Investigation into the long-term fate of NPs within the human body. For 
example, will NPs be filtered out by the kidney and excreted in the urine, 
or will they accumulate in certain organs such as the spleen and liver, 
resulting in long term toxicity problems over the course of months to 
years after treatment? 
 
• Tissue-equivalent 3D cell culture models such as the collagen gels used in 
chapter 3 have been proven very effective for assessing the in vivo 
response to therapeutic NPs. Such 3D models are easier, quicker and less 
expensive than animal models and so should be utilised in future high 
throughput toxicity testing and assessment of NP delivery strategies. 
6.9 Conclusion 
There are currently many different options for designing therapeutic NP delivery 
vehicles. This thesis has demonstrated that NPs composed of iron or gold both 
performed very successfully as potential drug delivery vehicles. Therefore, 
results suggest that a chimeric Fe-Au core/shell NP design would utilise 
advantages associated with both metals, since an iron core would provide 
magnetic targeting and MRI imaging and a gold surface would facilitate the use 
of gold-sulphur bonding of thiolated molecules and thermal ablation under NIR 
light. Furthermore, this thesis has shown that NP-mediated RNAi is a promising 
method of cancer treatment, which can silence key oncogenes, such as c-myc, 
resulting in reduced proliferation of cancer cells. Due to the heterogeneous 
nature of cancer, it is envisaged that future RNAi treatment will be most 
successful if therapeutic NPs are individually tailored according to the 
expression profile of each cancer patient. This would herald a new age of 
personalised medicine.
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